Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers

ABSTRACT

A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141-340 nM) of LCC6MDR cells, DOX (78-590 nM) and vincristine (82-550 nM) resistance of 2008/MRP1 cells and topotecan resistance (0.9-135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRP1 transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.

FIELD OF THE INVENTION

The invention relates to novel alkyne-, azide- and triazole-containingflavonoid compounds, methods of preparing the same, and use of thesecompounds for reducing multidrug resistance caused by overexpression ofABC transporters.

This invention relates to a new method of generating a new series ofcompounds that can be used to reverse cancer drug resistance.

This invention relates to the novelty of structure of the alkyne-,azide- and triazole-containing flavonoids that show highly potentactivities toward P-gp, MPR1 and BCRP, thereby reversing cancer drugresistance.

BACKGROUND OF THE INVENTION

The extensive multidrug resistance (MDR) in cancer cells has been amajor obstacle to successful cancer chemotherapy. An important mechanismfor MDR is the enhanced cellular efflux of anticancer agents due toover-expression of ATP-binding cassette (ABC) transporter proteins.¹Among the 48 ABC transporters identified so far, P-glycoprotein (P-gp,ABCB1), multidrug resistance protein (MRP1, ABCC1) and breast cancerresistance protein (BCRP, ABCG2) are three main efflux transportersassociated with MDR.² The structures and functions of ABC transportershave been studied extensively by scientists. It is known that all ABCproteins consist of transmembrane domains (TMDs), and nucleotide-bindingdomains (NBDs).³ P-gp has been identified to possess cytosolic N- andC-termini, two TMDs of 6 helices each, and two NBDs in a single1280-residue polypeptide.³⁻⁶

The structure of the 1531-residue MRP1 is similar to that of P-gp, butthe protein possesses an extra N-terminal TMD with 5 transmembrane (TM)helices, termed TMD₀, whose function remains unclear.^(3,5,7,8) BCRP isa 655-residue half-transporter that possesses an N-terminal NBD and a6-helix TMD. The functional protein of BCRP is assumed to operate as ahomodimer.^(3,5,9,10)

However, the binding modes and binding sites of these three transporterproteins with their substrates are not clear. There is no common“pharmacophore” that can be used to function as an inhibitor of thesethree ABC transporters.³ Structurally diverse inhibitors or modulatorsof ABC multidrug efflux pumps have been identified by homology modeling,combinatorial chemistry, QSAR analysis, and utilization of proteinstructure information.¹¹⁻¹⁴ There have been three generations of P-gpinhibitors. The first generation P-gp inhibitors include calcium channelblocker verapamil,¹⁵⁻¹⁷ antimalarial drug quinidine,¹⁸ calmodulinantagonists,^(19,20) the immunosuppressant cyclosporine A²¹⁻²⁴ and somesteroids.²⁵⁻²⁷ The second generation P-gp chemosensitizer includedexverapamil,²⁸ PSC833 (valspodar),^(26,29) dexniguldipine,³⁰ and VX-710(biricodar).^(31,32)

The third generation MDR modulators developed by structure-activityrelationships and combinatorial chemistry approaches include zosuquidarLY335979, tariquidar XR9576, laniquidar R101933, elacridar GF120918 andthe substituted diarylimidazole ONT-090.^(33,34) Among them, only a veryfew were selected for clinical trial and none of them has been approvedyet for clinical application.

Fewer MRP1 inhibitors have been identified. Most MRP1 substrates, aswell as inhibitors, are anionic compounds that enter cells poorly, thusmaking it difficult to design a good inhibitor for MRP1 compared toP-gp. The Leukotriene C4 (LTC4) analogue (MK571),^(3,35)glibenclamide,³⁶ probenecid³⁷ and some non-specific inhibitors oforganic anion transporters like NSAIDs (e.g. indomethacin)^(38,39) havebeen described as MRP1 modulators. Pantoprazole, fumitremorgin C, andits derivatives Ko132, Ko134 and Ko143^(3,40) are specific ABCG2inhibitors. Besides, some third generation P-gp inhibitors such aselacridar⁴¹ and tariquidar⁴² also modulate ABCG2 activity.

Flavonoids are polyphenolic compounds commonly found in fruits,vegetables, and plant-derived products of the human diet.⁴³ Becausehumans consume large amounts of flavonoids daily, it is generallyaccepted that flavonoids are not toxic. Moreover, it has been reportedthat some flavonoids have been found to reverse cancer MDR. Someflavonoids like genistein, chrysin, biochanin, quercetin, kaempferol andnaringenin have inhibitory activity on P-gp mediated transport of.⁴⁴⁻⁴⁹

Other flavonoids like aglycones and glycosides have been shown toinhibit MRP1-mediated transport to various degree.⁵⁰⁻⁵² Many flavonoidshave also been shown to interact with BCRP transporter. Theysignificantly inhibit the BCRP-mediated transport of topotecan andmitoxantrone in BCRP-overexpressing cancer cells.⁵³⁻⁵⁶ Flavonoids aretherefore promising candidates for development of novel modulators ofMDR.

OBJECTS OF THE INVENTION

It is an object of the invention to develop novel flavonoid derivativeshaving improved activites and/or selectivity to resolve or ameliorate atleast one or more of the problems associated with the prior art. As aminimum, it is an object of this invention to provide the public with auseful choice.

SUMMARY OF THE INVENTION

In a first aspect, the present invention provides a compound of formulaI:

flavonoid-linker-(flavonoid)_(n)  I

-   -   wherein    -   the flavonoid is selected from the group consisting of chalcone,        flavone, flavonol, flavanone, anthocyanin, and isoflavonoid;    -   n is 1 or 2; and    -   the linker is a group having at least one triazole bridged unit.

The linker may have 1 to 10 triazole bridged unit, and more preferably a1 to 5 triazole bridged unit or a 1 to 3 triazole bridged unit.

The at least one triazole bridged unit may further comprises at leastone polyethylene glycol unit.

In a second aspect, the present invention provides a compound of formulaII comprising of a flavonoid containing an acetylene group:

flavonoid-linker-CCH  II

-   -   wherein    -   the flavonoid is selected from the group consisting of chalcone,        flavone, flavonol, flavanone, anthocyanin, and isoflavonoid; and    -   the linker is a group having at least one carbon atom.

Preferably, the linker is selected from the group consisting of alkylenegroup, group having a plurality of ethylene glycol units, group having aplurality of propylene glycol units, group having a plurality of aminoalkyl units, and combinations thereof.

In a third aspect, the present invention provides a compound of formulaIII comprising of a flavonoid containing an azide group:

Flavonoid-linker-N₃  III

-   -   wherein    -   the flavonoid is selected from the group consisting of chalcone,        flavone, flavonol, flavanone, anthocyanin, and isoflavonoid; and    -   the linker is a group having at least one carbon atom.

Preferably the linker is selected from the group consisting of alkylenegroup, group having a plurality of ethylene glycol units, group having aplurality of propylene glycol units, group having a plurality of aminoalkyl units, and combinations thereof.

In a fourth aspect, the present invention provides a process ofsynthesizing a compound of the formula I as defined in the first aspect,comprising reacting a compound of formula II as defined in the secondaspect with a compound of formula III as defined by the third aspect bycatalytic 1,3-dipolar cycloaddition.

The catalytic 1,3-dipolar cycloaddition may be regioselective, and thecatalytic 1,3-dipolar cycloaddition may be Cu(I) catalyzed or Rucatalyzed.

In a fifth aspect, the present invention provides a method of reducingP-glycoprotein based multidrug resistance including the step ofadministering an effective amount of a compound of formula I as definedin the first aspect or a compound of formula II as defined in the secondaspect or a compound of formula III as defined in the third aspect.

In a sixth aspect, the present invention provides a method of reducingMRP1-based multidrug resistance including the step of administering aneffective amount of a compound of formula I as defined in the firstaspect or a compound of formula II as defined in the second aspect or acompound of formula III as defined in the third aspect.

In a seventh aspect, the present invention provides a method of reducingBCRP-based multidrug resistance including the step of administering aneffective amount of a compound of formula I as defined in the firstaspect or a compound of formula II as defined in the second aspect or acompound of formula III as defined in the third aspect.

In an eighth aspect, the present invention provides a method of reducingresistance of a drug caused by overexpression of ABC transportersincluding the step of administering an effective amount of a compound offormula I as defined in the first aspect or a compound of formula II asdefined in the second aspect or a compound of formula III as defined inthe third aspect.

In a ninth aspect, the present invention provides a method of treatingdrug-resistance cancers caused by overexpression of ABC transportersincluding the step of administering an effective amount of a compound offormula I as defined in the first aspect or a compound of formula II asdefined in the third aspect or a compound of formula III as defined inthe third aspect.

In a tenth aspect, the present invention provides a use of an effectiveamount of a compound of formula I as defined in the first aspect or acompound of formula II as defined in the second aspect or a compound offormula III as defined in the third aspect, in the manufacturing of amedicament for reducing P-glycoprotein based multidrug resistance.

In a further aspect, the present invention provides a use of aneffective amount of a compound of formula I as defined in the firstaspect or a compound of formula II as defined in the second aspect or acompound of formula III as defined in the third aspect in themanufacturing of a medicament for reducing MRP-1 based multidrugresistance.

In another aspect, the present invention provides a use of an effectiveamount of a compound of formula I as defined in the first aspect or acompound of formula II as defined in the second aspect or a compound offormula III as defined in the third aspect in the manufacturing of amedicament for reducing BCRP-based multidrug resistance.

In yet a further aspect, the present invention provides a use of aneffective amount of a compound of formula I as defined in the firstaspect or a compound of formula II as defined in the second aspect or acompound of formula III as defined in the third aspect in themanufacturing of a medicament for reducing resistance of a drug causedby overexpression of ABC transporters.

In yet another aspect, the present invention provides a use of aneffective amount of a compound of formula I as defined in the firstaspect or a compound of formula II as defined in the second aspect or acompound of formula III as defined in the third aspect in themanufacturing of a medicament for treating drug-resistant cancers causedby overexpression of ABC transporters.

In still another aspect, the present invention provides a medicament forreducing P-glycoprotein based multidrug resistance or for reducing MRP-1based multidrug resistance or for reducing BCRP-based multidrugresistance, said medicament including a compound of formula I as definedin the first aspect or a compound of formula II as defined in the secondaspect or a compound of formula III as defined in the third aspect.

In still a further aspect, the present invention provides a medicamentfor reducing resistance of a drug caused by overexpression of ABCtransporter, said medicament including a compound of formula I asdefined in the first aspect or a compound of formula II as defined inthe second aspect or a compound of formula III as defined in the thirdaspect.

In yet still another aspect, the present invention provides a medicamentfor treating drug-resistant cancers caused by overexpression of ABCtransporter, said medicament including a compound of formula I definedin the first aspect or a compound of formula II as defined in the secondaspect or a compound of formula III as defined in the third aspect.

In yet still a further aspect, the present invention provides a methodof generating a library of a predetermined number of compounds of theformula I as defined in the first aspect comprising:

-   -   a) providing a flavonoid containing an acetylene group of        formula II as defined in the second aspect;    -   b) selectively reacting the flavonoid containing an acetylene        group of formula II as defined in the second aspect with the        flavonoid containing an azido group of formula III as defined in        the third aspect; and    -   c) repeating steps (a) and (b) a predetermined number of times        to obtain a predetermined number of compounds of the formula I        as defined in the first aspect.

In still yet an alternate aspect, the present invention provides a useof a library of compounds of formula I as defined in the first aspectmade by a method as defined in the yet still a further aspect above toscreen the modulating potency of multidrug resistance caused byoverexpression of ABC transporter of each compound within the library.

It is a preferred feature of the present invention to provide a newclass of modulators of P-gp, MRP1 and BCRP, based on alkyne-, azide- andtriazole-containing flavonoids and have completely new chemicalstructure.

It is another preferred feature of the present invention to provide acombinatorial library of triazole-bridged flavonoid heterodimers thatallows rapid screening of P-gp, MRP1 and BCRP-modulating activities.

These newly synthesized compounds are highly potent in reversing cancerdrug resistance in vitro and can be used in the future to reverse cancerdrug resistance in cancer patients.

These newly synthesized compounds have different levels of selectivitytowards the three major transporters responsible for cancer drugresistance. Such wide range of selectivity will increase the versatilityof applications that these new compounds can be applied.

For example, dual-selective compounds (towards P-gp and BCRP) may beuseful in targeting these drug transporters in the blood brain barrier,thereby increasing the cancer drug concentration in the brain. This isextremely important for treating brain tumor which would otherwise bevery difficult due to the lack of uptake of cancer drug in the brain.

The present invention is more advantageous over the existing technologyfor the following reasons:

(1) Highly potent for reversing P-gp-mediated paclitaxel resistance(EC₅₀=141-340 nM) and doxorubicin resistance (EC₅₀=114-530 nM),MRP1-mediated vincristine resistance (EC₅₀=82-550 nM) and BCRP-mediatedtopotecan and mitoxantrone resistance (EC₅₀=0.9-135 nM)

(2) A highly efficient and inexpensive method to develop a largecombinatorial library of flavonoid dimers with different flavonoidmoieties for in vitro screening for P-gp, MRP1 and BCRP modulatingactivity.

(3) Most triazole flavonoid dimers are very safe to use, with very lowin vitro cytotoxicity towards normal fibroblast cells (IC₅₀>100 μM).This compares favorably to Ko143, the most potent BCRP modulator in theliterature (IC₅₀=29 μM). Therapeutic indexes of some triazole flavonoiddimers are 43-fold higher than the best BCRP modulator in theliterature, Ko143.

(4) Some triazole flavonoid dimers have extremely potent BCRP-modulatingactivity which 12-fold more potent than Ko143, the most potentBCRP-modulator in the literature.

(5) A wide range of selectivity towards P-gp, MRP1 and BCRP, thereforeaffording a versatile application of these new flavonoid dimers indifferent situation, including the reversal of cancer drug resistance orincrease bioavailability of cancer or epileptic drugs in the brain, justto name a few.

Thus, it is a preferred feature of the invention to design novelalkyne-, azide- and triazole-containing flavonoids, synthesis andcharacterization of the activity in inhibiting P-gp, MRP 1 and BCRP incancer cells in vitro.

Materials and Methods General

All NMR spectra were recorded on a Bruker MHz DPX400 spectrometer at 400MHz for ¹H and 100 MHz for ¹³C or Varian Unity Inova 500 NB NMRSpectrometer at 500 MHz for ¹H and 125 MHz for ¹³C. All NMR measurementswere carried out at room temperature and the chemical shifts arereported as parts per million (ppm) in unit relative to the resonance ofCDCl₃ (7.26 ppm in the ¹H, 77.0 ppm for the central line of the tripletin the ¹³C modes, respectively). Low-resolution and high-resolution massspectra were obtained on a Micromass Q-TOF-2 by electron sprayionization (ESI) mode or on Finnigan MAT95 ST by electron ionization(EI) mode. Melting points were measured using Electrothermal IA9100digital melting point apparatus and were uncorrected. All reagents andsolvents were reagent grade and were used without further purificationunless otherwise stated. The plates used for thin-layer chromatography(TLC) were E. Merck Silica Gel 60F₂₅₄ (0.25-mm thickness) and they werevisualized under short (254-nm) and long (365-nm) UV light.Chromatographic purifications were carried out using MN silica gel 60(230-400 mesh). Substituted 4′ or 7-hydroxyflavones 1a-h were preparedas reported previously.⁵⁸ The purity of tested compounds was determinedby HPLC, which was performed by using Agilent 1100 series installed withan analytic column of Agilent Prep-Sil Scalar column (4.6 mm×250 mm,5-μm) at UV detection of 320 nm (reference at 450 nm) with isocraticelution of hexane (50%)/ethyl acetate (25%)/methanol (25%) at a flowrate of 1.0 mL/min. All tested compounds were shown to >95% purityaccording to HPLC.

General Procedure for the Synthesis of Ac1 to Ac16 (Scheme 1)

(i) To a round-bottom flask was charged with corresponding4′-hydroxyflavones or 7-hydroxyflavones 1a-e (1 equiv.),5-chloropent-1-yne or 6-chlorohex-1-yne (1.2 equiv.), K₂CO₃ (1.5 equiv.)and DMF (3 ml per equiv (mmol)). The reaction mixture was stirred atrefluxing temperature for 2 h. When TLC indicated complete consumptionof starting material, the reaction mixture was poured into a separatingfunnel containing water. The mixture was continuously extracted withDCM. If the mixture could not be separated into two layers, small amountof 1M HCl was added. The combined organic layers were dried over MgSO₄,filtered and evaporated to give a brown crude reaction mixture.Purification was performed by flash column chromatography on silica gelwith acetone in DCM as eluent to furnish desired product.

(ii) Excess KOH (3M solution in 96% EtOH, 3-4 equiv) was added to amixture of 4-(hex-5-yn-1-yloxy)benzaldehyde (2a) (1.0 equiv) and thesubstituted 2′-hydroxyacetophenone 3a-e (1.0 equiv). The mixture wasstirred at room temperature for 16 h. When TLC indicated completeconsumption of starting material, the reaction mixture was acidified topH 5 with 1M HCl at ice-bath temperature. The yellow precipitate formedwas collected by suction filtration. The yellow solid was washed withn-hexane and subjected to crystallization from MeOH to afford thedesired chalcones. If no precipitate was formed after the addition of 1MHCl, then the mixture was continuously extracted with DCM. The combinedorganic layers were dried over MgSO₄, filtered, and evaporated underreduced pressure to give a crude mixture, which was subjected to flashcolumn chromatography using 15% EtOAc in hexane as eluent to furnish thedesired chalcones.

2-(4-(Pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (Ac1)

This compound (0.53 g, 82%) was obtained from2-(4-hydroxyphenyl)-4H-chromen-4-one (1a) and 5-chloropent-1-yneaccording to the general procedure (i) described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.98-2.06 (m, 3H), 2.40-2.44 (m, 2H), 4.13 (t,J=6.40 Hz, 2H), 6.71 (s, 1H), 7.00 (d, J=8.80 Hz, 2H), 7.38 (dd, J=7.60,7.20 Hz, 1H), 7.52 (d, J=8.40 Hz, 1H), 7.65 (ddd, J=7.60, 7.20, 1.60 Hz,1H), 7.85 (d, J=8.80 Hz, 2H), 8.21 (dd, J=7.60, 1.60 Hz, 1H); ¹³C NMR(100 MHz, CHLOROFORM-d) δ ppm 15.07, 27.92, 66.32, 69.12, 83.11, 106.07,114.87, 117.91, 123.86, 123.92, 125.02, 125.57, 127.94, 133.51, 156.10,161.68, 163.33, 178.32; LRMS (ESI) m/z 305 [M+H]⁺; HRMS (ESI) calcd forC₂₀H₁₇O₃ [M+H]⁺ 305.1178. found 305.1180;

7-(Pent-4-yn-1-yloxy)-2-phenyl-4H-chromen-4-one (Ac2)

This compound (0.33 g, 79%) was obtained from7-hydroxy-2-phenyl-4H-chromen-4-one (1e) and 5-chloropent-1-yneaccording to the general procedure (i) described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.99-2.07 (m, 3H), 2.40-2.44 (m, 2H), 4.16 (t,J=6.40 Hz, 2H), 6.71 (s, 1H), 6.93-6.95 (m, 2H), 7.47-7.49 (m, 3H),7.84-7.86 (m, 2H), 8.09 (dd, J=7.20, 2.80 Hz, 1H); ¹³C NMR (100 MHz,CHLOROFORM-d) δ ppm 15.06, 27.78, 66.74, 69.27, 82.97, 100.87, 107.38,114.67, 117.74, 126.06, 126.93, 128.94, 131.36, 131.73, 157.87, 162.90,163.39, 177.77; LRMS (ESI) m/z 305 [M+H]⁺; HRMS (ESI) calcd for C₂₀H₁₇O₃[M+H]⁺ 305.1178. found 305.1181;

7-Fluoro-2-(4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (Ac3)

This compound (0.31 g, 89%) was obtained from7-fluoro-2-(4-hydroxyphenyl)-4H-chromen-4-one (1b) and5-chloropent-1-yne according to the general procedure (i) describedabove. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.98-2.06 (m, 3H), 2.40-2.44(m, 2H), 4.14 (t, J=6.00 Hz, 2H), 6.68 (s, 1H), 6.99 (d, J=8.80 Hz, 2H),7.08-7.13 (m, 1H), 7.20 (dd, J=9.20, 2.40 Hz, 1H), 7.81 (t, J=8.80 Hz,2H), 8.20 (dd, J=6.40, 6.40 Hz, 1H); ¹³C NMR (100 MHz, CHLOROFORM-d) δppm 15.06, 27.91, 66.35, 69.12, 83.08, 104.50, 104.75, 106.04, 113.58,113.79, 114.93, 120.70, 123.52, 127.89, 156.98, 157.11, 161.80, 163.61,164.26, 166.79, 177.27; LRMS (ESI) m/z 323 [M+H]⁺; HRMS (ESI) calcd forC₂₀H₁₆FO₃ [M+H]⁺ 323.1083. found 323.1086;

5-(Benzyloxy)-7-(methoxymethoxy)-2-(4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one(Ac4)

This compound (0.11 g, 71%) was obtained from5-(benzyloxy)-2-(4-hydroxyphenyl)-7-(methoxymethoxy)-4H-chromen-4-one(1c) and 5-chloropent-1-yne according to the general procedure (i)described above. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.97-2.03 (m, 3H),2.38-2.42 (m, 2H), 3.47 (s, 3H), 4.09 (t, J=6.00 Hz, 2H), 5.20 (s, 2H),5.21 (s, 2H), 6.47 (d, J=1.60 Hz, 1H), 6.54 (s, 1H), 6.73 (d, J=1.60 Hz,1H), 6.95 (d, J=8.80 Hz, 2H), 7.26-7.40 (m, 3H), 7.62 (d, J=7.20 Hz,2H), 7.77 (d, J=8.40 Hz, 2H); ¹³C NMR (100 MHz, CHLOROFORM-d) δ ppm15.07, 27.94, 56.39, 66.28, 69.11, 70.66, 83.16, 94.29, 95.97, 98.69,107.48, 110.18, 114.75, 123.71, 126.60, 127.55, 128.50, 136.44, 159.38,159.55, 160.68, 161.19, 161.32, 177.32; LRMS (ESI) m/z 471 [M+H]⁺; HRMS(ESI) calcd for C₂₉H₂₇O₆ [M+H]⁺ 471.1808. found 471.1815;

2-(4-(Hex-5-yn-1-yloxy)phenyl)-6-methyl-4H-chromen-4-one (Ac5)

This compound (0.22 g, 73%) was obtained from2-(4-hydroxyphenyl)-6-methyl-4H-chromen-4-one (1d) and6-chloropent-1-yne according to the general procedure (i) describedabove. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.67-1.76 (m, 2H), 1.86-1.96(m, 2H), 1.97 (br. s., 1H), 2.23-2.31 (m, 2H), 2.41 (s, 3H), 4.02 (t,J=6.10 Hz, 2H), 6.67 (s, 1H), 6.95 (d, J=8.30 Hz, 2H), 7.37-7.46 (m,2H), 7.80 (d, J=8.79 Hz, 2H), 7.95 (s, 1H); ¹³C NMR (126 MHz,CHLOROFORM-d) δ ppm 18.06, 20.81, 24.87, 28.05, 67.49, 68.72, 83.81,105.82, 114.77, 117.60, 123.45, 123.87, 124.88, 127.80, 134.61, 134.86,154.32, 161.67, 163.15, 178.31; LRMS (ESI) m/z 333 [M+H]⁺; HRMS (ESI)calcd for C₂₂H₂₁O₃ [M+H]⁺ 333.1491. found 333.1495;

E)-3-(4-(Hex-5-yn-1-yloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one(Ac6)

This compound (0.36 g, 75%) was obtained from4-(hex-5-yn-1-yloxy)benzaldehyde (2a) and 2′-hydroxyacetophenone (3a)according to the general procedure (ii) described above. ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 1.82-1.85 (m, 2H), 1.93-2.01 (m, 3H), 2.31-2.35(m, 2H), 4.09 (t, J=6.00 Hz, 2H), 6.94-7.05 (m, 3H), 7.48-7.62 (m, 2H),7.64-7.95 (m, 2H), 12.97 (s, 1H); ¹³C NMR (100 MHz, CHLOROFORM-d) δ ppm18.16, 24.97, 28.15, 67.71, 68.84, 83.96, 114.74, 114.99, 117.52,118.59, 118.75, 120.14, 127.26, 129.54, 130.57, 131.99, 136.13, 145.40,161.50, 163.56, 193.67; LRMS (ESI) m/z 321 [M+H]⁺; HRMS (ESI) calcd forC₂₁H₂₁O₃ [M+H]⁺ 321.1491. found 321.1492;

E)-1-(5-Ethyl-2-hydroxyphenyl)-3-(4-(hex-5-yn-1-yloxy)phenyl)prop-2-en-1-one(Ac7)

This compound (0.23 g, 61%) was obtained from4-(hex-5-yn-1-yloxy)benzaldehyde (2a) and2′-hydroxy-5′-ethylacetophenone (3b) according to the general procedure(ii) described above. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.26 (t,J=6.00 Hz, 3H), 1.74-1.78 (m, 2H), 1.93-2.01 (m, 3H), 2.63-2.69 (m, 2H),4.09 (t, J=6.00 Hz, 2H), 6.94-6.98 (m, 3H), 7.35 (dd, J=2.00, 7.20 Hz,1H), 7.53-7.71 (m, 3H), 7.91 (d, J=7.20 Hz, 1H), 12.84 (s, 1H); ¹³C NMR(100 MHz, CHLOROFORM-d) δ ppm 15.94, 18.17, 24.99, 28.17, 67.52, 68.84,83.99, 114.96, 117.61, 118.41, 119.82, 127.32, 128.17, 130.57, 134.37,136.09, 145.18, 161.45, 161.69, 193.59; LRMS (ESI) m/z 349 [M+11]⁺; HRMS(ESI) calcd for C₂₃H₂₅O₃ [M+H]⁺ 349.1804. found 349.1806;

E)-3-(4-(Hex-5-yn-1-yloxy)phenyl)-1-(2-hydroxy-5-methylphenyl)prop-2-en-1-one(Ac8)

This compound (0.25 g, 70%) was obtained from4-(hex-5-yn-1-yloxy)benzaldehyde (2a) and 2‘-hydroxy-5’-methylacetophenone (3c) according to the general procedure(ii) described above. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.75-1.79 (m,2H), 1.94-2.01 (m, 3H), 2.29 (t, J=6.00 Hz, 2H), 2.43 (s, 3H), 4.08 (t,J=6.00 Hz, 2H), 6.95 (d, J=8.70 Hz, 2H), 7.46 (d, J=15.40 Hz, 1H), 7.64(d, J=8.70 Hz, 2H), 7.89-8.01 (m, 3H), 13.45 (s, 1H); ¹³C NMR (100 MHz,CHLOROFORM-d) δ ppm 18.15, 20.36, 24.96, 28.12, 67.59, 68.80, 83.92,115.08, 118.08, 124.29, 126.85, 128.00, 130.93, 131.02, 136.09, 137.23,146.98, 154.72, 161.95, 192.34; LRMS (ESI) m/z 335 [M+H]⁺; HRMS (ESI)calcd for C₂₂H₂₃O₃ [M+H]⁺ 335.1647. found 335.1649;

E)-3-(4-(Hex-5-yn-1-yloxy)phenyl)-1-(2-hydroxy-4-methylphenyl)prop-2-en-1-one(Ac9)

This compound (0.31 g, 65%) was obtained from4-(hex-5-yn-1-yloxy)benzaldehyde (2a) and2′-hydroxy-4′-methylacetophenone (3d) according to the general procedure(ii) described above. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.74-1.78 (m,2H), 1.93-2.01 (m, 3H), 2.30-2.34 (m, 2H), 2.39 (s, 3H), 4.08 (t, J=6.00Hz, 2H), 6.78 (d, J=7.20 Hz, 1H), 6.85 (s, 1H), 6.97 (d, J=8.00 Hz, 2H),7.55 (d, J=7.20 Hz, 1H), 7.64 (d, J=8.00 Hz, 2H), 7.82 (d, J=7.20 Hz,1H), 7.92 (d, J=7.20 Hz, 2H), 13.02 (s, 1H); ¹³C NMR (100 MHz,CHLOROFORM-d) δ ppm 18.15, 21.97, 24.98, 28.16, 67.52, 68.75, 83.94,114.97, 117.74, 117.94, 118.65, 120.05, 127.40, 129.41, 130.46, 144.86,147.77, 161.38, 163.75, 193.11; LRMS (ESI) m/z 335 [M+H]⁺; HRMS (ESI)calcd for C₂₂H₂₃O₃ [M+H]⁺ 335.1647. found 335.1650;

E)-1-(4-Fluoro-2-hydroxyphenyl)-3-(4-(hex-5-yn-1-yloxy)phenyl)prop-2-en-1-one(Ac10)

This compound (0.33 g, 69%) was obtained from4-(hex-5-yn-1-yloxy)benzaldehyde (2a) and2′-hydroxy-5′-fluoroacetophenone (3e) according to the general procedure(ii) described above. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.74-1.78 (m,2H), 1.93-2.01 (m, 3H), 2.30-2.33 (m, 2H), 4.07 (t, J=6.00 Hz, 2H),6.64-6.73 (m, 4H), 6.94 (d, J=8.00 Hz, 2H), 7.47 (d, J=15.40 Hz, 1H),7.63 (d, J=8.00 Hz, 2H), 7.89-7.96 (m, 2H), 13.37 (s, 1H); ¹³C NMR (100MHz, CHLOROFORM-d) δ ppm 18.15, 24.94, 28.14, 67.55, 68.81, 83.95,104.98, 105.21, 106.86, 107.08, 114.74, 115.01, 117.20, 127.11, 130.61,131.74, 131.86, 145.66, 161.60, 166.02, 166.06, 166.20, 192.49; LRMS(ESI) m/z 339 [M+H]⁺; HRMS (ESI) calcd for C₂₁H₂₀FO₃ [M+H]⁺ 339.1396.found 339.1398;

2-(4-(Pent-4-yn-1-yloxy)phenyl)quinazolin-4(3H)-one (Ac11)

To a well stirred solution of 4-(pent-4-yn-1-yloxy)benzaldehyde (2b) and2-aminobenzamide (4) in DMSO at 150° C., was added catalytic amount ofiodine. The reaction mixture was further heated for 3 h. When TLCindicated complete consumption of starting material, the reactionmixture was poured into a beaker containing water ice-bath temperature.The white precipitate formed was collected by suction filtration. Thewhite solid was washed with n-hexane and subjected to crystallizationfrom MeOH to afford the desired compound Ac11 (0.33 g, 65%). ¹H NMR (400MHz, DMSO-d₆) δ ppm 1.87-1.93 (m, 2H), 2.31-2.35 (m, 2H), 2.81 (s, 1H),4.10 (t, J=6.00 Hz, 2H), 7.06 (d, J=8.80 Hz, 2H), 7.46 (dd, J=7.60, 7.60Hz, 1H), 7.68 (d, J=7.60 Hz, 1H), 7.78 (dd, J=7.60, 7.60 Hz, 1H),8.10-8.17 (m, 3H), 12.38 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ ppm14.87, 28.03, 66.67, 72.09, 83.98, 114.82, 121.08, 125.26, 126.23,126.50, 127.63, 129.89, 134.91, 152.30, 161.51, 162.77; LRMS (ESI) m/z305 [M+H]⁺; HRMS (ESI) calcd for C₁₉H₁₇N₂O₂ [M+H]⁺ 305.1290. found305.1296;

7-(Hex-5-yn-1-yloxy)-2-phenyl-4H-chromen-4-one (Ac12)

This compound (0.13 g, 69%) was obtained from7-hydroxy-2-phenyl-4H-chromen-4-one (1e) and 6-chloropent-1-yneaccording to the general procedure (i) described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.71-1.81 (m, 3H), 1.95-2.04 (m, 3H), 2.31 (td,J=7.08, 2.44 Hz, 2H), 4.12 (t, J=6.34 Hz, 3H), 6.77 (s, 1H), 6.95-7.01(m, 2H), 7.49-7.55 (m, 3H), 7.89-7.94 (m, 2H), 8.13 (d, J=8.79 Hz, 1H);¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 18.01, 24.79, 27.87, 67.91, 68.81,83.71, 100.78, 107.34, 114.58, 117.63, 125.99, 126.83, 128.86, 131.25,131.72, 157.81, 162.78, 163.44, 177.63; LRMS (ESI) m/z 319 [M+H]⁺; HRMS(ESI) calcd for C₂₁H₁₉O₃ [M+H]⁺ 319.1334. found 319.1328.

2-Phenyl-7-(2-(prop-2-yn-1-yloxy)ethoxy)-4H-chromen-4-one (Ac13)

To a round-bottom flask was charged with corresponding 7-hydroxyflavones1e (0.021 mol, 5 g), 2-bromoethanol (0.022 mol, 1.6 ml), K₂CO₃ (0.021mol, 2.9 g) and anhydrous DMF (20 ml). The reaction mixture was stirredat refluxing temperature for 3 h. The reaction mixture was poured into abeaker containing ice water followed by filtration and washing (50 mlhexane). This (3.2 g, 54%) was used without further purification. Theobtained compound (7.1 mmol, 2 g) was then dissolved in anhydrous THF(10 ml). To this solution at room temperature, was added excess sodiumhydride (8.5 mmol, 0.2 g) and propargyl bromide (80% in xylene) (7.1mmol, 0.79 ml) solution successively at 0° C. for 1 hr. The reactionmixture was then stirred for 3 h at RT. When TLC indicated completeconsumption of starting material, the reaction mixture was poured into aseparating funnel containing water. The mixture was continuouslyextracted with DCM. The combined organic layers were dried over MgSO₄,filtered and evaporated to give a brown crude reaction mixture.Purification was performed by flash column chromatography on silica gelwith acetone in DCM (1:10) as eluent to furnish titled compound (1.7 g,75%). ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.49 (t, J=2.44 Hz, 1H),3.97-3.99 (m, 2H), 4.24-4.33 (m, 4H), 6.78 (s, 1H), 7.00 (d, J=2.44 Hz,1H), 7.03 (dd, J=8.79, 2.44 Hz, 1H), 7.49-7.57 (m, 3H), 7.88-7.94 (m,2H), 8.15 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm58.47, 67.68, 74.92, 79.13, 101.01, 107.30, 114.56, 117.83, 125.95,126.84, 128.81, 131.24, 131.62, 157.65, 162.79, 163.06, 177.50; LRMS(ESI) m/z 321 [M+H]⁺; HRMS (ESI) calcd for C₂₀H₁₇O₄ [M+H]⁺ 321.1127.found 321.1121.

2-(2-(di(prop-2-yn-1-yl)amino)ethoxy)ethanol (Ac14)

To a solution of 2-(2-aminoethoxy)ethanol (0.048 mol, 4.74 ml) inacetone (25 ml) at room temperature, was added excess propargyl bromide(0.1 mol, 11.6 ml) solution. The reaction mixture was then stirred atroom temperature for 12 h. evaporated to give a brown crude reactionmixture. The oily substance was obtained after evaporation. Purificationwas performed by flash column chromatography on silica gel with acetonein DCM (1:3) as eluent to furnish titled compound (0.012 mol, 2.2 g,25%). ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.23 (br. s., 2H), 2.78 (t,J=5.12 Hz, 2H), 3.49 (s, 4H), 3.54-3.59 (m, 2H), 3.62 (t, J=5.37 Hz,2H), 3.66-3.73 (m, 2H); ¹³C NMR (125 MHz, CHLOROFORM-d) δ ppm 42.45,52.12, 61.68, 68.69, 72.30, 73.36, 78.36; LRMS (ESI) calcd forC₁₀H₁₆NO₂, 182. found m/z 182 [M+H]⁺.

N-Benzyl-N,N-di(prop-2-yn-1-yl)amine (Ac15)

This compound was commercially available.

7-(2-(Benzyl(prop-2-yn-1-yl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16)

To a well stirred solution of 7-hydroxyflavones 1e (2.9 mmol, 0.7 g),2-(benzyl(prop-2-yn-1-yl)amino)ethanol (2.9 mmol, 0.56 g) and PPh₃ (0.77g, 1 equiv.) in THF (10 ml) at room temperature, was added DIAD (0.58ml, 1 equiv.) dropwise. The reaction mixture was then stirred for 12 h.The reaction mixture was evaporated to give a brown crude reactionmixture. Purification was performed by flash column chromatography onsilica gel with acetone in DCM (1:50) as eluent to furnish titledcompound (0.42 g, 35%). ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.30 (t,J=2.20 Hz, 1H), 3.07 (t, J=5.61 Hz, 2H), 3.48 (d, J=2.44 Hz, 2H), 3.79(s, 2H), 4.21 (t, J=5.61 Hz, 2H), 6.77 (s, 1H), 6.95-7.01 (m, 2H),7.27-7.29 (m, 1H), 7.31-7.35 (m, 2H), 7.37-7.40 (m, 2H), 7.50-7.55 (m,3H), 7.88-7.93 (m, 2H), 8.13 (d, J=8.78 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 42.61, 51.72, 58.53, 67.22, 70.04, 101.11, 107.54,114.72, 117.93, 126.16, 127.07, 127.46, 128.42, 128.98, 129.12, 131.39,131.89, 157.93, 163.03, 163.26, 177.82; LRMS (ESI) m/z 410 [M+H]⁺; HRMS(ESI) calcd for C₂₇H₂₄NO₃ [M+H]⁺ 410.1756. found 410.1750.

Tri(prop-2-yn-1-yl)amine (Ac17)

This compound was commercially available.

General Procedure for Synthesis of Az1 to Az15 (Scheme 2)

(i) To a round-bottom flask was charged with 4′-hydroxyflavones (1a, d,f, g, h) or 7-hydroxyflavones (1e) (1 equiv.), 2-bromoethanol or2-(2-chloroethoxy)ethanol or 2-(2-(2-chloroethoxy)ethoxy)ethanol (1.2equiv.), K₂CO₃ (1.5 equiv.) and DMF (3 mL per equiv.). The reactionmixture was stirred at refluxing temperature. When TLC indicatedcomplete consumption of starting material, the reaction mixture waspoured into a separating funnel containing water. The mixture wascontinuously extracted with DCM. If the mixture could not be separatedinto two layers, small amount of 1M HCl was added. The combined organiclayers were dried over MgSO₄, filtered and evaporated to give a browncrude reaction mixture. Purification was performed by flash columnchromatography on silica gel with acetone in DCM as eluent to furnishdesired product.

(ii) The hydroxylated flavone obtained from (i) above was then dissolvedin a solution of DCM (1 ml per equiv.) and triethylamine (1 mL perequiv.) at 0° C. Methanesulfonyl chloride (1.2 equiv.) was then addeddropwise and stirred for 1 hr at room temperature. When TLC indicatedcomplete consumption of the starting material, the white precipitateformed was removed by passing through a short pad of silica gel tofurnish the mesylated product which was sufficiently pure for the nextstep. To a solution of the mesylate in ACN (2 ml per equiv.) was addedexcess of sodium azide (3 equiv.). The solution was kept for reflux at80° C. for 15 h. The resulting solution was treated with water and thenextracted with DCM. The combined organic layer was dried over MgSO₄ andconcentrated at reduced pressure to give pale yellow viscous liquid.Purification was performed by flash column chromatography on silica gelwith acetone in DCM as eluent to furnish desired product.

2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-4H-chromen-4-one (Az1)

This compound (0.62 g, 45%) was obtained from2-(4-hydroxyphenyl)-4H-chromen-4-one (1a) and 2-(2-chloroethoxy)ethanolaccording to the general procedure (i) and (ii) described above. ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 3.32 (t, J=4.80 Hz, 2H), 3.65 (t, J=4.80Hz, 2H), 3.77 (t, J=4.80 Hz, 2H), 4.06 (t, J=4.80 Hz, 2H), 6.56 (s, 1H),6.86 (d, J=8.80 Hz, 2H), 7.26 (dd, J=7.60, 7.20 Hz, 1H), 7.37 (d, J=8.40Hz, 1H), 7.53 (ddd, J=7.60, 7.20, 1.60 Hz, 1H), 7.68 (d, J=8.80 Hz, 2H),8.05 (dd, J=7.60, 1.60 Hz, 1H); ¹³C NMR (100 MHz, CHLOROFORM-d) δ ppm50.54, 67.46, 69.38, 70.17, 105.83, 114.85, 117.87, 123.69, 123.83,124.92, 125.32, 127.76, 133.46, 155.91, 161.40, 163.05, 178.03; LRMS(ESI) m/z 352 [M+11]⁺; HRMS (ESI) calcd for C₁₉H₁₈N₃O₄ [M+H]⁺ 352.1297.found 352.1295;

2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (Az2)

This compound (0.36 g, 41%) was obtained from2-(4-hydroxyphenyl)-4H-chromen-4-one (1a) and2-(2-(2-chloroethoxy)ethoxy)ethanol according to the general procedure(i) and (ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.40(t, J=5.12 Hz, 2H), 3.68-3.73 (m, 4H), 3.74-3.78 (m, 2H), 3.91-3.93 (m,2H), 4.20-4.25 (m, 2H), 6.75 (s, 1H), 7.05 (d, J=10 Hz, 2H), 7.41 (t,J=7.57 Hz, 1H), 7.55 (d, J=8.30 Hz, 1H), 7.66-7.71 (m, 1H), 7.88 (d,J=10 Hz, 2H), 8.23 (d, J=7.81 Hz, 1H); ¹³C NMR (126 MHz, CHLOROFORM-d) δppm 50.56, 67.54, 69.51, 69.98, 70.62, 70.79, 106.01, 114.93, 117.83,123.78, 123.97, 124.92, 125.46, 127.81, 133.42, 156.01, 161.51, 163.19,163.20, 178.15; LRMS (ESI) m/z 396 [M+H]⁺, 418 [M+Na]⁺; HRMS (ESI) calcdfor C₂₁H₂₂N₃O₅ [M+H]⁺ 396.1559. found 396.1544; calcd for C₂₁H₂₁N₃O₅Na[M+Na]⁺ 418.1379. found 418.1378.

2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-6-methyl-4H-chromen-4-one(Az3)

This compound (0.21 g, 36%) was obtained from2-(4-hydroxyphenyl)-6-methyl-4H-chromen-4-one (1d) and2-(2-(2-chloroethoxy)ethoxy)ethanol according to the general procedure(i) and (ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.33(s, 3H), 3.30 (t, J=4.88 Hz, 2H), 3.58-3.64 (m, 4H), 3.64-3.69 (m, 2H),3.80 (t, J=4.64 Hz, 2H), 4.09 (t, J=4.64 Hz, 2H), 6.57 (s, 1H), 6.90 (d,J=10.0 Hz, 2H), 7.26-7.38 (m, 2H), 7.71 (d, J=10.0 Hz, 2H), 7.85 (s,1H); ¹³C NMR (126 MHz, CHLOROFORM-d) δ ppm 20.58, 50.38, 67.35, 69.32,69.77, 70.41, 70.59, 76.73, 76.99, 77.25, 105.57, 114.69, 117.40,123.19, 123.82, 124.57, 127.52, 134.39, 134.61, 154.04, 161.25, 162.77,177.93. LRMS (ESI) m/z 410 [M+H]⁺, 432 [M+Na]⁺; HRMS (ESI) calcd forC₂₂H₂₄N₃O₅ [M+H]⁺ 410.1716. found 410.1709; calcd for C₂₂H₂₃N₃O₅Na[M+Na]⁺ 432.1535. found 432.1544.

2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-6-fluoro-4H-chromen-4-one(Az4)

This compound (0.23 g, 31%) was obtained from6-fluoro-2-(4-hydroxyphenyl)-4H-chromen-4-one (10 and2-(2-(2-chloroethoxy)ethoxy)ethanol according to the general procedure(i) and (ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.39(t, J=4.88 Hz, 2H), 3.67-3.72 (m, 4H), 3.74-3.78 (m, 2H), 3.90-3.93 (m,2H), 4.20-4.24 (m, 2H), 6.73 (s, 1H), 7.05 (d, J=10.0 Hz, 2H), 7.40(ddd, J=9.03, 7.57, 2.93 Hz, 1H), 7.53-7.58 (m, 1H), 7.84-7.89 (m, 3H);¹³C NMR (126 MHz, CHLOROFORM-d) δ ppm 50.35, 67.37, 69.25, 69.72, 69.73,70.37, 70.55, 104.91, 110.07 (d, J=23.25 Hz, C5), 114.72, 119.74 (d,J=8.25 Hz, C8), 121.22 (d, J=25.63 Hz, C7), 123.28, 124.72 (d, J=7.25Hz, C10), 127.56, 151.90 (d, J=1.25 Hz, C9), 159.64 (d, J=244.88 Hz,C6), 161.46, 163.15, 176.85 (d, J=2.50 Hz, C4); LRMS (ESI) m/z 414[M+H]⁺, 436 [M+Na]⁺; HRMS (ESI) calcd for C₂₁H₂₁N₃O₅F [M+H]⁺ 414.1465.found 414.1472; calcd for C₂₁H₂₀N₃O₅FNa [M+Na]⁺ 436.1285. found436.1299.

2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-3-(benzyloxy)-4H-chromen-4-one(Az5)

This compound (0.17 g, 32%) was obtained from3-(benzyloxy)-2-(4-hydroxyphenyl)-4H-chromen-4-one (1g) and2-(2-(2-chloroethoxy)ethoxy)ethanol according to the general procedure(i) and (ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.29(t, J=4.88 Hz, 2H), 3.56-3.64 (m, 4H), 3.64-3.69 (m, 2H), 3.77-3.83 (m,2H), 4.06-4.12 (m, 2H), 5.05 (s, 2H), 6.89 (d, J=10.0 Hz, 2H), 7.17-7.24(m, 3H), 7.28 (t, J=7.50 Hz, 1H), 7.32-7.34 (m, 2H), 7.38 (d, J=8.30 Hz,1H), 7.50-7.55 (m, 1H), 7.95 (d, J=10.0 Hz, 2H), 8.18 (d, J=10.0 Hz,1H); ¹³C NMR (126 MHz, CHLOROFORM-d) δ ppm 50.22, 67.12, 69.19, 69.62,70.24, 70.42, 73.39, 113.94, 117.49, 122.92, 123.70, 124.10, 125.12,127.65, 127.80, 128.33, 130.01, 132.79, 136.43, 138.83, 154.63, 155.63,160.27, 174.31; LRMS (ESI) m/z 502 [M+H]⁺, 524 [M+Na]⁺; HRMS (ESI) calcdfor C₂₈H₂₈N₃O₆ [M+H]⁺ 502.1978. found 502.1989; calcd for C₂₈H₂₇N₃O₆Na[M+Na]⁺ 524.1798. found 524.1797.

2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-6,8-dichloro-4H-chromen-4-one(Az6)

This compound (0.25 g, 34%) was obtained from6,8-dichloro-2-(4-hydroxyphenyl)-4H-chromen-4-one (1h) and2-(2-(2-chloroethoxy)ethoxy)ethanol according to the general procedure(i) and (ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.39(t, J=5.0 Hz, 2H), 3.67-3.73 (m, 4H), 3.74-3.78 (m, 2H), 3.92 (t, J=5.0Hz, 2H), 4.23 (t, J=5.0 Hz, 2H), 6.77 (s, 1H), 7.06 (d, J=9.0 Hz, 2H),7.72 (dd, J=2.44, 0.98 Hz, 1H), 7.93 (d, J=9.0 Hz, 2H), 8.09 (d, J=2.44,1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.73, 67.78, 69.65, 70.14,70.79, 70.97, 105.80, 115.31, 123.33, 123.91, 124.34, 125.78, 128.23,130.72, 133.56, 150.45, 162.17, 163.51, 176.35; LRMS (ESI) m/z 464[M+11]⁺, 486 [M+Na]⁺; HRMS (ESI) calcd for C₂₁H₂₀N₃O₅Cl₂ [M+H]⁺464.0780. found 464.0783; calcd for C₂₁H₁₉N₃O₅NaCl₂ [M+Na]⁺ 486.0599.found 486.0598.

2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-6-fluoro-4H-chromen-4-one (Az7)

This compound (0.18 g, 37%) was obtained from6-fluoro-2-(4-hydroxyphenyl)-4H-chromen-4-one (10 and2-(2-chloroethoxy)ethanol according to the general procedure (i) and(ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.42 (t,J=4.88 Hz, 2H), 3.73-3.79 (m, 2H), 3.88-3.93 (m, 2H), 4.19-4.24 (m, 2H),6.71 (s, 1H), 7.03 (d, J=9.0, 2H), 7.35-7.42 (m, 1H), 7.54 (dd, J=9.03,4.15 Hz, 1H), 7.81-7.88 (m, 3H); ¹³C NMR (126 MHz, CHLOROFORM-d) δ ppm50.47, 67.43, 69.31, 70.09, 105.10, 110.22 (d, J=23.75 Hz, C5), 114.85,119.84 (d, J=8.25 Hz, C8), 121.37 (d, J=25.13 Hz, C7), 123.53, 124.83(d, J=7.83 Hz, C10), 127.72, 152.04, 159.27 (d, J=244.88 Hz, C6),161.48, 163.29, 177.07, 177.09; LRMS (ESI) m/z 370 [M+H]⁺; HRMS (ESI)calcd for C₁₉H₁₇N₃O₄F [M+H]⁺ 370.1203. found 370.1218.

Methyl3-(((2-(4-(2-(2-azidoethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate(Az8)

A round-bottom flask was charged with3-(benzyloxy)-2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-4H-chromen-4-one(5a) (5 mmol, 2.2 g), a catalytic amount of Pd(OH)₂ and THF/MeOH (1:1-10ml). The reaction mixture was stirred vigorously under H₂ atmosphere atballoon pressure and room temperature for 14 h. When TLC indicatedcomplete consumption of the starting material, the charcoal was removedby suction filtration. The pale-yellow filtrate was purified by passingthrough a short pad of silica gel to furnish debenzylated product3-hydroxy-2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-4H-chromen-4-one (6a)(76%, 1.3 g). To a round-bottom flask was charged with the debenzylatedproduct 6a, methyl 3-(bromomethyl)benzoate (4 mmol, 0.92 g), K₂CO₃ (4mmol, 0.55 g) and acetone (10 ml). The reaction mixture was stirred atrefluxing temperature for 12 h. When TLC indicated complete consumptionof starting material, Solvent was rotary evaporated to dryness.Purification was performed by flash column chromatography on silica gelwith acetone in DCM as eluent to furnish methyl3-(((2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate(7a) (86%, 1.6 g). The titled compound Az8 (0.29 g, 57%) was obtainedfrom 7a (1 mmol) according to the general procedure (ii) describedabove. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.44 (t, J=4.88 Hz, 2H),3.76-3.79 (m, 2H), 3.89 (s, 3H), 3.90-3.94 (m, 2H), 4.20-4.25 (m, 2H),5.15 (s, 2H), 6.99 (d, J=8.79 Hz, 2H), 7.35 (t, J=7.81 Hz, 1H), 7.41 (t,J=7.57 Hz, 1H), 7.52 (d, J=8.30 Hz, 1H), 7.59 (d, J=7.32 Hz, 1H),7.65-7.71 (m, 1H), 7.93 (d, J=7.81 Hz, 1H), 7.96-8.01 (m, 3H), 8.29 (dd,J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.73,52.03, 67.52, 69.64, 70.31, 73.36, 114.41, 117.93, 123.46, 124.19,124.65, 125.77, 128.29, 129.27, 129.81, 130.13, 130.54, 133.24, 133.30,137.18, 139.07, 155.22, 156.51, 160.62, 166.82, 174.87; LRMS (ESI) m/z516 [M+H]⁺, 538 [M+Na]⁺; HRMS (ESI) calcd for C₂₈H₂₆N₃O₇ [M+H]⁺516.1771. found 516.1783; calcd for C₂₈H₂₄N₃O₇Na [M+Na]⁺ 538.1590. found538.1583.

Methyl3-(((2-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate(Az9)

The titled compound Az9 (0.62 g, 37%) was obtained from3-(benzyloxy)-2-(4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(5b) (3 mmol, 1.5 g) according to the procedure for the synthesis of Az8described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.40 (t, J=4.39Hz, 2H), 3.67-3.74 (m, 5H), 3.74-3.79 (m, 2H), 3.89 (s, 3H), 3.92 (t,J=4.15 Hz, 2H), 4.22 (t, J=4.15 Hz, 2H), 5.15 (s, 2H), 6.98 (d, J=8.79Hz, 2H), 7.35 (t, J=7.81 Hz, 1H), 7.42 (t, J=7.57 Hz, 1H), 7.52 (d,J=8.79 Hz, 1H), 7.59 (d, J=6.34 Hz, 1H), 7.65-7.70 (m, 1H), 7.93 (d,J=7.50 Hz, 1H), 7.96-8.01 (m, 3H), 8.29 (d, J=8.30 Hz, 1H); ¹³C NMR (101MHz, CHLOROFORM-d) δ ppm 50.71, 52.04, 67.55, 69.71, 70.12, 70.78,70.94, 73.35, 114.41, 117.92, 123.36, 124.20, 124.64, 125.78, 128.29,129.28, 129.80, 130.14, 130.52, 133.23, 133.30, 137.19, 139.07, 155.23,156.53, 160.73 166.82, 174.87; LRMS (ESI) m/z 560 [M+H]⁺, 582 [M+Na]⁺;HRMS (ESI) calcd for C₃₀H₃₀N₃O₈ [M+H]⁺ 560.2033. found 560.2028; calcdfor C₃₀H₂₉N₃O₈Na [M+Na]⁺ 582.1852. found 582.1831.

2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-3-(benzyloxy)-4H-chromen-4-one(Az10)

This compound (0.23 g, 31%) was obtained from3-(benzyloxy)-2-(4-hydroxyphenyl)-4H-chromen-4-one (1g) and2-(2-chloroethoxy)ethanol according to the general procedure (i) and(ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.43-3.45 (m,2H), 3.77-3.79 (m, 2H), 3.91-3.93 (m, 2H), 4.22-4.24 (m, 2H), 5.12 (s,2H), 6.99 (d, J=8.79 Hz, 2H), 7.26-7.28 (m, 3H), 7.34-7.44 (m, 3H), 7.52(d, J=8.30 Hz, 1H), 7.67 (t, J=7.81 Hz, 1H), 8.04 (d, J=8.79 Hz, 2H),8.29 (d, J=7.81 Hz, 1H); ¹³C NMR (126 MHz, CHLOROFORM-d) δ ppm 50.49,67.34, 69.39, 70.09, 73.70, 114.18, 117.72, 123.34, 123.97, 124.36,125.45, 127.88, 128.03, 128.60, 130.31, 133.03, 136.62, 139.10, 154.93,155.97, 160.39, 174.68; LRMS (ESI) m/z 458 [M+H]⁺, 480 [M+Na]⁺; HRMS(ESI) calcd for C₂₆H₂₄N₃O₅ [M+H]⁺ 458.1716. found 458.1738; calcd forC₂₆H₂₃N₃O₅Na [M+Na]⁺ 480.1535. found 480.1527.

7-(2-(2-Azidoethoxy)ethoxy)-2-phenyl-4H-chromen-4-one (Az11)

This compound (0.12 g, 32%) was obtained from7-hydroxy-2-phenyl-4H-chromen-4-one (1e) and 2-(2-chloroethoxy)ethanolaccording to the general procedure (i) and (ii) described above. ¹H NMR(500 MHz, CHLOROFORM-d) δ ppm 3.43 (t, J=5.0 Hz, 2H), 3.78 (t, J=5.0 Hz,2H), 3.93 (t, J=5.0 Hz, 2H), 4.27 (t, J=5.0 Hz, 2H), 6.79 (s, 1H),6.99-7.04 (m, 2H), 7.49-7.56 (m, 3H), 7.88-7.93 (m, 2H), 8.14 (d, J=8.30Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.32, 67.68, 69.00,69.98, 100.79, 106.92, 114.37, 117.52, 125.69, 126.49, 128.60, 131.06,131.27, 157.39, 162.50, 162.87, 177.25; LRMS (ESI) m/z 352 [M+H]⁺; HRMS(ESI) calcd for C₁₉H₁₈N₃O₄ [M+H]⁺ 352.1297. found 352.1288.

7-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)-2-phenyl-4H-chromen-4-one (Az12)

This compound (0.14 g, 38%) was obtained from7-hydroxy-2-phenyl-4H-chromen-4-one (1e) and2-(2-(2-chloroethoxy)ethoxy)ethanol according to the general procedure(i) and (ii) described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 3.39(t, J=4.88 Hz, 2H), 3.67-3.72 (m, 4H), 3.75-3.78 (m, 2H), 3.93-3.95 (m,2H), 4.26 (t, J=5.0 Hz, 2H), 6.77 (s, 1H), 6.98-7.04 (m, 2H), 7.49-7.56(m, 3H), 7.88-7.93 (m, 2H), 8.13 (d, J=8.78 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 50.53, 67.95, 69.33, 69.96, 70.59, 70.79, 101.00,107.28, 114.64, 117.73, 125.97, 126.80, 128.83, 131.25, 131.61, 157.70,162.86, 163.22, 177.63; LRMS (ESI) m/z 396 [M+H]⁺; HRMS (ESI) calcd forC₂₁H₂₂N₃O₅ [M+H]⁺ 396.1559. found 396.1544.

7-(2-Azidoethoxy)-2-phenyl-4H-chromen-4-one (Az13)

This compound (0.11 g, 29%) was obtained from7-hydroxy-2-phenyl-4H-chromen-4-one (1e) and 2-bromoethanol according tothe general procedure (i) and (ii) described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.68 (t, J=4.88 Hz, 2H), 4.26 (t, J=4.64 Hz, 2H),6.74-6.80 (m, 1H), 6.96-7.05 (m, 2H), 7.47-7.56 (m, 3H), 7.85-7.93 (m,2H), 8.11-8.19 (m, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 49.91,67.48, 101.38, 107.52, 114.37, 118.30, 126.15, 127.31, 129.0, 131.47,131.74, 157.80, 162.64, 163.15, 177.70; LRMS (ESI) m/z 308 [M+H]⁺; HRMS(ESI) calcd for C₁₇H₁₄N₃O₃ [M+H]⁺ 308.1035. found 308.1037.

2-(4-(2-((2-Azidoethyl)(benzyl)amino)ethoxy)phenyl)-4H-chromen-4-one(Az14)

To a well stirred solution of 4′-hydroxyflavones 1a (3 mmol, 0.71 g),N-benzyl-N,N-di(2-hydroxyethyl)amine (3 mmol, 0.6 g) and PPh₃ (3 mmol,0.79 g) in THF (20 ml) at room temperature was added DIAD (3 mmol, 0.59ml) dropwise. The reaction mixture was then stirred for 12 h at roomtemperature. When TLC indicated complete consumption of startingmaterial, the reaction mixture was evaporated to give a brown crudereaction mixture. Purification was performed by flash columnchromatography on silica gel with acetone in DCM (1:10) as eluent tofurnish intermediate compound2-(4-(2-(benzyl(2-hydroxyethyl)amino)ethoxy)phenyl)-4H-chromen-4-one(0.13 g, 10.4%). The titled compound Az14 (64.9 mg, 47%) was obtainedfrom the intermediate compound according to the general procedure (ii)described above. ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.91 (br. s., 2H),3.03 (br. s., 2H), 3.32 (br. s., 2H), 3.80 (br. s., 2H), 4.15 (br. s.,2H), 6.77 (s, 1H), 6.92-6.96 (m, 2H), 7.27-7.37 (m, 5H), 7.49-7.56 (m,3H), 7.89-7.93 (m, 2H), 8.13 (d, J=8.30 Hz, 1H); LRMS (ESI) m/z 441[M+H]⁺; HRMS (ESI) calcd for C₂₆H₂₅N₄O₃ [M+H]⁺ 441.1927. found 441.1909.

7-(2-((2-Azidoethyl)(benzyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Az15)

The titled compound Az15 (96 mg, 42%) was obtained from 7-hydroxyflavone1e according to the procedure for the synthesis of Ac14 described above.¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.90 (br. s., 2H), 3.00 (br. s.,2H), 3.32 (br. s., 2H), 3.79 (s, 2H), 4.11 (br. s., 2H), 6.75 (s, 1H),6.98 (m, J=8.79 Hz, 2H), 7.26-7.44 (m, 6H), 7.54-7.58 (m, 1H), 7.66-7.71(m, 1H), 7.84-7.91 (m, 2H), 8.23 (dd, J=7.81, 1.46 Hz, 1H); LRMS (ESI)m/z 441 [M+H]⁺; HRMS (ESI) calcd for C₂₆H₂₅N₄O₃ [M+H]⁺ 441.1927. found441.1908. Synthesis of anti-triazole bridged flavonoid dimers (Scheme 3and Table 1)

General Procedure for the Synthesis of Anti-Triazole Bridged FlavonoidDimers Catalyzed by Cu(I)

The Cu(PPh₃)₃Br catalyst (MW=929) (0.05 mmol), prepared according toliterature⁶⁶, was added to a THF solution (2 mL) containing the azide(Az 0.1 mmol) and the alkyne (Ac, 0.1 mmol). For Ac14- or Ac15, 0.2 mmolof azide was added. For Ac17, 0.3 mmol of azide was added. The reactionmixture was stirred overnight under reflux condition. Solvent wasremoved by evaporation and the resulting crude mixture showed theproduct to be only the anti-regioisomer except Ac13Az4 (anti:syn=97:3)and Ac13Az7 (anti:syn=85:15). The crude residue was purified by flashchromatography on silica gel using gradient of 10-50% of acetone withCH₂Cl₂ to afford the desired compound.

2-(4-(3-(1-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one(Ac1Az1)

This compound (90 mg) was obtained from Ac1 and Az1 in 81% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.08 (t, J=6.40 Hz, 2H), 2.82 (t, J=6.40 Hz, 2H),3.75 (t, J=6.40 Hz, 2H), 3.87-3.96 (m, 4H), 4.04 (t, J=6.40 Hz, 2H),4.50 (t, J=6.40 Hz, 2H), 6.57 (s, 1H), 6.60 (s, 1H), 6.85 (d, J=8.40 Hz,2H), 6.89 (d, J=8.40 Hz, 2H), 7.25-7.28 (m, 2H), 7.39 (dd, J=7.20, 7.20Hz, 2H), 7.48 (s, 1H), 7.55-7.56 (m, 2H), 7.69 (d, J=8.40 Hz, 2H), 7.74(d, J=8.40 Hz, 2H), 8.08 (dd, J=7.20, 7.20 Hz, 2H); ¹³C NMR (100 MHz,CHLOROFORM-d) δ ppm 21.99, 28.66, 50.05, 67.07, 67.32, 69.40, 69.71,105.81, 105.98, 114.72, 114.80, 117.86, 117.89, 122.16, 123.58, 123.70,124.08, 124.98, 125.37, 127.80, 127.87, 133.49, 146.81, 155.93, 161.27,161.66, 162.96, 163.16, 178.09, 178.14; LRMS (ESI) m/z 656 [M+H]⁺; HRMS(ESI) calcd for C₃₉H₃₄N₃O₇ [M+H]⁺ 656.2397. found 656.2394.

7-(3-(1-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)-2-phenyl-4H-chromen-4-one(Ac2Az1)

This compound (82 mg) was obtained from Ac1 and Az1 in 85% yield yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.13 (t, J=6.40 Hz, 2H), 2.84 (t, J=6.40 Hz, 2H),3.76 (t, J=6.40 Hz, 2H), 3.89 (t, J=6.40 Hz, 2H), 3.99-4.06 (m, 4H),4.51 (t, J=6.40 Hz, 2H), 6.61 (s, 1H), 6.63 (s, 1H), 6.81-6.91 (m, 4H),7.28 (dd, J=7.20, 7.20 Hz, 1H), 7.38-7.42 (m, 4H), 7.49 (s, 1H), 7.50(dd, J=7.20, 7.20 Hz, 1H), 7.74-7.79 (m, 4H), 7.99 (d, J=7.20 Hz, 1H),8.01 (d, J=7.20 Hz, 1H); ¹³C NMR (100 MHz, CHLOROFORM-d) δ ppm 21.94,28.53, 50.08, 67.34, 67.55, 69.41, 69.71, 100.81, 106.00, 107.22,114.56, 114.81, 117.57, 117.84, 122.16, 123.70, 124.13, 125.01, 125.36,125.99, 126.78, 127.89, 128.90, 131.34, 131.57, 133.53, 146.69, 155.95,157.76, 161.26, 162.80, 162.98, 163.39, 177.64, 178.12; LRMS (ESI) m/z656 [M+H]⁺; HRMS (ESI) calcd for C₃₉H₃₄N₃O₇ [M+H]⁺ 656.2397. found656.2401.

7-Fluoro-2-(4-(3-(1-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one(Ac3Az1)

This compound (92 mg) was obtained from Ac3 and Az1 in 91% yield yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.09 (t, J=6.40 Hz, 2H), 2.82 (t, J=6.40 Hz, 2H),3.76 (t, J=4.80 Hz, 2H), 3.89 (t, J=4.80 Hz, 2H), 3.95 (t, J=6.40 Hz,2H), 4.05 (t, J=6.40 Hz, 2H), 4.51 (t, J=6.40 Hz, 2H), 6.53 (s, 1H),6.59 (s, 1H), 6.84 (d, J=8.20 Hz, 2H), 6.89 (d, J=8.20 Hz, 2H),6.98-7.02 (m, 2H), 7.25-7.27 (m, 2H), 7.48 (d, J=7.40 Hz, 1H), 7.48 (s,1H), 7.55 (dd, J=7.20, 7.20 Hz, 1H), 7.65 (d, J=8.20 Hz, 2H), 7.74 (d,J=8.20 Hz, 2H), 8.06-8.09 (m, 2H); ¹³C NMR (100 MHz, CHLOROFORM-d) δ ppm21.98, 28.66, 50.05, 67.12, 67.33, 69.40, 69.71, 105.77, 105.98, 114.77,114.79, 117.84, 120.57, 122.13, 123.17, 123.70, 124.09, 124.98, 125.37,127.75, 127.86, 133.50, 146.80, 155.93, 156.82, 156.95, 161.27, 161.78,162.93, 163.44, 164.14, 166.67, 177.10, 178.05; LRMS (ESI) m/z 674[M+H]⁺; HRMS (ESI) calcd for C₃₉H₃₃N₃O₇ [M+H]⁺ 674.2303. found 674.2309.

5-(Benzyloxy)-7-(methoxymethoxy)-2-(4-(3-(1-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one(Ac4Az1)

This compound (120 mg) was obtained from Ac4 and Az1 in 85% yield yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.09 (t, J=6.40 Hz, 2H), 2.83 (t, J=6.40 Hz, 2H),3.44 (s, 3H), 3.75 (t, J=6.40 Hz, 2H), 3.88 (t, J=6.40 Hz, 2H), 3.96 (t,J=6.40 Hz, 2H), 4.04 (t, J=6.40 Hz, 2H), 4.49 (t, J=6.40 Hz, 2H), 5.16(s, 2H), 5.17 (s, 2H), 6.43 (d, J=2.00 Hz, 1H), 6.46 (s, 1H), 6.63 (s,1H), 6.68 (d, J=2.00 Hz, 1H), 6.86 (d, J=8.20 Hz, 2H), 6.92 (d, J=8.20Hz, 2H), 7.24-7.35 (m, 5H), 7.46 (s, 1H), 7.58-7.67 (m, 5H), 7.78 (d,J=7.40 Hz, 2H), 8.13 (t, J=7.40 Hz, 2H); ¹³C NMR (100 MHz, CHLOROFORM-d)δ ppm 22.00, 28.67, 50.05, 56.37, 67.03, 67.33, 69.40, 69.72, 70.59,94.27, 95.95, 98.64, 106.02, 107.34, 110.07, 114.63, 114.83, 117.88,122.16, 123.48, 123.74, 124.15, 125.00, 126.57, 127.52, 127.90, 128.47,133.53, 136.42, 146.82, 155.98, 159.29, 159.47, 160.58, 161.18, 161.28,161.33, 163.00, 177.23, 178.13; LRMS (ESI) m/z 822 [M+H]⁺; HRMS (ESI)calcd for C₄₈H₄₄N₃O₁₀ [M+H]¹ 822.3027. found 822.3034.

5-Hydroxy-7-(methoxymethoxy)-2-(4-(3-(1-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one(Ac4Az1(5OH))

A round-bottom flask was charged with compound Ac4Az1 (25 mg, 0.03mmol), a catalytic amount of Pd (20 mg, 10% on activated charcoal) andMeOH (20 mL). The reaction mixture was stirred vigorously under H₂atmosphere at balloon pressure and room temperature for 14 h. When TLCindicated complete consumption of the starting material, the charcoalwas removed by suction filtration. The pale-yellow filtrate was purifiedby passing through a short pad of silica gel to furnish the titledproduct (18 mg, 82%) as a white foam: ¹H NMR (400 MHz, CHLOROFORM-d) δppm 2.12 (t, J=4.80 Hz, 2H), 2.85 (t, J=4.80 Hz, 2H), 3.46 (s, 3H), 3.79(t, J=4.80 Hz, 2H), 3.91-3.98 (m, 4H), 4.09 (t, J=4.80 Hz, 2H), 4.52 (t,J=4.80 Hz, 2H), 5.19 (s, 2H), 6.38 (d, J=2.00 Hz, 1H), 6.44 (s, 1H),6.57 (d, J=1.60 Hz, 1H), 6.65 (s, 1H), 6.85-6.94 (m, 4H), 7.26-7.48 (m,3H), 7.66-7.79 (m, 5H), 8.11 (d, J=6.40 Hz, 1H), 12.71 (s, 1H); ¹³C NMR(100 MHz, CHLOROFORM-d) δ ppm 21.99, 28.67, 50.08, 56.37, 67.13, 67.35,69.44, 69.74, 94.15, 94.22, 99.90, 104.02, 106.02, 106.05, 114.77,114.84, 117.85, 122.15, 123.10, 123.75, 124.19, 125.01, 125.47, 127.88,133.53, 146.81, 156.00, 157.35, 161.29, 161.84, 161.90, 162.78, 162.99,163.89, 178.14, 182.30; LRMS (ESI) m/z 732 [M+H]⁺; HRMS (ESI) calcd forC₄₁H₃₈N₃O₁₀ [M+H]⁺ 732.2557. found 732.2563.

6-Methyl-2-(4-(4-(1-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-4H-chromen-4-one (Ac5Az1)

This compound (52 mg) was obtained from Ac5 and Az1 in 76% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) 6 ppm 1.82 (br. s., 4H), 2.39 (s, 3H), 2.71-2.77 (m, 2H),3.77-3.82 (m, 2H), 3.89-3.97 (m, 4H), 4.08-4.14 (m, 2H), 4.52 (t, J=5.12Hz, 2H), 6.61 (s, 1H), 6.65 (s, 1H), 6.87 (d, J=10.0 Hz, 2H), 6.94 (d,J=10.0 Hz, 2H), 7.31 (t, J=10.0 Hz, 1H), 7.35 (d, J=8.79 Hz, 1H), 7.41(dd, J=8.54, 2.20 Hz, 1H), 7.44 (d, J=8.30 Hz, 1H), 7.47 (s, 1H), 7.59(t, J=7.5 Hz, 1H), 7.73 (d, J=10.0 Hz, 2H), 7.78 (d, J=10.0 Hz, 2H),7.91 (s, 1H), 8.11 (dd, J=5.0 Hz, 1H); ¹³C NMR (126 MHz, CHLOROFORM-d) δppm 20.77, 25.21, 25.75, 28.50, 49.97, 67.35, 67.68, 69.40, 69.71,105.71, 106.05, 114.66, 114.82, 117.57, 117.76, 121.81, 123.38, 123.72,124.19, 124.77, 124.91, 125.42, 127.70, 127.81, 133.41, 134.56, 134.79,147.46, 154.23, 155.93, 161.24, 161.60, 162.91, 163.00, 178.00, 178.18;LRMS (ESI) m/z 684 [M+H]⁺; HRMS (ESI) calcd for C₄₁H₃₈N₃O₇ [M+H]⁺684.2710. found 684.2727.

6-Methyl-2-(4-(4-(1-(2-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-4H-chromen-4-one(Ac5Az2)

This compound (63 mg) was obtained from Ac5 and Az2 in 86% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.86 (br. s., 3H), 2.42-2.47 (m, 2H), 2.78 (br. s.,1H), 3.63-3.66 (m, 2H), 3.68-3.72 (m, 2H), 3.86 (dt, J=17.81, 4.76 Hz,4H), 3.99-4.03 (m, 1H), 4.15-4.19 (m, 2H), 4.52 (t, J=5.12 Hz, 1H), 6.68(s, 1H), 6.71 (s, 1H), 6.94 (d, J=8.79 Hz, 2H), 7.00 (d, J=8.79 Hz, 2H),7.34-7.40 (m, 1H), 7.40-7.43 (m, 1H), 7.44-7.48 (m, 1H), 7.48-7.53 (m,2H), 7.63-7.68 (m, 1H), 7.80 (d, J=8.79 Hz, 2H), 7.85 (d, J=9.27 Hz,2H), 7.97 (s, 1H), 8.19 (dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.73, 25.18, 25.77, 28.48, 49.94, 67.44, 67.65,69.35, 69.44, 70.36, 70.45, 70.55, 71.15, 105.66, 105.93, 114.63,114.80, 117.52, 117.76, 121.80, 123.35, 123.66, 123.70, 123.99, 124.73,124.87, 125.36, 127.68, 127.76, 133.38, 134.55, 134.77, 147.38, 154.19,155.91, 161.33, 161.57, 162.97, 163.00, 178.16; LRMS (ESI) m/z 728[M+H]⁺, 750 [M+Na]⁺; HRMS (ESI) calcd for C₄₃H₄₂N₃O₈ [M+H]⁺ 728.2972.found 728.2955; calcd for C₄₃H₄₁N₃O₈Na [M+Na]⁺ 750.2791. found 750.2815.

6-Methyl-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az3)

This compound (68 mg) was obtained from Ac5 and Az3 in 92% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.85-1.87 (m, 4H), 2.45 (s, 3H), 2.43 (s, 3H),2.77-2.79 (m, 2H), 3.63-3.67 (m, 2H), 3.67-3.72 (m, 2H), 3.85 (t, J=4.39Hz, 2H), 3.88 (t, J=4.88 Hz, 2H), 3.99-4.03 (m, 2H), 4.17 (t, J=4.64 Hz,2H), 4.52 (t, J=4.88 Hz, 2H), 6.69 (s, 1H), 6.70 (s, 1H), 6.94 (d,J=8.79 Hz, 2H), 7.00 (m, J=7.81 Hz, 2H), 7.41 (t, J=9.03 Hz, 2H), 7.47(t, J=8.79 Hz, 2H), 7.51 (s, 1H), 7.84 (d, J=8.79 Hz, 2H), 7.81 (d,J=8.79 Hz, 2H), 7.97 (s, 1H), 7.97 (s, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.85, 25.32, 25.91, 28.61, 29.24, 50.06, 67.56,67.77, 69.50, 69.58, 70.50, 70.69, 105.88, 106.04, 114.76, 114.89,117.61, 117.64, 121.87, 123.54, 123.87, 124.36, 124.92, 127.81, 127.86,134.66, 134.70, 134.90, 134.96, 154.36, 161.36, 161.69, 162.95, 163.13;LRMS (ESI) m/z 742 [M+H]⁺; HRMS (ESI) calcd for C₄₄H₄₄N₃O₈ [M+H]⁺742.3128. found 742.3103.

6-Fluoro-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az4)

This compound (59 mg) was obtained from Ac5 and Az4 in 79% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.84-1.89 (m, 4H), 2.44 (s, 3H), 2.75-2.81 (m, 2H),3.62-3.67 (m, 2H), 3.67-3.72 (m, 2H), 3.82-3.86 (m, 2H), 3.88 (t, J=5.12Hz, 2H), 3.99-4.04 (m, 2H), 4.13-4.18 (m, 2H), 4.52 (t, J=5.12 Hz, 2H),6.69 (s, 1H), 6.69 (s, 1H), 6.94 (d, J=10 Hz, 2H), 6.70 (d, J=10 Hz,2H), 7.37 (ddd, J=9.15, 7.69, 3.17 Hz, 1H), 7.41 (d, J=8.30 Hz, 1H),7.47 (dd, J=8.54, 2.20 Hz, 1H), 7.49-7.53 (m, 2H), 7.78-7.85 (m, 5H),7.97 (s, 1H); ¹³C NMR (126 MHz, CHLOROFORM-d) δ ppm 20.73, 25.20, 25.79,28.49, 49.95, 67.47, 67.67, 69.35, 69.45, 70.38, 70.58, 105.21, 105.65,110.29 (d, J=23.38 Hz, C5), 114.63, 114.84, 117.51, 119.85 (d, J=7.75Hz, C8), 121.41 (d, J=25.63 Hz, C7), 121.76, 123.33, 123.67, 124.73,124.88 (d, J=7.38 Hz, C10), 127.66, 127.78, 134.53, 134.77, 147.37,152.07, 154.17, 159.31 (d, J=244.88 Hz, C6), 161.49, 161.57, 162.94,163.22, 177.12, 178.12; LRMS (ESI) m/z 746 [M+H]⁺, 768 [M+Na]⁺; HRMS(ESI) calcd for C₄₃H₄₀N₃O₈F [M+H]⁺ 746.2878. found 746.2845; calcd forC₄₃H₄₀N₃O₈FNa [M+Na]⁺ 768.2697. found 768.2685.

3-(Benzyloxy)-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az5)

This compound (56 mg) was obtained from Ac5 and Az5 in 63% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.81 (br. s., 4H), 2.38 (s, 3H), 2.74 (br. s., 2H),3.59-3.63 (m, 2H), 3.78-3.82 (m, 2H), 3.84 (t, J=5.07 Hz, 2H), 3.91-3.97(m, 2H), 4.09-4.15 (m, 2H), 4.48 (t, J=4.88 Hz, 2H), 5.07 (s, 2H), 6.62(s, 1H), 6.85-6.93 (m, 4H), 7.20-7.26 (m, 3H), 7.28-7.37 (m, 4H),7.38-7.44 (m, 2H), 7.50 (br. s., 1H), 7.58 (ddd, J=8.59, 7.03, 1.56 Hz,1H), 7.70-7.77 (m, 2H), 7.91 (br. s., 1H), 7.98 (d, J=8.0, 2H), 8.19(dd, J=8.20, 1.56 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 20.74,25.21, 25.76, 28.49, 49.98, 67.36, 67.66, 69.44, 70.38, 70.56, 73.70,105.70, 114.14, 114.66, 117.54, 117.71, 121.80, 123.37, 123.40, 123.70,123.97, 124.40, 124.75, 125.48, 127.69, 127.91, 128.06, 128.60, 130.34,133.08, 134.54, 134.76, 136.65, 139.14, 154.21, 154.93, 155.81, 160.39,161.58, 163.01, 174.69, 178.18; LRMS (ESI) m/z 834 [M+H]⁺, 856 [M+Na]⁺;HRMS (ESI) calcd for C₅₀H₄₈N₃O₉ [M+H]⁺834.3391. found 834.3367; calcdfor C₅₀H₄₇N₃O₉Na [M+Na]⁺ 856.3210. found 856.3195.

3-Hydroxy-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az5(OH))

A round-bottom flask was charged with compound Ac5Az5 (15 mg, 0.02mmol), a catalytic amount of Pd (10 mg, 10% on activated charcoal), andMeOH (10 mL). The reaction mixture was stirred vigorously under H₂atmosphere at balloon pressure and room temperature for 14 h. When TLCindicated complete consumption of the starting material, the charcoalwas removed by suction filtration. The pale-yellow filtrate was purifiedby passing through a short pad of silica gel to furnish the titledproduct (12 mg, 92%): ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.81-1.89 (m,4H), 2.43 (s, 3H), 2.76-2.78 (m, 2H), 3.62-3.67 (m, 2H), 3.67-3.73 (m,2H), 3.83-3.86 (m, 2H), 3.87 (t, J=5.12 Hz, 2H), 3.96-4.01 (m, 2H),4.15-4.20 (m, 2H), 4.52 (t, J=5.12 Hz, 2H), 6.67 (s, 1H), 6.92 (d, J=10Hz, 2H), 7.02-7.00 (m, 3H), 7.36 (t, J=7.57 Hz, 1H), 7.40 (d, J=8.30 Hz,1H), 7.45 (dd, J=8.30, 1.95 Hz, 1H), 7.50-7.55 (m, 2H), 7.65 (t, J=8.30,1H), 7.78 (d, J=10 Hz, 2H), 7.97 (s, 1H), 8.16-8.24 (m, 3H); ¹³C NMR(101 MHz, CHLOROFORM-d) δ ppm 20.89, 25.35, 25.94, 28.65, 50.10, 67.49,67.82, 69.61, 70.55, 70.72, 105.92, 114.60, 114.78, 117.66, 118.09,120.65, 121.91, 123.55, 123.84, 123.91, 124.36, 124.98, 125.34, 127.84,129.47, 133.33, 134.67, 134.94, 137.65, 144.98, 147.56, 154.40, 155.20,160.13, 161.73, 163.18, 173.06, 178.40; LRMS (ESI) m/z 744 [M+H]⁺, 766[M+Na]⁺; HRMS (ESI) calcd for C₄₃H₄₂N₃O₉ [M+H]⁺ 744.2921. found744.2892; calcd for C₄₃H₄₁N₃O₉Na [M+Na]⁺ 766.2741. found 766.2736.

6,8-Dichloro-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az6)

This compound (46 mg) was obtained from Ac5 and Az6 in 58% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.86 (br. s., 4H), 2.46 (s, 3H), 2.75-2.80 (m, 2H),3.62-3.67 (m, 2H), 3.70 (d, J=2.44 Hz, 2H), 3.84-3.86 (m, 2H), 3.89 (t,J=4.88 Hz, 2H), 4.00 (br. s., 2H), 4.17-4.19 (m, 2H), 4.53 (t, J=4.88Hz, 2H), 6.69 (s, 1H), 6.73 (s, 1H), 6.93 (d, J=10 Hz, 2H), 7.02 (d,J=10 Hz, 2H), 7.42 (d, J=8.30 Hz, 1H), 7.47 (d, J=8.79 Hz, 1H), 7.51 (s,1H), 7.79-7.81 (d, J=10 Hz, 2H), 7.88-7.90 (d, J=10 Hz, 2H), 7.98 (s,1H), 8.01-8.05 (m, 1H); LRMS (ESI) m/z 796 [M+H]⁺, 818 [M+Na]⁺; HRMS(ESI) calcd for C₄₃H₄₀N₃O₈Cl₂ [M+H]⁺ 796.2192. found 796.2206; calcd forC₄₃H₃₉N₃O₈NaCl₂ [M+Na]⁺ 818.2012. found 818.1998.

6-Fluoro-2-(4-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az7)

This compound (61 mg) was obtained from Ac5 and Az7 in 87% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.85 (br. s., 4H), 2.43 (s, 3H), 2.77 (br. s., 2H),3.81-3.85 (m, 2H), 3.94 (t, J=4.88 Hz, 2H), 3.99 (br. s., 2H), 4.11-4.16(m, 2H), 4.54 (t, J=4.88 Hz, 2H), 6.65 (s, 1H), 6.67 (s, 1H), 6.91 (d,J=8.79 Hz, 2H), 6.97 (d, J=8.79 Hz, 2H), 7.30-7.36 (m, 1H), 7.37-7.41(m, 1H), 7.43-7.50 (m, 3H), 7.74-7.82 (m, 5H), 7.95 (s, 1H); ¹³C NMR(126 MHz, CHLOROFORM-d) δ ppm 20.85, 25.28, 25.84, 28.57, 50.08, 67.44,67.77, 69.48, 69.81, 105.49, 105.85, 110.51 (d, J=23.75 Hz, C5) 114.76,114.94, 117.63, 119.89 (d, J=7.75 Hz, C8), 121.58 (d, J=25.75 Hz, C7),121.89, 123.47, 123.89, 124.05, 124.90, 125.02 (d, J=7.38 Hz, C10),127.80, 127.96, 134.66, 134.93, 147.60, 152.21, 152.22, 154.33, 159.47(d, J=245.25 Hz, C6), 161.46, 161.67, 163.09, 163.30, 177.27, 178.31;LRMS (ESI) m/z 702 [M+H]⁺; HRMS (ESI) calcd for C₄₂H₃₇N₃O₈F [M+H]⁺702.2503. found 702.2534.

Methyl3-(((2-(4-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate(Ac5Az8)

This compound (44 mg) was obtained from Ac5 and Az8 in 51% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.84 (br. s., 4H), 2.43 (s, 3H), 2.77 (br. s., 2H),3.82-3.84 (m, 2H), 3.86 (s, 3H), 3.94 (t, J=4.88 Hz, 2H), 3.98 (br. s.,2H), 4.11-4.17 (m, 2H), 4.54 (t, J=4.88 Hz, 2H), 5.13 (s, 2H), 6.65 (s,1H), 6.92 (t, J=8.30 Hz, 4H), 7.32-7.37 (m, 2H), 7.40 (d, J=5 Hz, 1H),7.45 (d, J=8.79 Hz, 2H), 7.50 (br. s., 1H), 7.58 (d, J=6.83 Hz, 1H),7.60-7.64 (m, 1H), 7.77 (d, J=8.30 Hz, 2H), 7.86-8.01 (m, 5H), 8.22 (d,J=7.81 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 20.86, 25.29,25.83, 28.58, 50.07, 51.98, 67.29, 67.76, 69.56, 69.79, 73.26, 105.86,114.25, 114.77, 117.65, 117.81, 121.88, 123.51, 123.86, 124.07, 124.61,124.91, 125.66, 127.81, 128.25, 129.20, 129.73, 130.07, 130.49, 133.15,133.29, 134.65, 134.90, 137.15, 139.03, 147.58, 154.35, 155.08, 156.15,160.40, 161.68, 163.13, 166.72, 174.72, 178.33; LRMS (ESI) m/z 848[M+H]⁺, 870 [M+Na]⁺; HRMS (ESI) calcd for C₅₀H₄₆N₃O₁₀ [M+H]⁺ 848.3183.found 848.3145; calcd for C₅₀H₄₅N₃O₁₀Na [M+Na]⁺ 870.3003. found870.2966.

Methyl3-(((2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate(Ac5Az9)

This compound (83 mg) was obtained from Ac5 and Az9 in 93% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.86 (br. s., 4H), 2.44 (s, 3H), 2.78 (br. s., 2H),3.62-3.67 (m, 2H), 3.68-3.72 (m, 2H), 3.81-3.90 (m, 7H), 4.01 (br. s.,2H), 4.17 (t, J=4.39 Hz, 2H), 4.52 (t, J=4.88 Hz, 2H), 5.14 (s, 2H),6.69 (s, 1H), 6.91-6.97 (m, 4H), 7.34 (t, J=7.81 Hz, 1H), 7.36-7.40 (m,1H), 7.42 (d, J=10 Hz, 1H), 7.44-7.50 (m, 2H), 7.51 (br. s., 1H), 7.60(d, J=5 Hz, 1H), 7.61-7.68 (m, 1H), 7.80-7.82 (d, J=10 Hz, 2H),7.87-8.02 (m, 5H), 8.25 (d, J=10, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δppm 20.76, 25.22, 25.79, 28.51, 29.17, 49.99, 51.91, 67.36, 67.69,69.45, 69.49, 70.41, 70.59, 73.15, 105.74, 114.20, 114.68, 117.56,117.77, 121.81, 123.26, 123.40, 123.74, 123.97, 124.50, 124.79, 125.53,127.72, 128.17, 129.12, 129.61, 129.99, 130.36, 133.05, 133.19, 134.56,134.80, 137.08, 138.92, 154.24, 154.99, 156.11, 160.46, 161.61, 163.04,166.63, 174.62, 178.20; LRMS (ESI) m/z 892 [M+H]⁺, 914 [M+Na]⁺; HRMS(ESI) calcd for C₅₂H₅₀N₃O₁₁ [M+H]⁺ 892.3445. found 892.3410; calcd forC₅₂H₄₉N₃O₁₁Na [M+Na]⁺ 914.3265. found 914.3301.

3-(Benzyloxy)-2-(4-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az10)

This compound (77 mg) was obtained from Ac5 and Az10 in 98% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.83 (br. s., 3H), 2.41 (s, 2H), 2.67-2.81 (m, 2H),3.78-3.85 (m, 2H), 3.89-3.98 (m, 4H), 4.09-4.17 (m, 2H), 4.53 (t, J=5.07Hz, 2H), 5.09 (s, 2H), 6.63 (s, 1H), 6.92 (d, J=9.37 Hz, 2H), 6.89 (d,J=8.98 Hz, 2H), 7.22-7.28 (m, 3H), 7.29-7.46 (m, 6H), 7.48 (s, 1H), 7.59(ddd, J=8.59, 7.03, 1.56 Hz, 1H), 7.75 (d, J=10 Hz, 2H), 7.95 (s, 1H),8.0 (d, J=10 Hz, 2H), 8.21 (d, J=10.0 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.84, 25.27, 25.81, 28.56, 50.05, 67.29, 67.73,69.53, 69.76, 73.81, 105.83, 114.20, 114.75, 117.63, 117.76, 121.89,123.47, 123.67, 123.82, 124.07, 124.51, 124.87, 125.62, 127.79, 128.01,128.15, 128.68, 130.46, 133.18, 134.63, 134.87, 136.74, 139.27, 147.55,154.32, 155.02, 155.81, 160.34, 161.66, 163.11, 174.78, 178.30; LRMS(ESI) m/z 790 [M+11]⁺, 812 [M+Na]⁺; HRMS (ESI) calcd for C₄₈H₄₄N₃O₈[M+H]⁺ 790.3128. found 790.3140; calcd for C₄₈H₄₃N₃O₈Na [M+Na]⁺812.2948. found 812.2961.

3-Hydroxy-2-(4-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac5Az10(OH))

A round-bottom flask was charged with compound Ac5Az10 (17 mg, 0.03mmol), a catalytic amount of Pd (15 mg, 10% on activated charcoal), andMeOH (10 mL). The reaction mixture was stirred vigorously under H₂atmosphere at balloon pressure and room temperature for 14 h. When TLCindicated complete consumption of the starting material, the charcoalwas removed by suction filtration. The pale-yellow filtrate was purifiedby passing through a short pad of silica gel to furnish the titledproduct (14 mg, 90%). ¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.82-1.87 (m,4H), 2.45 (s, 3H), 2.76-2.81 (m, 2H), 3.83-3.86 (m, 2H), 3.95 (t, J=5.0Hz, 2H), 3.97-4.01 (m, 2H), 4.17 (dd, J=5.12, 3.66 Hz, 2H), 4.55 (t,J=5.0 Hz, 2H), 6.67 (s, 1H), 6.92 (d, J=10.0 Hz, 2H), 6.97 (br. s., 1H),7.03 (d, J=10.0 Hz, 2H), 7.36 (t, J=7.32 Hz, 1H), 7.41 (d, J=8.30 Hz,1H), 7.47 (dd, J=8.30, 1.95 Hz, 1H), 7.50 (s, 1H), 7.51-7.54 (m, 1H),7.62-7.68 (m, 1H), 7.78 (d, J=8.79 Hz, 2H), 7.98 (s, 1H), 8.19 (d,J=7.81 Hz, 1H), 8.22 (d, J=9.27 Hz, 2H); ¹³C NMR (101 MHz, CHLOROFORM-d)δ ppm 20.92, 25.34, 25.88, 28.63, 50.15, 67.37, 67.83, 69.67, 69.88,105.94, 114.61, 114.81, 117.69, 118.08, 120.65, 121.99, 123.57, 123.93,124.00, 124.42, 125.02, 125.38, 127.85, 129.52, 133.39, 134.70, 134.97,137.67, 144.90, 147.66, 154.42, 155.23, 160.04, 161.75, 163.21, 173.08,178.43; LRMS (ESI) m/z 700 [M+H]⁺; HRMS (ESI) calcd for C₄₁H₃₈N₃O₈[M+H]⁺ 700.2659. found 700.2672.

6-Methyl-2-(4-(4-(1-(2-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-4H-chromen-4-one(Ac5Az11)

This compound (40 mg) was obtained from Ac5 and Az11 in 59% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.85 (br. s., 4H), 2.45 (s, 3H), 2.78 (br. s., 2H),3.84-3.88 (m, 2H), 3.95-4.01 (m, 4H), 4.17-4.21 (m, 2H), 4.55-4.75 (m,2H), 6.69 (s, 1H), 6.75 (s, 1H), 6.90-7.00 (m, 4H), 7.40-7.54 (m, 6H),7.81 (d, J=9.0 Hz, 2H), 7.83-7.90 (m, 2H), 7.97-8.00 (m, 1H), 8.13 (d,J=8.79 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 20.80, 25.20,25.74, 28.51, 50.10, 67.69, 67.75, 69.27, 69.74, 101.05, 105.74, 107.35,114.42, 114.70, 117.60, 117.96, 123.43, 123.75, 124.82, 125.96, 127.00,127.75, 128.88, 131.36, 131.54, 134.60, 134.83, 154.28, 157.71, 161.63,162.90, 162.98, 163.11, 177.50, 178.26; LRMS (ESI) m/z 684 [M+H]⁺; HRMS(ESI) calcd for C₄₁H₃₈N₃O₇ [M+H]⁺ 684.2710. found 684.2692.

6-Methyl-2-(4-(4-(1-(2-(2-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-4H-chromen-4-one(Ac5Az12)

This compound (33 mg) was obtained from Ac5 and Az12 in 46% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.83-1.89 (m, 4H), 2.45 (s, 3H), 2.76-2.81 (m, 2H),3.62-3.67 (m, 2H), 3.68-3.73 (m, 2H), 3.86-3.90 (m, 4H), 4.00-4.02 (m,2H), 4.19-4.24 (m, 2H), 4.52 (t, J=4.88 Hz, 2H), 6.70 (s, 1H), 6.74 (s,1H), 6.91-7.02 (m, 4H), 7.40-7.54 (m, 6H), 7.82 (d, J=9.0 Hz, 2H), 7.87(dd, J=7.57, 1.71 Hz, 2H), 7.99 (s, 1H), 8.13 (d, J=8.79 Hz, 1H); ¹³CNMR (101 MHz, CHLOROFORM-d) δ ppm 20.90, 25.21, 25.89, 28.62, 50.29,67.80, 68.07, 69.41, 69.55, 70.56, 70.78, 101.19, 105.94, 107.53,114.59, 114.84, 117.68, 118.04, 122.03, 123.54, 123.97, 125.00, 126.12,127.15, 127.91, 128.99, 131.44, 131.76, 134.73, 135.00, 154.44, 157.87,161.74, 163.06, 163.23, 163.27, 177.70, 178.44; LRMS (ESI) m/z 728[M+H]⁺; HRMS (ESI) calcd for C₄₃H₄₂N₃O₈ [M+H]⁺ 728.2972. found 728.3006.

2-(4-(4-(1-(2-(Benzyl(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethyl)amino)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-6-methyl-4H-chromen-4-one(Ac5Az14)

This compound (38 mg) was obtained from Ac5 and Az14 in 49% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.81 (br. s., 4H), 2.44 (s, 3H), 2.71 (br. s., 2H),2.97-3.00 (m, 2H), 3.11 (br. s., 2H), 3.76 (s, 2H), 3.89-4.03 (m, 4H),4.40 (br. s., 2H), 6.66 (s, 1H), 6.72 (s, 1H), 6.84-6.94 (m, 4H),7.20-7.32 (m, 5H), 7.33-7.53 (m, 6H), 7.74-7.81 (m, 2H), 7.82-7.88 (m,2H), 7.97 (d, J=0.78 Hz, 1H), 8.09 (d, J=8.98 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.88, 25.29, 25.88, 28.61, 48.65, 52.89, 54.75,59.79, 67.14, 67.75, 100.97, 105.90, 107.46, 114.48, 114.78, 117.66,117.97, 121.48, 123.55, 123.89, 124.96, 126.08, 127.10, 127.47, 127.85,128.46, 128.69, 128.95, 131.41, 131.69, 134.67, 134.94, 138.36, 154.40,157.87, 161.70, 162.98, 163.03, 163.22, 177.63, 178.39; LRMS (ESI) m/z773 [M+H]⁺; HRMS (ESI) calcd for C₄₈H₄₅N₄O₆ [M+H]⁺ 773.3339. found773.3314.

2-(4-(4-(1-(2-(Benzyl(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethyl)amino)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-6-methyl-4H-chromen-4-one(Ac5Az15)

This compound (41 mg) was obtained from Ac5 and Az15 in 53% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) 6 ppm 1.84 (br. s., 4H), 2.46 (s, 3H), 2.73 (br. s., 2H),2.97 (br. s., 2H), 3.11 (br. s., 2H), 3.77 (br. s., 2H), 3.89-4.05 (m,4H), 4.40 (br. s., 2H), 6.68 (s, 1H), 6.72 (s, 1H), 6.88-6.97 (m, 4H),7.21-7.33 (m, 5H), 7.33-7.40 (m, 2H), 7.40-7.44 (m, 1H), 7.45-7.52 (m,2H), 7.61-7.67 (m, 1H), 7.76-7.81 (m, 2H), 7.84 (d, J=8.79 Hz, 2H), 7.99(s, 1H), 8.18 (dd, J=8.05, 1.71 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d)δ ppm 20.92, 25.33, 25.92, 28.68, 48.70, 53.06, 54.79, 59.87, 66.78,67.82, 105.97, 106.26, 114.82, 114.87, 117.71, 117.90, 123.59, 123.92,123.99, 124.29, 125.01, 125.07, 125.65, 127.47, 127.88, 128.03, 128.48,128.73, 133.55, 134.72, 134.99, 154.44, 156.14, 161.33, 161.74, 163.18,163.21, 178.26, 178.44; LRMS (ESI) m/z 773 [M+H]⁺; HRMS (ESI) calcd forC₄₈H₄₅N₄O₆ [M+H]⁺ 773.3339. found 773.3353.

E)-2-(4-(2-(2-(4-(4-(4-(3-(2-Hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac6Az1

This compound (44 mg) was obtained from Ac6 and Az1 in 53% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.06-2.08 (m, 4H), 2.81 (t, J=6.40 Hz, 2H), 3.74 (t,J=6.40 Hz, 2H), 3.84-3.94 (m, 4H), 4.03 (t, J=6.40 Hz, 2H), 4.45 (t,J=6.40 Hz, 2H), 6.57 (s, 1H), 6.85 (d, J=8.40 Hz, 2H), 6.89 (d, J=8.40Hz, 2H), 7.25-7.28 (m, 3H), 7.39 (dd, J=7.20, 7.20 Hz, 2H), 7.48 (s,1H), 7.55-7.56 (m, 3H), 7.69 (d, J=8.40 Hz, 2H), 7.74 (d, J=8.40 Hz,2H), 8.08 (dd, J=7.20, 7.20 Hz, 2H), 13.50 (s, 1H); LRMS (ESI) m/z 673[M+H]⁺.

E)-2-(4-(2-(2-(4-(4-(4-(3-(5-Ethyl-2-hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac7Az1

This compound (53 mg) was obtained from Ac7 and Az1 in 59% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.63 (t, J=6.00, 3H), 2.06-2.08 (m, 4H), 2.81-2.86(m, 4H), 3.75 (t, J=6.40 Hz, 2H), 3.84-3.95 (m, 4H), 4.02 (t, J=6.40 Hz,2H), 4.47 (t, J=6.40 Hz, 2H), 6.57 (s, 1H), 6.86 (d, J=8.40 Hz, 2H),6.89 (d, J=8.40 Hz, 2H), 7.25-7.28 (m, 2H), 7.39 (dd, J=7.20, 7.20 Hz,2H), 7.48 (s, 1H), 7.55-7.56 (m, 3H), 7.69 (d, J=8.40 Hz, 2H), 7.74 (d,J=8.40 Hz, 2H), 8.08 (dd, J=7.20, 7.20 Hz, 2H), 13.60 (s, 1H); LRMS(ESI) m/z 701 [M+11]⁺.

E)-2-(4-(2-(2-(4-(4-(4-(3-(2-Hydroxy-5-methylphenyl)-3-oxoprop-1-en-1-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac8Az1

This compound (63 mg) was obtained from Ac8 and Az1 in 63% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.06-2.08 (m, 2H), 2.43 (s, 3H), 2.81-2.86 (m, 4H),3.75 (t, J=6.40 Hz, 2H), 3.84-3.95 (m, 4H), 4.02 (t, J=6.40 Hz, 2H),4.47 (t, J=6.40 Hz, 2H), 6.57 (s, 1H), 6.86 (d, J=8.40 Hz, 2H), 6.89 (d,J=8.40 Hz, 2H), 7.25-7.28 (m, 2H), 7.39 (dd, J=7.20, 7.20 Hz, 2H), 7.48(s, 1H), 7.55-7.56 (m, 3H), 7.69 (d, J=8.40 Hz, 2H), 7.74 (d, J=8.40 Hz,2H), 8.08 (dd, J=7.20, 7.20 Hz, 2H), 13.60 (s, 1H); LRMS (ESI) m/z 687[M+H]⁺.

E)-2-(4-(2-(2-(4-(4-(4-(3-(2-Hydroxy-4-methylphenyl)-3-oxoprop-1-en-1-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac9Az1

This compound (48 mg) was obtained from Ac9 and Az1 in 56% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.06-2.08 (m, 2H), 2.39 (s, 3H), 2.82-2.86 (m, 4H),3.76 (t, J=6.40 Hz, 2H), 3.84-3.95 (m, 4H), 4.02 (t, J=6.40 Hz, 2H),4.47 (t, J=6.40 Hz, 2H), 6.57 (s, 1H), 6.86 (d, J=8.40 Hz, 2H), 6.89 (d,J=8.40 Hz, 2H), 7.25-7.28 (m, 2H), 7.39 (dd, J=7.20, 7.20 Hz, 2H), 7.48(s, 1H), 7.55-7.56 (m, 3H), 7.69 (d, J=8.40 Hz, 2H), 7.74 (d, J=8.40 Hz,2H), 8.08 (dd, J=7.20, 7.20 Hz, 2H), 13.55 (s, 1H); LRMS (ESI) m/z 687[M+H]⁺.

E)-2-(4-(2-(2-(4-(4-(4-(3-(4-Fluoro-2-hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac10Az1

This compound (41 mg) was obtained from Ac10 and Az1 in 51% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.04-2.08 (m, 2H), 2.83-2.86 (m, 4H), 3.79 (t,J=6.40 Hz, 2H), 3.84-3.96 (m, 4H), 4.02 (t, J=6.40 Hz, 2H), 4.47 (t,J=6.40 Hz, 2H), 6.57 (s, 1H), 6.86 (m, 4H), 7.25-7.28 (m, 2H), 7.39 (dd,J=7.20, 7.20 Hz, 2H), 7.48 (s, 1H), 7.55-7.56 (m, 3H), 7.69 (m, 4H),8.08 (dd, J=7.20, 7.20 Hz, 2H), 13.40 (s, 1H); LRMS (ESI) m/z 691[M+H]⁺.

2-(4-(3-(1-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)quinazolin-4(3H)-one(Ac11Az1)

This compound (48 mg) was obtained from Ac11 and Az1 in 59% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.05-2.20 (m, 4H), 3.78 (s, 2H), 3.94 (s, 2H),4.05-4.08 (m, 4H), 4.57 (s, 2H), 6.65 (s, 1H), 6.93-6.99 (m, 4H),7.25-7.81 (m, 8H), 8.11-8.26 (m, 4H), 11.56 (s, 1H); LRMS (ESI) m/z 657[M+H]⁺.

2-(4-(3-(1-(2-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)quinazolin-4(3H)-one (Ac11Az2)

This compound (39 mg) was obtained from Ac11 and Az2 in 45% yieldaccording to the general procedure described above. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.04-2.20 (m, 6H), 3.76 (s, 2H), 3.93 (s, 2H),4.05-4.09 (m, 4H), 4.59 (s, 2H), 6.66 (s, 1H), 6.43-6.98 (m, 4H),7.26-7.82 (m, 8H), 8.13-8.27 (m, 4H), 11.66 (s, 1H); LRMS (ESI) m/z 701[M+H]⁺.

7-(4-(1-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)-2-phenyl-4H-chromen-4-one(Ac12Az1)

This compound (63 mg) was obtained from Ac12 and Az1 in 91% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.79-1.91 (m, 4H), 2.74-2.77 (m, 2H), 3.77-3.83 (m,2H), 3.92 (t, J=4.88 Hz, 2H), 3.98-4.04 (m, 2H), 4.08-4.15 (m, 2H), 4.52(t, J=4.88 Hz, 2H), 6.66 (s, 1H), 6.67 (s, 1H), 6.82-6.89 (m, 2H),6.92-6.98 (m, 2H), 7.33 (t, J=7.32 Hz, 1H), 7.41-7.50 (m, 5H), 7.59-7.62(m, 1H), 7.77-7.85 (m, 4H), 8.03 (d, J=8.75 Hz, 1H), 8.13 (dd, J=7.75,1.45 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 25.17, 25.74, 28.36,50.00, 67.36, 68.17, 69.43, 69.73, 100.70, 106.08, 107.29, 114.58,114.84, 117.57, 117.78, 121.84, 123.74, 124.23, 124.96, 125.45, 125.97,126.76, 127.83, 128.84, 131.25, 131.66, 133.45, 147.41, 155.96, 157.79,161.25, 162.77, 162.93, 163.42, 177.58, 178.04; LRMS (ESI) m/z 670[M+H]⁺, 692 [M+Na]⁺; HRMS (ESI) calcd for C₄₀H₃₆N₃O₇ [M+H]⁺ 670.2553.found 670.2525; calcd for C₄₀H₃₅N₃O₇Na [M+Na]⁺ 692.2373. found 692.2357.

7-(4-(1-(2-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)-2-phenyl-4H-chromen-4-one(Ac12Az2)

This compound (70 mg) was obtained from Ac12 and Az2 in 98% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.89 (br. s., 4H), 2.80 (br. s., 2H), 3.62-3.68 (m,2H), 3.68-3.75 (m, 2H), 3.85 (t, J=4.15 Hz, 2H), 3.89 (t, J=5.12 Hz,2H), 4.07 (br. s., 2H), 4.18 (t, J=4.39 Hz, 2H), 4.53 (t, J=4.88 Hz,2H), 6.72 (s, 1H), 6.74 (s, 1H), 6.91 (s, 1H), 6.94 (dd, J=9.03, 1.22Hz, 1H), 7.01 (d, J=8.30 Hz, 2H), 7.39 (t, J=7.57 Hz, 1H), 7.52 (d,J=4.88 Hz, 5H), 7.66 (t, J=7.57 Hz, 1H), 7.82-7.93 (m, 4H), 8.10 (d,J=8.79 Hz, 1H), 8.20 (d, J=7.81 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d)δ ppm 25.13, 25.73, 28.31, 49.93, 67.44, 68.13, 69.35, 69.44, 70.35,70.55, 100.65, 105.92, 107.19, 114.52, 114.79, 117.48, 117.74, 121.76,123.67, 123.98, 124.86, 125.35, 125.89, 126.67, 127.74, 128.78, 131.20,131.56, 133.36, 147.28, 155.89, 157.71, 161.33, 162.68, 162.94, 163.36,177.50, 177.98; LRMS (ESI) m/z 714 [M+H]⁺, 736 [M+Na]⁺; FIRMS (ESI)calcd for C₄₂H₄₀N₃O₈ [M+H]⁺ 714.2815. found 714.2804; calcd forC₄₂H₃₉N₃O₈Na [M+Na]⁺ 736.2635. found 736.2625.

6-Methyl-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac12Az3)

This compound (62 mg) was obtained from Ac12 and Az3 in 85% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.83 (br. s., 4H), 2.37 (s, 3H), 2.74 (br. s., 2H),3.61 (br. s., 2H), 3.63-3.70 (m, 2H), 3.80 (br. s., 2H), 3.84 (t, J=4.88Hz, 2H), 4.00 (br. s., 2H), 4.12 (br. s., 2H), 4.48 (t, J=4.88 Hz, 2H),6.63 (s, 1H), 6.67 (s, 1H), 6.83 (s, 1H), 6.86 (d, J=9.27 Hz, 1H), 6.94(d, J=8.30 Hz, 2H), 7.33 (d, J=8.30 Hz, 1H), 7.39 (d, J=8.79 Hz, 1H),7.41-7.48 (m, 3H), 7.50 (s, 1H), 7.77 (d, J=8.30 Hz, 2H), 7.81 (d,J=6.83 Hz, 2H), 7.90 (s, 1H), 8.02 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.76, 25.18, 25.77, 28.36, 49.96, 67.48, 68.17,69.40, 69.48, 70.39, 70.59, 100.70, 105.85, 107.24, 114.55, 114.81,117.53, 121.80, 123.36, 124.21, 124.79, 125.95, 126.74, 127.75, 128.82,131.23, 131.62, 134.61, 134.86, 147.32, 154.22, 157.77, 161.28, 162.75,162.85, 163.41, 177.57, 178.18; LRMS (ESI) m/z 728 [M+H]⁺, 750 [M+Na]⁺;HRMS (ESI) calcd for C₄₃H₄₂N₃O₈ [M+H]⁺ 728.2972. found 728.2949; calcdfor C₄₃H₄₁N₃O₈Na [M+Na]⁺ 750.2791. found 750.2790.

6-Fluoro-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac12Az4)

This compound (53 mg) was obtained from Ac12 and Az4 in 73% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.89 (br. s., 4H), 2.79 (br. s., 2H), 3.61-3.67 (m,2H), 3.67-3.71 (m, 2H), 3.81-3.86 (m, 2H), 3.88 (t, J=5.12 Hz, 2H), 4.06(br. s., 2H), 4.13-4.20 (m, 2H), 4.52 (t, J=4.39 Hz, 2H), 6.69 (s, 1H),6.73 (s, 1H), 6.90 (s, 1H), 6.93 (d, J=8.79 Hz, 1H), 6.99 (d, J=8.79 Hz,2H), 7.34-7.40 (m, 1H), 7.46-7.55 (m, 5H), 7.80-7.85 (m, 3H), 7.85-7.90(m, 2H), 8.09 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm25.07, 25.63, 28.22, 49.94, 67.38, 68.05, 69.24, 69.31, 70.26, 70.47,100.56, 105.04, 107.03, 110.13 (d, J=23.63 Hz, C5), 114.42, 114.73,117.37, 119.77 (d, J=8.08 Hz, C8), 121.30 (d, J=25.15 Hz, C7), 123.49,124.75 (d, J=6.67 Hz, C10), 125.77, 126.52, 127.67, 128.68, 131.11,131.40, 151.94 (d, J=2.02 Hz, C9), 157.59, 159.18 (d, J=247.85 Hz, C6),161.39, 162.54, 163.11, 163.26, 176.94 (d, J=3.03 Hz, C4), 177.32; LRMS(ESI) m/z 732 [M+11]⁺, 754 [M+Na]⁺; HRMS (ESI) calcd for C₄₂H₃₉N₃O₈F[M+H]⁺ 732.2721. found 732.2712; calcd for C₄₂H₃₈N₃O₈FNa [M+Na]⁺754.2541. found 754.2524.

3-(Benzyloxy)-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac12Az5)

This compound (58 mg) was obtained from Ac12 and Az5 in 71% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.83-1.94 (m, 4H), 2.77-2.80 (m, 2H), 3.62-3.68 (m,2H), 3.68-3.74 (m, 2H), 3.84-3.86 (m, 2H), 3.88 (t, J=5.12 Hz, 2H),4.01-4.08 (m, 2H), 4.17-4.19 (m, 2H), 4.52 (t, J=5.12 Hz, 2H), 5.11 (s,2H), 6.74 (s, 1H), 6.89-6.97 (m, 4H), 7.25-7.30 (m, 3H), 7.34-7.41 (m,3H), 7.45-7.54 (m, 5H), 7.61-7.67 (m, 1H), 7.85-7.91 (m, 2H), 8.00-8.05(m, 2H), 8.09 (d, J=8.79 Hz, 1H), 8.26 (dd, J=8.30, 1.46 Hz, 1H); ¹³CNMR (101 MHz, CHLOROFORM-d) δ ppm 25.13, 25.73, 28.32, 49.94, 67.35,68.14, 69.42, 69.44, 70.36, 70.56, 73.71, 100.68, 107.24, 114.14,114.55, 117.49, 117.71, 121.79, 123.40, 123.95, 124.41, 125.48, 125.94,126.71, 127.91, 128.05, 128.58, 128.79, 130.33, 131.21, 131.60, 133.08,136.64, 139.13, 147.30, 154.91, 155.84, 157.75, 160.38, 162.74, 162.76,163.39, 174.71, 177.58; LRMS (ESI) m/z 820 [M+H]⁺, 842 [M+Na]⁺; HRMS(ESI) calcd for C₄₉H₄₆N₃O₉ [M+H]⁺ 820.3234. found 820.3246; calcd forC₄₉H₄₅N₃O₉Na [M+Na]⁺ 842.3054. found 842.3068.

6-Fluoro-2-(4-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac12Az7)

This compound (63 mg) was obtained from Ac12 and Az7 in 91% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.82-1.94 (m, 5H), 2.78-2.80 (m, 2H), 3.80-3.86 (m,2H), 3.95 (t, J=5.00, 2H), 4.01-4.09 (m, 2H), 4.15-4.16 (m, 2H), 4.55(t, J=5.12 Hz, 2H), 6.70 (s, 1H), 6.73 (s, 1H), 6.88-6.93 (m, 2H),6.97-7.02 (m, 2H), 7.37 (ddd, J=9.15, 7.69, 3.17 Hz, 1H), 7.47-7.54 (m,5H), 7.78-7.89 (m, 5H), 8.09 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 25.07, 25.64, 28.24, 49.89, 67.28, 68.08, 69.28,69.61, 100.58, 105.15, 107.08, 110.16 (d, J=23.23 Hz, C5), 114.48,114.76, 117.39, 119.78 (d, J=8.08 Hz, C8), 121.38 (d, J=25.25 Hz, C7),121.77, 123.67, 124.78 (d, J=6.06 Hz, C10), 125.82, 126.57, 127.73,128.73, 131.17, 131.44, 147.29, 151.97, 157.63, 159.23 (d, J=248.46 Hz,C6), 161.31, 162.61, 163.09, 163.30, 177.00, 177.41; LRMS (ESI) m/z 688[M+H]⁺, 710 [M+Na]⁺; HRMS (ESI) calcd for C₄₀H₃₅N₃O₇F [M+H]⁺ 688.2459.found 688.2454; calcd for C₄₀H₃₄N₃O₇FNa [M+Na]⁺ 710.2278. found710.2261.

Methyl3-(((4-oxo-2-(4-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)benzoate(Ac12Az8)

This compound (63 mg) was obtained from Ac12 and Az8 in 76% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.84-1.92 (m, 4H), 2.77-2.80 (m, 2H), 3.82-3.86 (m,2H), 3.87 (s, 3H), 3.96 (t, J=4.88 Hz, 2H), 4.03-4.07 (m, 2H), 4.14-4.18(m, 2H), 4.55 (t, J=4.88 Hz, 2H), 5.13 (s, 2H), 6.73 (s, 1H), 6.89-6.96(m, 4H), 7.34 (t, J=7.57 Hz, 1H), 7.36-7.41 (m, 1H), 7.45-7.53 (m, 5H),7.59 (d, J=7.81 Hz, 1H), 7.64 (ddd, J=8.42, 6.95, 1.71 Hz, 1H),7.85-7.90 (m, 2H), 7.92 (dd, J=7.56, 1.22 Hz, 1H), 7.95-8.00 (m, 3H),8.08 (d, J=8.79 Hz, 1H), 8.25 (dd, J=8.05, 1.71 Hz, 1H); ¹³C NMR (101MHz, CHLOROFORM-d) δ ppm 25.18, 25.74, 28.37, 50.02, 51.93, 67.25,68.18, 69.50, 69.73, 73.21, 100.73, 107.33, 114.21, 114.61, 117.57,117.77, 121.88, 123.44, 124.00, 124.57, 125.59, 126.00, 126.79, 128.19,128.86, 129.14, 129.66, 130.01, 130.42, 131.25, 131.69, 133.08, 133.24,137.10, 138.97, 147.44, 155.02, 156.08, 157.81, 160.36, 162.80, 163.44,166.67, 174.65, 177.61; LRMS (ESI) m/z 834 [M+H]⁺, 856 [M+Na]⁺; HRMS(ESI) calcd for C₄₉H₄₄N₃O₁₀ [M+H]⁺ 834.3027. found 834.3041; calcd forC₄₉H₄₃N₃O₁₀Na [M+Na]⁺ 856.2846. found 856.2834.

Methyl3-(((4-oxo-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)benzoate(Ac12Az9)

This compound (78 mg) was obtained from Ac12 and Az9 in 89% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.84-1.93 (m, 4H), 2.74-2.82 (m, 2H), 3.63-3.67 (m,2H), 3.68-3.73 (m, 2H), 3.84-3.87 (m, 2H), 3.87-3.90 (m, 5H), 4.04-4.09(m, 2H), 4.15-4.20 (m, 2H), 4.52 (t, J=5.12 Hz, 2H), 5.14 (s, 2H), 6.74(s, 1H), 6.89-6.97 (m, 4H), 7.34 (t, J=7.56 Hz, 1H), 7.39 (t, J=7.57 Hz,1H), 7.46-7.54 (m, 5H), 7.59 (d, J=7.81 Hz, 1H), 7.65 (ddd, J=8.54,7.08, 1.46 Hz, 1H), 7.86-7.90 (m, 2H), 7.92 (d, J=7.81 Hz, 1H),7.95-8.01 (m, 3H), 8.09 (d, J=8.79 Hz, 1H), 8.26 (dd, J=7.81, 1.46 Hz,1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 25.19, 25.80, 28.39, 50.00,51.93, 67.39, 68.20, 69.49, 69.52, 70.44, 70.62, 73.19, 100.75, 107.33,114.23, 114.60, 117.60, 117.79, 121.81, 123.31, 124.00, 124.55, 125.59,126.01, 126.80, 128.20, 128.86, 129.14, 129.64, 130.01, 130.40, 131.26,131.69, 133.08, 133.23, 137.10, 138.96, 147.36, 155.03, 156.17, 157.83,160.49, 162.83, 163.47, 166.68, 174.68, 177.63; LRMS (ESI) m/z 878[M+H]⁺, 900 [M+Na]⁺; HRMS (ESI) calcd for C₅H₄₈N₃O₁₁ [M+H]⁺ 878.3289.found 878.3313; calcd for C₅H₄₇N₃O₁₁Na [M+Na]⁺ 900.3108. found 900.3151.

3-(Benzyloxy)-2-(4-(2-(2-(4-(4-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (Ac12Az10)

This compound (74 mg) was obtained from Ac12 and Az10 in 96% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.82-1.94 (m, 4H), 2.78-2.80 (m, 2H), 3.81-3.87 (m,2H), 3.96 (t, J=4.88 Hz, 2H), 4.01-4.08 (m, 2H), 4.13-4.20 (m, 2H), 4.55(t, J=4.88 Hz, 2H), 5.12 (s, 2H), 6.73 (s, 1H), 6.88-6.98 (m, 4H),7.25-7.30 (m, 3H), 7.34-7.41 (m, 3H), 7.44-7.54 (m, 5H), 7.61-7.67 (m,1H), 7.85-7.91 (m, 2H), 8.01-8.06 (m, 2H), 8.09 (d, J=8.75, 1H), 8.25(dd, J=8.54, 1.22 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 25.22,25.79, 28.40, 50.05, 67.30, 68.20, 69.55, 69.77, 73.82, 100.76, 107.40,114.21, 114.64, 117.63, 117.77, 121.87, 123.70, 124.07, 124.53, 125.64,126.05, 126.85, 128.00, 128.15, 128.66, 128.90, 130.46, 131.28, 131.76,133.18, 136.75, 139.28, 147.47, 155.03, 155.80, 157.86, 160.33, 162.85,163.48, 174.78, 177.66; LRMS (ESI) m/z 776 [M+H]⁺, 798 [M+Na]⁺; HRMS(ESI) calcd for C₄₇H₄₂N₃O₈ [M+H]¹ 776.2972. found 776.2946; calcd forC₄₇H₄₁N₃O₈Na [M+Na]⁺798.2791. found 798.2767.

7-(2-(2-(4-(4-((4-Oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)-2-phenyl-4H-chromen-4-one(Ac12Az11)

This compound (30 mg) was obtained from Ac12 and Az11 in 45% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 1.87 (br. s., 4H), 2.78 (br. s., 2H), 3.85-3.87 (m,2H), 3.96 (t, J=4.88 Hz, 2H), 4.04 (br. s., 2H), 4.18-4.22 (m, 2H), 4.55(t, J=4.39 Hz, 2H), 6.72 (s, 1H), 6.73 (s, 1H), 6.86-7.00 (m, 4H),7.45-7.55 (m, 7H), 7.83-7.90 (m, 4H), 8.07 (d, J=8.79 Hz, 1H), 8.13 (d,J=8.78 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 25.17, 25.71,28.36, 50.10, 67.75, 68.18, 69.28, 69.74, 100.73, 101.08, 107.31,107.36, 114.41, 114.62, 117.58, 117.97, 125.97, 126.02, 126.77, 127.01,128.87, 128.89, 131.28, 131.37, 131.55, 131.70, 157.71, 157.81, 162.81,162.92, 162.99, 163.45, 177.50, 177.64; LRMS (ESI) m/z 670 [M+H]⁺; HRMS(ESI) calcd for C₄₀H₃₆N₃O₇ [M+H]⁺ 670.2553. found 670.2565.

7-(2-(2-(2-(4-(4-((4-Oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)-2-phenyl-4H-chromen-4-one (Ac12Az12)

This compound (17 mg) was obtained from Ac12 and Az12 in 24% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) 6 ppm 1.85-1.91 (m, 4H), 2.80 (br. s., 2H), 3.62-3.68 (m,2H), 3.68-3.72 (m, 2H), 3.86-3.90 (m, 4.70 Hz, 4H), 4.06 (s, 2H),4.19-4.23 (m, 2H), 4.52 (t, J=5.12 Hz, 2H), 6.73 (s, 1H), 6.74 (s, 1H),6.88-7.01 (m, 4H), 7.46-7.55 (m, 7H), 7.84-7.91 (m, 4H), 8.09 (d, J=8.79Hz, 1H), 8.12 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm25.26, 25.90, 28.48, 50.16, 68.05, 68.27, 69.41, 69.61, 70.54, 70.79,100.84, 101.18, 107.48, 107.54, 114.59, 114.72, 117.73, 118.04, 121.92,126.12, 126.14, 126.97, 127.15, 128.98, 128.99, 131.37, 131.44, 131.77,131.85, 157.86, 157.97, 162.97, 163.05, 163.22, 163.57, 177.70, 177.80;LRMS (ESI) m/z 714 [M+H]⁺; HRMS (ESI) calcd for C₄₂H₄₀N₃O₈ [M+H]⁺714.2815. found 714.2818.

7-(2-((1-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4H-chromen-4-one(Ac13Az1)

This compound (56 mg) was obtained from Ac13 and Az1 in 84% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.82-3.84 (m, 2H), 3.92-3.96 (m, 4H), 4.11-4.16 (m,2H), 4.18-4.23 (m, 2H), 4.57 (t, J=4.88 Hz, 2H), 4.74 (s, 2H), 6.70 (d,J=3.90 Hz, 2H), 6.91 (d, J=2.44 Hz, 1H), 6.94 (dd, J=8.79, 2.44 Hz, 1H),6.96-7.00 (m, 2H), 7.35-7.40 (m, 1H), 7.44-7.53 (m, 4H), 7.64 (ddd,J=8.42, 6.95, 1.71 Hz, 1H), 7.76 (s, 1H), 7.80-7.87 (m, 4H), 8.07 (d,J=8.79 Hz, 1H), 8.17 (dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 50.25, 64.81, 67.40, 67.93, 68.43, 69.55, 69.66,101.09, 106.25, 107.47, 114.70, 114.95, 117.87, 117.95, 123.80, 123.87,124.41, 125.06, 125.61, 126.08, 126.98, 127.95, 128.95, 131.37, 131.75,133.54, 144.73, 156.10, 157.80, 161.30, 162.97, 163.06, 163.22, 177.67,178.20; LRMS (ESI) m/z 672 [M+H]⁺; HRMS (ESI) calcd for C₃₉H₃₄N₃O₈[M+H]⁺ 672.2346. found 672.2334.

7-(2-((1-(2-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4H-chromen-4-one(Ac13Az2)

This compound (54 mg) was obtained from Ac13 and Az2 in 76% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.69 (m, 4H), 3.80-3.82 (m, 2H), 3.86-3.88 (m,2H), 3.92-3.93 (m, 2H), 4.13-4.15 (m, 2H), 4.20-4.22 (m, 2H), 4.53 (t,J=4.88 Hz, 2H), 4.73 (s, 2H), 6.69 (d, J=11.2 Hz, 2H), 6.90 (s, 1H),6.92-7.00 (m, 3H), 7.36 (t, J=7.57 Hz, 1H), 7.43-7.51 (m, 4H), 7.61-7.67(m, 1H), 7.76-7.87 (m, 5H), 8.07 (d, J=8.79, 1H), 8.17 (d, J=8.0, 1H);¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.22, 64.76, 67.54, 67.93, 68.40,69.40, 69.48, 70.50, 70.66, 101.06, 106.13, 107.42, 114.65, 114.94,117.86, 117.92, 123.77, 123.85, 124.19, 125.00, 125.56, 126.05, 126.96,127.88, 128.92, 131.35, 131.70, 133.48, 144.57, 156.06, 157.77, 161.43,162.93, 163.12, 163.19, 177.63, 178.18; LRMS (ESI) m/z 716 [M+H]⁺, 738[M+Na]⁺; HRMS (ESI) calcd for C₄₁H₃₈H₃O₉ [M+H]⁺ 716.2608. found716.2574; calcd for C₄₁H₃₇N₃O₉Na [M+Na]⁺ 738.2427. found 738.2396.

6-Methyl-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (Ac13Az3)

This compound (47 mg) was obtained from Ac13 and Az3 in 65% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.69 (m, 4H), 3.78-3.83 (m, 2H), 3.87 (t,J=4.88 Hz, 2H), 3.90-3.92 (m, 2H), 4.11-4.16 (m, 2H), 4.18-4.22 (m, 2H),4.53 (t, J=4.88 Hz, 2H), 4.73 (s, 2H), 6.65 (s, 1H), 6.69 (s, 1H),6.88-6.99 (m, 4H), 7.34-7.39 (m, 1H), 7.41-7.51 (m, 4H), 7.76-7.86 (m,5H), 7.94 (s, 1H), 8.06 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.83, 50.21, 64.75, 67.52, 67.91, 68.37, 69.39,69.47, 70.49, 70.64, 101.05, 105.97, 107.39, 114.63, 114.90, 117.60,117.90, 123.46, 123.76, 124.30, 124.90, 126.03, 126.93, 127.83, 128.90,131.33, 131.68, 134.67, 134.94, 144.55, 154.32, 157.75, 161.34, 162.91,162.97, 163.18, 177.62, 178.29; LRMS (ESI) m/z 730 [M+11]⁺, 752 [M+Na]⁺;HRMS (ESI) calcd for C₄₂H₄₀N₃O₉ [M+H]⁺ 730.2765. found 730.2753; calcdfor C₄₂H₄₀N₃O₉Na [M+Na]⁺ 752.2584. found 752.2604.

6-Fluoro-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (Ac13Az4)

This compound (48 mg) was obtained from Ac13 and Az4 in 65% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.70 (m, 4H), 3.78-3.83 (m, 2H), 3.88-3.89 (m,2H), 3.95 (br. s., 2H), 4.11-4.17 (m, 2H), 4.22 (br. s., 2H), 4.50-4.58(m, 2H), 4.73 (br. s., 2H), 6.66 (s, 1H), 6.71 (s, 1H), 6.88-6.99 (m,4H), 7.32-7.38 (m, 1H), 7.43-7.51 (m, 4H), 7.76-7.86 (m, 6H), 8.07 (d,J=8.78 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 64.80, 64.82,67.57, 67.94, 68.40, 69.36, 69.47, 70.50, 70.67, 101.05, 105.42, 107.41,110.50 (d, J=23.23 Hz, C5), 114.66, 114.99, 119.92 (d, J=8.08 Hz, C8),121.56 (d, J=25.25 Hz, C7), 123.86, 126.04, 126.95, 127.93, 128.92,131.37, 131.67, 152.24 (d, J=2.22 Hz, C9), 157.78, 159.46 (d, J=247.45Hz, C6), 161.58, 162.92, 163.19, 163.41, 177.31 (d, J=2.53 Hz, C4),177.61; LRMS (ESI) m/z 734 [M+H]⁺; HRMS (ESI) calcd for C₄₁H₃₇N₃O₉F[M+H]⁺734.2514. found 734.2546.

3-(Benzyloxy)-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac13Az5)

This compound (54 mg) was obtained from Ac13 and Az5 in 66% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.61-3.71 (m, 4H), 3.80-3.85 (m, 2H), 3.88 (t,J=5.12 Hz, 2H), 3.90-3.95 (m, 2H), 4.13-4.18 (m, 2H), 4.18-4.24 (m, 2H),4.54 (t, J=5.12 Hz, 2H), 4.74 (s, 2H), 5.10 (s, 2H), 6.72 (s, 1H),6.91-6.99 (m, 4H), 7.23-7.30 (m, 3H), 7.34-7.40 (m, 3H), 7.45-7.51 (m,4H), 7.63 (ddd, J=8.54, 7.08, 1.95 Hz, 1H), 7.78 (s, 1H), 7.83-7.88 (m,2H), 7.99-8.03 (m, 2H), 8.09 (d, J=8.79 Hz, 1H), 8.25 (dd, J=8.30, 1.46Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.24, 64.77, 67.46,67.93, 68.40, 69.43, 69.57, 70.54, 70.70, 73.85, 101.10, 107.49, 114.29,114.68, 117.83, 117.96, 123.59, 123.78, 124.14, 124.54, 125.70, 126.09,126.99, 128.02, 128.19, 128.73, 128.95, 130.47, 131.36, 131.77, 133.19,136.79, 139.29, 144.59, 155.10, 155.99, 157.81, 160.50, 162.96, 163.22,174.86, 177.67; LRMS (ESI) m/z 822 [M+H]⁺, 844 [M+Na]⁺; HRMS (ESI) calcdfor C₄₈H₄₄N₃O₁₀ [M+H]⁺ 822.3027. found 822.3003; calcd for C₄₈H₄₄N₃O₁₀Na[M+Na]⁺ 844.2846. found 844.2825.

6-Fluoro-2-(4-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac13Az7)

This compound (30 mg) was obtained from Ac13 and Az7 in 44% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.83-3.83 (m, 2H), 3.95-3.97 (m, 4H), 4.14-4.15 (m,2H), 4.22 (br. s., 2H), 4.59 (t, J=4.88 Hz, 2H), 4.75 (br. s., 2H), 6.69(s, 1H), 6.72 (s, 1H), 6.90-7.01 (m, 4H), 7.36 (ddd, J=9.15, 7.44, 2.93Hz, 1H), 7.47-7.52 (m, 4H), 7.78-7.87 (m, 6H), 8.08 (d, J=8.79 Hz, 1H);¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.37, 64.85, 67.43, 67.96, 68.44,69.55, 69.66, 101.09, 105.57, 107.48, 110.59 (d, J=24.24 Hz, C5),114.72, 115.01, 119.94 (d, J=8.08 Hz, C8), 121.63 (d, J=26.26 Hz, C7),124.14, 126.09, 127.01, 128.01, 128.98, 131.41, 131.74, 152.28 (d,J=1.46 Hz, C9), 157.81, 159.53 (d, J=247.45 Hz, C6), 161.45, 162.98,163.23, 163.36, 177.34, 177.35 (d, J=2.02 Hz, C4), 177.66; LRMS (ESI)m/z 690 [M+H]⁺; HRMS (ESI) calcd for C₃₉H₃₃N₃O₈F [M+H]⁺ 690.2252. found690.2220.

Methyl3-(((4-oxo-2-(4-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)benzoate(Ac13Az8)

This compound (78 mg) was obtained from Ac13 and Az8 in 94% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.80-3.84 (m, 2H), 3.85 (s, 3H), 3.89-3.93 (m, 2H),3.95 (t, J=4.88 Hz, 2H), 4.10-4.16 (m, 2H), 4.16-4.21 (m, 2H), 4.57 (t,J=4.88 Hz, 2H), 4.73 (s, 2H), 5.11 (s, 2H), 6.70 (s, 1H), 6.88-6.96 (m,4H), 7.32 (t, J=7.57 Hz, 1H), 7.37 (t, J=7.57 Hz, 1H), 7.43-7.51 (m,4H), 7.57 (d, J=7.81 Hz, 1H), 7.63 (ddd, J=8.54, 7.08, 1.95 Hz, 1H),7.78 (br. s., 1H), 7.81-7.86 (m, 2H), 7.90 (d, J=7.81 Hz, 1H), 7.92-7.98(m, 3H), 8.06 (d, J=9.27 Hz, 1H), 8.23 (dd, J=8.05, 1.71 Hz, 1H); ¹³CNMR (101 MHz, CHLOROFORM-d) δ ppm 50.51, 52.23, 65.01, 67.50, 68.15,68.64, 69.83, 69.87, 73.51, 76.95, 77.26, 77.47, 77.58, 101.32, 107.70,114.52, 114.94, 118.09, 123.78, 124.33, 124.88, 125.93, 126.32, 127.18,128.51, 129.18, 129.44, 129.96, 130.33, 130.73, 131.59, 131.99, 133.40,133.54, 137.42, 139.29, 155.35, 156.40, 158.02, 160.62, 163.18, 163.46,166.99, 174.97, 177.87; LRMS (ESI) m/z 836 [M+H]⁺, 858 [M+Na]⁺; HRMS(ESI) calcd for C₄₈H₄₂N₃O_(ii) [M+H]⁺ 836.2819. found 836.2792; calcdfor C₄₈H₄₂N₃O₁₁Na [M+Na]⁺ 858.2639. found 858.2606.

Methyl3-(((4-oxo-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-ylethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)benzoate(Ac13Az9)

This compound (47 mg) was obtained from Ac13 and Az9 in 53% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.62-3.66 (m, 2H), 3.66-3.70 (m, 2H), 3.81-3.85 (m,2H), 3.87 (s, 3H), 3.88 (t, J=4.75 Hz, 2H), 3.91-3.95 (m, 2H), 4.14-4.17(m, 2H), 4.19-4.23 (m, 2H), 4.54 (t, J=5.12 Hz, 2H), 4.74 (s, 2H), 5.13(s, 2H), 6.72 (s, 1H), 6.90-6.99 (m, 4H), 7.33 (t, J=7.57 Hz, 1H),7.36-7.41 (m, 1H), 7.45-7.52 (m, 4H), 7.58 (d, J=7.32 Hz, 1H), 7.64(ddd, J=8.42, 6.95, 1.71 Hz, 1H), 7.79 (br. s., 1H), 7.83-7.87 (m, 2H),7.91 (d, J=7.81 Hz, 1H), 7.93-7.98 (m, 3H), 8.09 (d, J=8.79 Hz, 1H),8.25 (dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm50.29, 52.00, 64.76, 67.44, 67.93, 68.40, 69.42, 69.56, 70.53, 70.68,73.27, 101.10, 107.48, 114.31, 114.69, 117.86, 123.39, 124.11, 124.62,125.70, 126.09, 126.99, 128.27, 128.95, 129.21, 129.70, 130.09, 130.46,131.36, 131.77, 133.16, 133.28, 137.18, 139.04, 155.12, 156.26, 157.81,160.55, 162.97, 163.22, 166.76, 174.76, 177.66; LRMS (ESI) m/z 880[M+H]⁺; HRMS (ESI) calcd for C₅₀H₄₆N₃O₁₂ [M+H]⁺880.3081. found 880.3043.

3-(Benzyloxy)-2-(4-(2-(2-(4-((2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-4-one(Ac13Az10)

This compound (39 mg) was obtained from Ac13 and Az10 in 50% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.79-3.84 (m, 2H), 3.88-3.93 (m, 2H), 3.95 (t,J=4.88 Hz, 2H), 4.10-4.15 (m, 2H), 4.15-4.21 (m, 2H), 4.57 (t, J=4.88Hz, 2H), 4.73 (s, 2H), 5.10 (s, 2H), 6.71 (s, 1H), 6.87-6.96 (m, 4H),7.22-7.29 (m, 3H), 7.33-7.39 (m, 3H), 7.43-7.51 (m, 4H), 7.59-7.65 (m,1H), 7.77 (br. s., 1H), 7.80-7.86 (m, 2H), 7.98-8.04 (m, 2H), 8.06 (d,J=8.75, 1H), 8.23 (dd, J=8.05, 1.71 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 50.27, 64.76, 67.26, 67.89, 68.40, 69.57, 69.61,73.83, 101.07, 107.45, 114.23, 114.70, 117.80, 123.73, 124.11, 124.55,125.67, 126.07, 126.94, 128.02, 128.18, 128.69, 128.92, 130.48, 131.34,131.74, 133.20, 136.77, 139.30, 155.07, 155.84, 157.78, 160.31, 162.95,163.21, 174.82, 177.63; LRMS (ESI) m/z 778 [M+H]⁺; HRMS (ESI) calcd forC₄₆H₄₀N₃O₉ [M+11]⁺ 778.2765. found 778.2791.

7-(2-((1-(2-(2-((4-Oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4H-chromen-4-one (Ac13Az11)

This compound (38 mg) was obtained from Ac13 and Az11 in 57% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) 6 ppm 3.80-3.85 (m, 2H), 3.91 (br. s., 2H), 3.94 (t,J=4.88 Hz, 2H), 4.12-4.19 (m, 4H), 4.57 (t, J=4.88 Hz, 2H), 4.72 (s,2H), 6.65 (s, 1H), 6.67 (s, 1H), 6.85 (dd, J=7.32, 2.44 Hz, 2H), 6.90(dd, J=9.03, 2.20 Hz, 1H), 6.93 (dd, J=8.79, 1.95 Hz, 1H), 7.41-7.51 (m,6H), 7.80 (ddd, J=7.69, 3.29, 1.71 Hz, 5H), 8.03 (d, J=8.78 Hz, 1H),8.07 (d, J=9.27 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.24,64.76, 67.69, 67.87, 68.41, 69.28, 69.59, 100.97, 101.03, 107.34,107.37, 114.51, 114.68, 117.82, 117.97, 126.00, 126.02, 126.82, 127.00,128.88, 128.90, 131.33, 131.37, 131.58, 131.64, 157.70, 162.86, 162.92,162.95, 163.14, 177.52, 177.59; LRMS (ESI) m/z 672 [M+H]⁺; HRMS (ESI)calcd for C₃₉H₃₄N₃O₈ [M+H]⁺ 672.2346. found 672.2317.

7-(2-((1-(2-(2-(2-((4-Oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4H-chromen-4-one (Ac13Ac12)

This compound (32 mg) was obtained from Ac13 and Az12 in 45% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.66 (m, 2H), 3.66-3.70 (m, 2H), 3.81-3.86 (m,2H), 3.88-3.90 (m, 2H), 3.94 (br. s., 2H), 4.17-4.25 (m, 4H), 4.53-4.55(m, 2H), 4.73 (br. s., 2H), 6.71 (s, 2H), 6.87-6.98 (m, 4H), 7.43-7.54(m, 6H), 7.80-7.88 (m, 5H), 8.08 (t, J=8.54 Hz, 2H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 50.45, 64.80, 67.93, 67.99, 68.43, 69.36, 69.37,70.51, 70.71, 101.07, 101.16, 107.44, 107.45, 114.58, 114.68, 118.01,126.08, 126.96, 127.04, 128.94, 131.37, 131.72, 157.79, 157.80, 162.97,163.18, 163.20, 177.63; LRMS (ESI) m/z 716 [M+H]⁺; HRMS (ESI) calcd forC₄₁H₃₈N₃O₉ [M+H]⁺ 716.2608. found 716.2577.

2,2′-((((((4,4′-(((2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)azanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(4H-chromen-4-one)(Ac14Az1)

This compound (63 mg) was obtained from Ac14 and Az1 in 71% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 2.71-2.73 (m, 2H) 3.52-3.56 (m, 2H) 3.64-3.70 (m,4H) 3.79 (s, 4H) 3.80-3.85 (m, 4H) 3.96 (t, J=5.12 Hz, 4H) 4.15-4.17 (m,4H) 4.56 (t, J=5.12 Hz, 4H) 6.72 (s, 2H) 6.97-7.02 (m, 4H) 7.37-7.42 (m,2H) 7.53 (d, J=8.30 Hz, 2H) 7.67 (ddd, J=8.54, 7.08, 1.46 Hz, 2H)7.82-7.86 (m, 4H) 7.88 (s, 2H) 8.20 (dd, J=7.81, 1.95 Hz, 2H); ¹³C NMR(126 MHz, CHLOROFORM-d) δ ppm 47.56, 50.11, 52.62, 61.67, 67.43, 68.39,69.46, 69.62, 72.35, 106.08, 114.95, 117.89, 123.77, 124.17, 124.64,125.04, 125.52, 127.93, 133.55, 143.38, 156.06, 161.32, 163.21, 178.30;LRMS (ESI) m/z 906 [M+Na]⁺; HRMS (ESI) calcd for C₄₈H₄₉N₇O₁₀Na [M+Na]⁺906.3439. found 906.3398.

2,2′-((((((4,4′-((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(4H-chromen-4-one)(Ac15Az1)

This compound (88 mg) was obtained from Ac15 and Az1 in 99% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.62-3.74 (m, 2H), 3.75-3.81 (m, 2H), 3.93 (br. s.,2H), 4.06-4.12 (m, 2H), 4.52-4.54 (m, 2H), 6.65 (s, 1H), 6.91 (d, J=9.27Hz, 2H), 7.11-7.18 (m, 1H), 7.22 (t, J=7.08 Hz, 1H), 7.29-7.39 (m, 2H),7.48 (d, J=8.30 Hz, 1H), 7.63 (ddd, J=8.54, 7.08, 1.46 Hz, 1H),7.68-7.79 (m, 3H), 8.15 (dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 50.11, 67.34, 69.37, 69.55, 106.00, 114.84, 117.83,123.74, 124.08, 124.94, 125.41, 126.89, 127.83, 127.89, 128.13, 128.73,133.44, 155.97, 161.22, 163.06, 178.10; LRMS (ESI) m/z 886 [M+H]⁺; HRMS(ESI) calcd for C₅₁H₄₈N₇O₈ [M+H]⁺ 886.3564. found 886.3524.

2,2′-((((((((4,4′((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(4H-chromen-4-one)(Ac15Az2)

This compound (48 mg) was obtained from Ac15 and Az2 in 49% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.90 (m, 10H), 4.10-4.18 (m, 2H), 4.53 (br. s.,2H), 6.72 (s, 1H), 6.99 (d, J=8.79 Hz, 2H), 7.17-7.33 (m, 2H), 7.33-7.43(m, 2H), 7.50-7.56 (m, 1H), 7.64-7.70 (m, 1H), 7.72-7.89 (m, 3H), 8.20(dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 67.62,69.53, 70.59, 70.72, 106.19, 115.01, 117.93, 124.19, 125.04, 125.60,127.12, 127.94, 128.32, 133.52, 156.14, 161.50, 163.25, 178.26; LRMS(ESI) m/z 974 [M+H]⁺; HRMS (ESI) calcd for C₅₅H₅₆N₇O₁₀ [M+H]⁺ 974.4089.found 974.4064.

2,2′-((((((((4,4′-((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(6-methyl-4H-chromen-4-one) (Ac15Az3)

This compound (99 mg) was obtained from Ac15 and Az3 in 99% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 2.41 (s, 3H), 3.59-3.70 (m, 5H), 3.73 (br. s., 1H),3.76-3.81 (m, 2H), 3.87 (br. s., 2H), 4.10-4.12 (m, 2H), 4.51 (br. s.,2H), 6.66 (s, 1H), 6.95 (d, J=8.79 Hz, 2H), 7.14-7.23 (m, 1H), 7.23-7.31(m, 1H), 7.31-7.47 (m, 3H), 7.70-7.82 (m, 3H), 7.95 (s, 1H); ¹³C NMR(101 MHz, CHLOROFORM-d) δ ppm 20.80, 67.50, 69.37, 69.43, 70.50, 70.62,105.90, 114.87, 117.60, 123.43, 124.16, 124.83, 126.95, 127.80, 128.20,128.84, 134.64, 134.89, 154.29, 161.33, 163.01, 178.27; LRMS (ESI) m/z1002 [M+H]⁺; HRMS (ESI) calcd for C₅₇H₆₀N₇O₁₀ [M+H]⁺ 1002.4402. found1002.4353.

2,2′-((((((((4,4′-((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(3-(benzyloxy)-4H-chromen-4-one) (Ac15Az5)

This compound (110 mg) was obtained from Ac15 and Az5 in 92% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.61-3.66 (m, 2H), 3.66-3.72 (m, 2H), 3.76 (br. s.,2H), 3.80-3.86 (m, 2H), 3.88 (t, J=5.12 Hz, 2H), 4.12-4.19 (m, 2H), 4.53(t, J=4.88 Hz, 2H), 5.11 (s, 2H), 6.94 (d, J=9.27 Hz, 2H), 7.24-7.30 (m,4H), 7.35-7.42 (m, 4H), 7.51 (d, J=7.81 Hz, 1H), 7.66 (ddd, J=8.54,7.08, 1.95 Hz, 1H), 7.74 (br. s., 1H), 7.99-8.05 (m, 2H), 8.28 (dd,J=8.05, 1.71 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.10,67.44, 69.47, 69.54, 70.56, 70.68, 73.83, 114.26, 117.83, 123.47,124.11, 124.52, 125.64, 126.98, 127.99, 128.14, 128.23, 128.71, 128.88,130.44, 133.17, 136.71, 139.23, 155.08, 156.09, 160.50, 174.85; LRMS(ESI) m/z 1186 [M+H]⁺; HRMS (ESI) calcd for C₆₉H₆₈H₇O₁₂ [M+H]⁺1186.4926. found 1186.4880.

Dimethyl3,3′-(((2,2′-((((((4,4′-((benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(4-oxo-4H-chromene-3,2-diyl))bis(oxy))bis(methylene))dibenzoate(Ac15Az8)

This compound (120 mg) was obtained from Ac15 and Az8 in 98% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.74 (br. s., 2H), 3.80-3.82 (m, 2H), 3.86 (s, 3H),3.94 (t, J=5.12 Hz, 2H), 4.10-4.15 (m, 2H), 4.54 (t, J=5.12 Hz, 2H),5.12 (s, 2H), 6.87-6.93 (m, 2H), 7.17 (d, J=7.32 Hz, 1H), 7.24 (t,J=7.57 Hz, 1H), 7.32 (t, J=7.81 Hz, 1H), 7.35-7.42 (m, 2H), 7.49 (d,J=7.81 Hz, 1H), 7.56-7.60 (m, 1H), 7.65 (ddd, J=8.54, 7.08, 1.46 Hz,1H), 7.75 (br. s., 1H), 7.89-7.98 (m, 4H), 8.26 (dd, J=8.05, 1.71 Hz,1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 47.53, 50.11, 51.98, 57.43,67.30, 69.55, 69.69, 73.27, 114.28, 117.88, 123.43, 124.10, 124.22,124.63, 125.68, 126.99, 128.21, 128.25, 128.89, 129.20, 129.72, 130.07,130.48, 133.16, 133.30, 137.14, 139.02, 144.38, 155.13, 156.31, 160.39,166.73, 174.78; LRMS (ESI) m/z 1214 [M+H]⁺; HRMS (ESI) calcd forC₆₉H₆₄N₇O₁₄ [M+H]⁺ 1214.4511. found 1214.4476.

Dimethyl3,3′-(((2,2′-((((((((4,4′-((benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene))bis(4-oxo-4H-chromene-3,2-diyl))bis(oxy))bis(methylene))dibenzoate(Ac15Az9)

This compound (120 mg) was obtained from Ac15 and Az9 in 90% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.65 (m, 3H), 3.65-3.70 (m, 3H), 3.77 (br. s.,2H), 3.80-3.84 (m, 2H), 3.85-3.90 (m, 5H), 4.14 (t, J=4.64 Hz, 2H), 4.52(t, J=5.12 Hz, 2H), 5.13 (s, 2H), 6.93 (d, J=8.79 Hz, 2H), 7.20-7.22 (d,J=6.83 Hz, 1H), 7.29 (t, J=7.08 Hz, 1H), 7.33 (t, J=7.81 Hz, 1H), 7.40(t, J=7.57 Hz, 2H), 7.50 (d, J=8.79 Hz, 1H), 7.58 (d, J=7.32 Hz, 1H),7.63-7.69 (m, 1H), 7.75 (br. s., 1H), 7.91 (d, J=7.81 Hz, 1H), 7.93-7.99(m, 3H), 8.27 (d, J=7.81 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm50.20, 52.03, 67.49, 69.56, 69.61, 70.64, 70.75, 73.32, 114.36, 117.92,123.38, 124.16, 124.66, 125.75, 128.29, 129.25, 129.76, 130.12, 130.51,133.21, 133.31, 137.19, 139.07, 155.19, 156.42, 160.62, 166.80, 174.84;LRMS (ESI) m/z 1302 [M+H]⁺; HRMS (ESI) calcd for C₇₃H₇₂N₇O₁₆ [M+11]⁺1302.4980. found 1302.5036.

7,7′-(((((4,4′-((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(2-phenyl-4H-chromen-4-one)(Ac15Az11)

This compound (88 mg) was obtained from Ac15 and Az11 in 99% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.61-4.17 (m, 8H), 4.56 (br. s., 2H), 6.73 (s, 1H),6.92 (br. s., 2H), 7.16 (br. s., 1H), 7.26 (d, J=1.46 Hz, 1H), 7.44-7.56(m, 3H), 7.86 (d, J=7.81 Hz, 2H), 8.07 (d, J=8.30 Hz, 1H); ¹³C NMR (101MHz, CHLOROFORM-d) δ ppm 67.89, 69.36, 101.25, 107.51, 114.56, 126.16,127.10, 128.99, 131.42, 131.78, 157.83, 163.05, 177.68; LRMS (ESI) m/z886 [M+H]⁺; HRMS (ESI) calcd for C₅₁H₄₈N₇O₈ [M+H]⁺ 886.3564. found886.3521.

7,7′-(((((((4,4′-((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(2-phenyl-4H-chromen-4-one)(Ac15Az12)

This compound (58 mg) was obtained from Ac15 and Az12 in 60% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.59-3.65 (m, 2H), 3.65-3.71 (m, 2H), 3.77 (br. s.,2H), 3.81-3.86 (m, 2H), 3.87-3.89 (m, 2H), 4.16-4.22 (m, 2H), 4.52 (t,J=4.88 Hz, 2H), 6.74 (s, 1H), 6.91-6.99 (m, 2H), 7.19-7.22 (m, 1H), 7.28(t, J=7.08 Hz, 1H), 7.39 (br. s., 1H), 7.46-7.55 (m, 3H), 7.77 (br. s.,1H), 7.85-7.91 (m, 2H), 8.10 (d, J=8.79 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 50.21, 68.06, 69.42, 69.52, 70.64, 70.79, 101.20,107.53, 114.65, 117.98, 126.15, 127.05, 128.33, 128.98, 131.40, 131.83,157.86, 163.04, 163.26, 177.74; LRMS (ESI) m/z 974 [M+H]⁺; HRMS (ESI)calcd for C₅₅H₅₆N₇O₁₀ [M+H]⁺ 974.4089. found 974.4063.

7,7′-(((4,4′-((Benzylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))bis(2-phenyl-4H-chromen-4-one)(Ac15Az13)

This compound (69 mg) was obtained from Ac15 and Az13 in 87% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.75 (br. s., 2H), 4.50 (br. s., 2H), 4.83 (br. s.,2H), 6.73 (s, 1H), 6.94 (br. s., 2H), 7.31 (br. s., 1H), 7.46-7.56 (m,3H), 7.86 (d, J=7.81 Hz, 2H), 8.10 (d, J=8.30 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 53.84, 69.47, 101.42, 107.51, 114.28, 126.14,127.36, 128.48, 128.99, 131.49, 131.61, 157.71, 162.13, 163.14, 177.52;LRMS (ESI) m/z 798 [M+H]⁺; HRMS (ESI) calcd for C₄₇H₄₀N₇O₆ [M+11]⁺798.3040. found 798.3013.

7-(2-(Benzyl((1-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one (Ac16Az1)

This compound (69 mg) was obtained from Ac16 and Az1 in 90% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 2.98 (br. s., 2H), 3.71-3.85 (m, 4H), 3.95 (t,J=5.12 Hz, 4H), 4.06-4.12 (m, 2H), 4.14 (br. s., 2H), 4.57 (t, J=5.12Hz, 2H), 6.67 (s, 1H), 6.71 (s, 1H), 6.83-6.95 (m, 4H), 7.20-7.25 (m,1H), 7.29 (t, J=7.32 Hz, 2H), 7.36-7.39 (m, 3H), 7.43-7.52 (m, 4H),7.62-7.67 (m, 1H), 7.71 (br. s., 1H), 7.75-7.81 (m, 2H), 7.82-7.87 (m,2H), 8.06 (d, J=8.79, 1H), 8.14-8.20 (m, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 49.33, 50.21, 51.66, 58.89, 67.17, 67.42, 69.50,69.76, 100.91, 106.18, 107.38, 114.64, 114.85, 117.76, 117.85, 123.84,124.33, 125.03, 125.56, 126.05, 126.90, 127.20, 127.89, 128.32, 128.76,128.92, 131.35, 131.69, 133.50, 156.05, 157.83, 161.22, 162.89, 163.00,163.22, 177.65, 178.15; LRMS (ESI) m/z 761 [M+H]⁺, 783 [M+Na]⁺; HRMS(ESI) calcd for C₄₆H₄₁N₄O₇ [M+H]⁺ 761.2975. found 761.2980; calcd forC₄₆H₄₀N₄O₇Na [M+Na]⁺ 783.2795. found 783.2794.

7-(2-(Benzyl((1-(2-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16Az2)

This compound (19 mg) was obtained from Ac16 and Az2 in 24% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.02 (br. s., 2H), 3.59-3.69 (m, 4H), 3.73-3.84 (m,4H), 3.88 (t, J=5.0 Hz, 2H), 3.96 (br. s., 2H), 4.07-4.14 (m, 2H), 4.19(br. s., 2H), 4.54 (t, J=5.12 Hz, 2H), 6.70 (s, 1H), 6.73 (s, 1H),6.88-6.98 (m, 4H), 7.22-7.28 (m, 1H), 7.32 (t, J=7.57 Hz, 2H), 7.35-7.44(m, 3H), 7.45-7.54 (m, 4H), 7.66 (ddd, J=8.66, 6.95, 1.46 Hz, 1H), 7.74(br. s., 1H), 7.81 (d, J=9.25 Hz, 2H), 7.85-7.90 (m, 2H), 8.08 (d,J=8.79 Hz, 1H), 8.19 (dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 49.28, 50.24, 51.69, 58.87, 67.22, 67.55, 69.51,69.55, 70.56, 70.74, 100.98, 106.19, 107.44, 114.67, 114.95, 117.82,117.89, 123.89, 124.24, 125.04, 125.61, 126.10, 126.96, 127.21, 127.92,128.35, 128.81, 128.95, 131.37, 131.76, 133.52, 156.11, 157.89, 161.43,162.95, 163.17, 163.25, 177.71, 178.24; LRMS (ESI) m/z 805 [M+H]⁺, 827[M+Na]⁺; HRMS (ESI) calcd for C₄₈H₄₅N₄O₈ [M+H]⁺805.3237. found 805.3260;calcd for C₄₈H₄₄N₄O₈Na [M+Na]⁺ 827.3057. found 827.3070.

7-(2-(Benzyl((1-(2-(2-(2-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16Az3)

This compound (28 mg) was obtained from Ac16 and Az3 in 34% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 2.38 (s, 3H), 2.94 (br. s., 2H), 3.45-3.68 (m, 6H),3.68-3.76 (m, 3H), 3.82 (br. s., 3H), 4.05 (m, 2H), 4.11 (br. s., 2H),4.48 (br. s., 2H), 6.62 (s, 1H), 6.67 (s, 1H), 6.81-6.92 (m, 4H),7.16-7.21 (m, 2H), 7.26 (br. s., 2H), 7.31-7.37 (m, 2H), 7.37-7.48 (m,5H), 7.74 (d, J=8.79 Hz, 2H), 7.78-7.83 (m, 2H), 7.91 (s, 1H), 8.02 (d,J=8.79 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 20.90, 67.58,69.52, 69.55, 70.59, 70.76, 101.05, 106.10, 107.48, 114.66, 114.95,117.67, 124.41, 125.01, 126.13, 127.03, 127.91, 128.44, 128.98, 131.40,131.78, 134.75, 135.02, 154.42, 157.91, 161.37, 162.99, 163.05, 177.72,178.39; LRMS (ESI) m/z 819 [M+H]⁺, 841 [M+Na]⁺; HRMS (ESI) calcd forC₄₉H₄₇N₄O₈ [M+H]⁺ 819.3394. found 819.3392; calcd for C₄₉H₄₆N₄O₈Na[M+Na]⁺ 841.3213. found 841.3220.

7-(2-(Benzyl((1-(2-(2-(2-(4-(3-(benzyloxy)-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16Az5)

This compound (29 mg) was obtained from Ac16 and Az5 in 31% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.00 (br. s., 2H), 3.57-3.70 (m, 4H), 3.70-3.85 (m,4H), 3.88-3.98 (m, 4H), 4.09-4.23 (m, 4H), 4.53 (t, J=4.88 Hz, 2H), 5.10(s, 2H), 6.73 (s, 1H), 6.87-6.95 (m, 4H), 7.20-7.42 (m, 11H), 7.45-7.52(m, 4H), 7.64 (td, J=7.81, 1.46 Hz, 1H), 7.70 (br. s., 1H), 7.86-7.59(m, 2H), 8.00 (d, J=8.75 Hz, 2H), 8.08 (d, J=8.79 Hz, 1H), 8.25 (dd,J=8.05, 1.71 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 50.33,67.44, 69.51, 69.57, 70.55, 70.72, 73.85, 100.98, 107.45, 114.26,114.67, 117.83, 123.58, 124.14, 124.55, 125.70, 126.11, 126.94, 127.18,128.02, 128.17, 128.34, 128.72, 128.79, 128.94, 130.47, 131.36, 131.77,133.19, 136.77, 139.29, 155.10, 156.01, 157.89, 160.46, 162.95, 163.28,174.87, 177.70; LRMS (ESI) m/z 911 [M+H]⁺, 933 [M+Na]⁺; HRMS (ESI) calcdfor C₅₅H₅₁N₄O₉ [M+H]⁺ 911.3656. found 911.3662; calcd for C₅₅H₅₀N₄O₉Na[M+Na]⁺ 933.3475. found 933.3487.

7-(2-(Benzyl((1-(2-(2-(4-(6-fluoro-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16Az7)

This compound (20 mg) was obtained from Ac16 and Az7 in 25% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 2.99 (br. s., 2H), 3.68-3.92 (m, 4H), 3.92-4.05 (m,4H), 4.08-4.27 (m, 4H), 4.58 (br. s., 2H), 6.66 (s, 1H), 6.72 (s, 1H),6.85-6.96 (m, 4H), 7.21-7.44 (m, 7H), 7.45-7.53 (m, 4H), 7.77 (d, J=8.79Hz, 2H), 7.80 (dd, J=8.05, 3.17 Hz, 1H), 7.82-7.88 (m, 2H), 8.07 (d,J=8.79 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 67.50, 69.55,69.73, 101.00, 105.54, 107.45, 110.59 (d, J=24.24 Hz, C5), 114.62,114.95, 119.94 (d, J=8.08 Hz, C8), 121.63 (d, J=25.25 Hz, C7), 124.09,126.09, 127.03, 127.99, 128.97, 131.42, 131.69, 152.27, 152.28, 157.86,159.53 (d, J=247.45 Hz, C6), 161.40, 162.97, 163.33, 177.37, 177.67;LRMS (ESI) m/z 799 [M+H]⁺, 801 [M+Na]⁺; HRMS (ESI) calcd for C₄₆H₄₀N₄O₇F[M+H]⁺ 799.2881. found 799.2916; calcd for C₄₆H₃₉N₄O₇FNa [M+Na]⁺801.2700. found 801.2738.

7-(2-(Benzyl((1-(2-(2-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16Az12)

This compound (33 mg) was obtained from Ac16 and Az12 in 41% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 2.99 (br. s., 2H), 3.58-3.69 (m, 4H), 3.71-3.84 (m,4H), 3.88 (t, J=5.12 Hz, 2H), 3.93 (br. s., 2H), 4.11-4.20 (m, 4H), 4.53(t, J=5.12 Hz, 2H), 6.72 (s, 1H), 6.72 (s, 1H), 6.87-6.96 (m, 4H),7.20-7.25 (m, 1H), 7.30 (t, J=7.57 Hz, 2H), 7.33-7.41 (m, 2H), 7.45-7.54(m, 6H), 7.68 (br. s., 1H), 7.82-7.89 (m, 4H), 8.08 (dd, J=8.79, 2.93Hz, 2H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 49.28, 50.25, 51.69,58.83, 67.24, 67.99, 69.38, 69.55, 70.57, 70.78, 100.97, 101.14, 107.45,107.51, 114.56, 114.67, 117.83, 118.00, 123.80, 126.11, 126.96, 127.06,127.20, 128.36, 128.78, 128.96, 131.37, 131.39, 131.77, 138.96, 157.80,157.88, 162.95, 162.97, 163.16, 163.25, 177.65, 177.69; LRMS (ESI) m/z805 [M+H]⁺, 827 [M+Na]⁺; HRMS (ESI) calcd for C₄₈H₄₅N₄O₈ [M+H]⁺805.3237. found 805.3265; calcd for C₄₈H₄₄N₄O₈Na [M+Na]⁺ 827.3057. found827.3078.

7-(2-(Benzyl((1-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one(Ac16Az13)

This compound (18 mg) was obtained from Ac16 and Az13 in 25% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.00 (br. s., 2H), 3.75 (br. s., 2H), 3.97 (br. s.,2H), 4.16 (br. s., 2H), 4.47 (t, J=4.88 Hz, 2H), 4.81 (t, J=4.64 Hz,2H), 6.99 (s, 1H), 6.70 (s, 1H), 6.84-6.93 (m, 4H), 7.20-7.25 (m, 1H),7.30 (t, J=7.32 Hz, 2H), 7.36 (br. s., 2H), 7.44-7.53 (m, 6H), 7.73 (br.s., 1H), 7.85 (dd, J=7.56, 1.71 Hz, 2H), 7.82 (dd, J=8.05, 1.22 Hz, 2H),8.06 (dd, J=9.03, 2.20 Hz, 2H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm49.48, 51.83, 58.83, 66.84, 67.21, 101.02, 101.34, 107.44, 107.51,114.08, 114.59, 117.84, 118.54, 124.00, 126.09, 126.11, 126.96, 127.28,127.39, 128.38, 128.73, 128.95, 128.98, 131.38, 131.49, 131.58, 131.76,138.71, 157.67, 157.85, 162.08, 162.93, 163.09, 163.21, 177.44, 177.66;LRMS (ESI) m/z 717 [M+H]⁺, 739 [M+Na]⁺; HRMS (ESI) calcd for C₄₄H₃₇N₄O₆[M+H]⁺ 717.2713. found 717.2729; calcd for C₄₄H₃₆N₄O₆Na [M+Na]⁺739.2533. found 739.2541.

2,2′,2″-((((((((4,4′,4″-(nitrilotris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris(ethane-2,1-diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))tris(benzene-4,1-diyl))tris(4H-chromen-4-one)(Ac17Az2)

This compound (21 mg) was obtained from Ac17 and Az2 in 31% yieldaccording to the general procedure described above. ¹H NMR (500 MHz,CHLOROFORM-d) δ ppm 3.60-3.67 (m, 2H), 3.67-3.74 (m, 2H), 3.79-3.98 (m,6H), 4.15-4.20 (m, 2H), 4.54 (t, J=5.12 Hz, 2H), 6.72 (s, 1H), 6.98-7.03(m, 2H), 7.35-7.42 (m, 1H), 7.50-7.55 (m, 1H), 7.63-7.70 (m, 1H),7.82-7.88 (m, 2H), 8.06 (br. s., 1H), 8.16-8.23 (dd, J=8.0, 1.50 Hz,1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm 46.72, 50.32, 67.67, 69.44,69.58, 70.70, 70.78, 106.20, 115.06, 117.94, 123.92, 124.19, 125.06,125.63, 127.97, 133.53, 156.16, 161.58, 163.30, 178.29. LRMS (ESI) m/z1317 [M+H]⁺; HRMS (ESI) calcd for C₇₂H₇₃N₁₀O₁₅ [M+H]⁺ 1317.5257. found1317.5303.

Synthesis of Syn-Triazole Bridged Flavonoid Dimers (Scheme 3) GeneralProcedure for the Synthesis of Syn-Triazole Bridged Flavonoid DimersCatalyzed by Ru(II) Catalyst

The catalystchloro(pentamethylcyclopentadienyl)bis(triphenylphosphine)ruthenium (II)(0.01 mmol) was added to a PhMe solution (2.0 mL) containing the azide(Az, 0.2 mmol) and the alkyne (Ac, 0.2 mmol). The reaction mixture wasstirred overnight under reflux condition. Solvent was removed byevaporation, and the resulting crude mixture was purified by flashchromatography on silica gel using gradient of 10-50% of acetone withCH₂Cl₂ to afford the desired syn- compound.

6-Methyl-2-(4-(4-(1-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethyl)-1H-1,2,3-triazol-5-yl)butoxy)phenyl)-4H-chromen-4-one (syn-Ac5Az1)

This compound (100% syn, 46 mg) was obtained from Ac5 and Az1 in 67%yield according to the general procedure described above. ¹H NMR (400MHz, CHLOROFORM-d) 6 ppm 1.74-1.88 (m, 4H), 2.45 (s, 3H), 2.76-2.79 (m,2H), 3.73-3.80 (m, 2H), 3.88 (t, J=5.66 Hz, 2H), 4.02 (t, J=5.27 Hz,2H), 4.04-4.09 (m, 2H), 4.48 (t, J=5.27 Hz, 2H), 6.62 (s, 1H), 6.69 (s,1H), 6.88 (d, J=10.0 Hz, 2H), 6.95 (d, J=10.0 Hz, 2H), 7.30 (t, J=7.42Hz, 1H), 7.36-7.42 (m, 1H), 7.43-7.50 (m, 3H), 7.61 (ddd, J=8.49, 7.12,1.56 Hz, 1H), 7.75 (d, J=8.98 Hz, 2H), 7.81 (d, J=8.98 Hz, 2H), 7.96 (s,1H), 8.11 (dd, J=8.00, 1.37 Hz, 1H); ¹³C NMR (101 MHz, CHLOROFORM-d) δppm 20.90, 22.96, 24.70, 28.70, 47.73, 67.45, 67.48, 69.66, 70.46,105.96, 106.21, 114.69, 114.85, 117.70, 117.81, 123.53, 123.84, 124.13,124.37, 124.96, 125.02, 125.58, 127.83, 127.94, 131.83, 133.53, 134.72,134.99, 137.94, 154.36, 156.05, 161.34, 161.45, 162.93, 162.96, 178.17,178.35. LRMS (ESI) m/z 684 [M+H]⁺, 706 [M+Na]⁺; HRMS (ESI) calcd forC₄₁H₃₈N₃O₇ [M+H]⁺ 684.2710. found 684.2732; calcd for C₄₁H₃₇N₃O₇Na[M+Na]⁺ 706.2529. found 706.2553.

6-Methyl-2-(4-(4-(1-(2-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-5-yl)butoxy)phenyl)-4H-chromen-4-one(syn-Ac5Az2

This compound (90% syn, 54 mg) was obtained from Ac5 and Az2 in 74%yield according to the general procedure described above. ¹H NMR (500MHz, CHLOROFORM-d) δ ppm 1.86-1.90 (m, 4H), 2.44 (s, 3H), 2.78-2.81 (m,2H), 3.55-3.60 (m, 2H), 3.63-3.65 (m, 2H), 3.78-3.80 (m, 2H), 3.95 (t,J=5.37 Hz, 2H), 4.00-4.04 (m, 2H), 4.12-4.15 (m, 2H), 4.45 (t, J=5.37Hz, 2H), 6.69 (s, 1H), 6.71 (s, 1H), 6.96 (d, J=10.0 Hz, 2H), 7.00 (d,J=10.0 Hz, 2H), 7.37 (t, J=7.81 Hz, 1H), 7.41 (d, J=10.0 Hz, 1H),7.45-7.49 (m, 2H), 7.51 (d, J=10.0 Hz, 1H), 7.63-7.67 (m, 1H), 7.80-7.86(m, 4H), 7.97 (s, 1H), 8.18 (dd, J=7.81, 1.46 Hz, 1H); ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm 20.92, 22.93, 24.78, 28.70, 47.73, 67.55, 67.65,69.53, 70.13, 70.72, 70.77, 106.10, 106.26, 114.82, 115.01, 117.69,117.91, 123.58, 123.93, 124.31, 125.06, 125.66, 127.96, 131.84, 133.55,134.76, 135.04, 137.77, 154.44, 156.16, 161.52, 163.18, 163.17, 178.40;LRMS (ESI) m/z 728 [M+H]⁺; HRMS (ESI) calcd for C₄₃H₄₂N₃O₈ [M+H]⁺728.2972. found 728.2946.

Materials for Biological Studies.

Dimethyl sulfoxide (DMSO), vincristine, paclitaxel, DOX, verapamil,topotecan and phenazine methosulfate (PMS) were purchased fromSigma-Aldrich. Dulbecco's Modified Eagle's Medium (DMEM), Roswell ParkMemorial Institute (RPMI) 1640 medium,trypsin-ethylenediaminetetraacetic acid (EDTA) andpenicillin/streptomycin were purchased from Gibco BRL. Fetal bovineserum (FBS) was purchased from HyClone Laboratories.3-(4,5-Dimethylthiazol-2-yl)-5-[3-(carboxymethoxy)phenyl]-2-(4-sulfo-phenyl)-2H-tetrazolium(MTS) was purchased from Promega. The human breast cancer cell linesMDA435/LCC6 and MDA435/LCC6MDR were kindly provided by Dr. Robert Clarke(Georgetown University, United States). The human ovarian carcinoma celllines 2008/P and 2008/MRP1 were generous gifts from Prof. P. Borst (TheNetherlands Cancer Institute, Amsterdam, Netherlands). The humanembryonic kidney (HEK) 293 cell lines, HEK293/pcDNA3.1 (emptyvector-transfected) and HEK293/R2 (BCRP-transfected) and MCF7-MX100mitoxantrone selected cell lines were kindly provided by Dr. Kenneth To(The Chinese University of Hong Kong, Hong Kong). MCF7 was kindlyprovided by Prof. Thomas Leung (The Hong Kong Polytechnic University,Hong Kong).

Cell Culture.

MDA435/LCC6, MDA435/LCC6MDR cell lines were cultured in supplementedDMEM media with 10% heat inactivated FBS and 100 U/mL penicillin and 100μg/mL of streptomycin. 2008/P and 2008/MRP1 cells or HEK293/pcDNA3.1 andHEK293/R2 or MCF7 and MCF7-MX100 were cultured in RPMI 1640 mediumcontaining heat inactivated 10% FBS and 100 U/mL penicillin and 100μg/mL of streptomycin. They were maintained at 37° C. in a humidifiedatmosphere with 5% CO₂. The cells were split constantly after aconfluent monolayer has been formed. To split cells, the plate waswashed briefly with phosphate-buffered saline (PBS), treated with 0.05%trypsin-EDTA and harvested by centrifugation.

Cell Proliferation Assay.

6,000 cells of LCC6 or LCC6MDR and paclitaxel were mixed with or without1 μM modulator to a final volume of 200 μL in each well of 96-wellplates. 4,000 cells of 2008/P or 2008/MRP1 and DOX or vincristine wereco-incubated with or without 1 μM modulator to a final volume of 200 μL.6,500 cells of HEK293/pcDNA3.1 or HEK293/R2 and topotecan wereco-incubated with or without 1 μM modulator to a final volume of 200 μL.7,500 cells of MCF7 or MCF7-MX100 and topotecan were co-incubated withor without 1 μM modulator to a final volume of 200 pt. The plates werethen incubated for 5 days at 37° C. After 5 days, the % of survival orviability was determined by MTS according to procedures reportedpreviously.^(59,67) These results were represented as mean±standarderror of mean. IC₅₀ values were calculated from the dose-response curvesof MTS assays (Prism 4.0).

Results and Discussions Chemistry

Design.

With the success of applying bivalent approach in P-gp and MRP1modulators as well as the appealing ease and chemoselectivity of clickchemistry, we started to explore the cycloaddition reaction of azideswith alkynes as the key dimerization process for construction of atriazole bridged flavonoid dimer library. With one flavonoid bearing anacetylene group and another flavonoid bearing an azido group, a triazolebridged flavonoid dimer would be easily obtained by employingCu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC). Abis-triazole bridged flavonoid dimer can be obtained by using adiacetylene compound “clicked” with two molecules of flavonoid bearingan azido group or a diazido compound “clicked” with two molecules offlavonoid bearing an acetylene group. More importantly, CuAAC was to bethe crucial step affording an anti-1,2,3-triazole element for connectingflavonoid moieties. On the other hand, a ruthenium-catalyzedcycloaddition would afford the corresponding syn-1,2,3-triazoleregioisomers^(68,69).

Synthesis of Alkynes.

The synthesis of the required acetylene bearing flavonoids is shown inScheme 1. Treatment of 4′ or 7-hydroxyflavones (1a-e) with varioushaloalkynes afforded acetylene bearing flavonoids (Ac1-5, 12) in highyield. Base-catalyzed aldol condensation of aldehyde 2 with various2-hydroxyl acetophenones afforded chalcones which was further convertedto acetylenes (Ac6-10). 2-Phenylquinazolin-4(3H)-one derivative (Ac11)was obtained by treatment of 2-aminobenzamide (4) with aldehyde 2 in thepresent of catalytic amount of iodine. Acetylene bearing flavonoid(Ac13) was prepared in two steps: treatment of flavone 1a withbromoethanol followed by alkylation of the hydroxyl group with propargylbromide in the presence of sodium hydride. Acetylene bearing flavonoid(Ac16) was obtained simply from 2-(benzyl(prop-2-yn-1-yl)amino)ethanolunder Mitsunobu condition. Treatment of 2-(2-aminoethoxy)ethanol withpropargyl bromide afforded the diacetylene (Ac14). Diacetylene Ac15 andtriacetylene Ac17 are commercially available.

Synthesis of Azides.

The synthesis of the required azide bearing flavonoids is shown inScheme 2. 4′ or 7-Hydroxyflavones (1a, d-h) were conveniently convertedto the corresponding azides (Az1-7, 10-13) with good yield in threesteps: (1) alkylation of hydroxyl group of flavones with varioushydroxyl halides such as bromoethanol, 2-(2-chloroethoxy)ethanol and2-(2-(2-chloroethoxy)ethoxy)ethanol under basic medium; (2) mesylationof the hydroxyl flavones; (3) reaction of the mesylated flavones withexcess sodium azide. All reactions proceeded smoothly to furnish thedesired products. Azides Az8-9 were prepared to investigate thesubstituent effect on the benzyl group. Starting from compounds 5,debenzylation gave compounds 6 which was followed by alkylation withmethyl 3-(bromomethyl)benzoate to furnish compound 7. Azides (Az8-9)were realized after the conversion of hydroxyl group to azido group. Forthe azides Az14-15 with amine-containing chain homolog, a Mitsunobureaction of flavones 1a or 1e with 2,2′-(benzylimino)-diethanol wasemployed, followed by conversion of the hydroxyl group to azido group.

Fusion of Alkynes and Azides to Triazoles.

The syntheses of the flavonoid dimers were completed by a CuAAC betweenthe azides and the alkynes as shown in Scheme 3. Treatment of acetylenes(Ac1-17) with azides (Az1-15) in the presence of catalytic amount ofCu(PPh₃)₃Br under THF refluxing temperature afforded the desiredtriazole bridged flavonoid dimers with anti-regiochemistry. Table 9shows the flavonoid dimers thus synthesized. The dimeric nature oftriazole bridge flavonoid dimers was evident from high-resolution massspectrometric data. In the examples of Ac4Az1, Ac5Az5 and Ac5Az10,deprotection of the benzyl group were performed as shown in Scheme 4. Inorder to investigate whether the syn-isomer of triazole would givesimilar biological effect as the anti-isomer, ruthenium-catalyzedazide-alkyne 1,3-dipolar cycloaddition (RuAAC) was employed to preparecompound syn-Ac5Ac1 and syn-Ac5Ac2.

Biological Study

These new compounds were investigated for the P-gp-, MRP1- andBCRP-modulating potencies. Four different cell lines were employed inthis study, P-gp-transfected human breast cancer cell line, LCC6MDR(IC₅₀=158.7±6.1 nM), displayed about 99.2-fold greater resistance topaclitaxel than the parental LCC6 cells (IC₅₀=1.6±0.3 nM) (Table 1).MRP1-transfected ovarian cancer cell line, 2008/MRP1 (IC₅₀=419.9±17.4nM) was about 8.4-fold more resistant to DOX than the parental 2008/Pcells (IC₅₀=50.1±3.9 nM) (Table 1). BCRP-transfected human embryonickidney cell line, HEK293/R2 (IC₅₀=508.1±31.1 nM) was about 32.2-foldmore resistant to topotecan than the wild type, HEK293/pcDNA3.1 cellline (IC₅₀=15.8±1.5 nM) (Table 1). MCF7-MX100 is a mitoxantrone-selectedbreast cancer cell line in which the BCRP transporter protein was foundto be overexpressed. MCF7-MX100 (IC₅₀=33.4±2.1 μM) exhibited about104.4-fold more resistance to topotecan than the wild type MCF7(IC₅₀=0.32±0.07 μM) (Table 1). Relative Fold (RF) and % of reversionwere employed as parameters for measuring the MDR reversalactivity.^(70,71) Verapamil (RF=3.6 in LCC6MDR), PSC388 (RF=88.2 inLCC6MDR) and cyclosporine A (RF=79.4 in LCC6MDR) are known P-gpinhibitors, whereas Ko143 (RF=21.2 in HEK293/R2 and RF=69.6 inMCF7-MX100) is a BCRP-specific modulator. Flavonoid dimer, 1 d(5,7H-6Me)n=5 (RF=6.5 in 2008/MRP1) was reported previously to possess promisingMRP1-modulating activity.⁵⁹ Here, all these compounds were used aspositive controls in the cell proliferation assays. The triazole bridgedflavonoid dimers would be considered as potent MDR chemosensitizers ifthey exhibit a relatively high RF values as the positive controls. Thecytotoxicity and MDR reversal activity of these triazole dimers werelisted in Table 1 and compared with the monomeric precursors as well. Ingeneral, they displayed varied level of toxicity towards normalfibroblasts L929 and MDR-reversal activity among the ABCtransporter-overexpressed cancer cell lines.

Intrinsic Cytotoxicity of Triazole Bridged Dimers and their Monomers

In terms of intrinsic cytotoxicity, most of Ac monomers (Group A) arenon-toxic to L929 cells as their IC₅₀ values were above 81 μM. Only Ac13(IC₅₀=32.2 μM) and Ac16 (IC₅₀=58.2 μM) monomers showed moderatecytotoxicity towards L929. Az monomers (Group B) generally were morecytotoxic than the Ac monomers (Group A) as their IC₅₀ values for L929cells were below 68 μM. When the Ac monomers were coupled with the Azmonomers, the resultant triazole bridged dimers interestingly becameless cytotoxic as compared to the Az monomers. Az1-2 triazole dimers(Group C), Ac5 triazole dimers (Group D), Ac12 triazole dimers (GroupF), Ac13 triazole dimers (Group H), Ac15 triazole dimers (Group J) andAc16 triazole dimers (Group K) were generally non-cytotoxic towardsnormal cells L929 because their IC₅₀ values were at least above 50 μM.From Groups C, D, F, H, J and K, only Ac4Az1, Ac11Az2, Ac5Az5OH,Ac5Az100H, Ac13Az2 and Ac13Az12 displayed remarkable killing activitytowards L929 cells as their IC₅₀ values were below 12.1 μM. Of 69triazole dimers tested, 63 dimers generally exhibited no inherentcytotoxicity towards L929 cells (IC₅₀>50 μM), suggesting that thesetriazole dimers are potential MDR reversal candidates because of theirlow toxicity.

P-Gp-Modulating Activity of the Alkyne-, Azide and Triazole-ContainingFlavonoids

In order to determine whether anticancer drug resistance reversalactivity of these triazole dimers is due solely to the dimeric nature,their MDR reversal activities were compared with those of thecorresponding monomeric precursors at doubled concentration (2.0 μM).Most Ac monomers (Group A) showed no Pgp-modulating activity as all RFvalues were close to or below the 1.0 except for Ac4 monomer. Azmonomers (Group B) generally showed higher P-gp-modulating activity thanAc monomers (Group A), suggesting that Az monomers may bind to P-gpbetter than the Ac monomers (Group A). The Az monomers including Az5,Az9 and Az10 at 2.0 μM gave about 20.5% to 24.2% of reversion ofsensitivity in LCC6MDR cells. Nevertheless, their reversal potencieswere still weaker than the triazole dimers as shown below.

Among the different groups of triazole dimers, Ac5 triazole dimers(Group D) were the most potent group in chemo-sensitizingPgp-overexpressed LCC6MDR cell line towards paclitaxel. Of the 18triazole dimers tested, 9 compounds at 1.0 μM can reduce the IC₅₀ ofpaclitaxel of LCC6MDR from 158.7 nM to below 3.0 nM. Ac5Az4, Ac5Az5,Ac5Az7, Ac5Az8 and Ac5Az9 caused at least 94.1% of reversion ofpaclitaxel sensitivity in LCC6MDR cell line. Ac5Az1, Ac5Az3, Ac5Az11 andAc5Az15 achieved about 55.2% to 69.6% of reversion. The group containingAc12 triazole dimers (Group F) was the second most potent group inmodulating P-gp-mediated drug resistance. Of the 11 triazole dimersinvestigated, 5 compounds showed promising P-gp-reversal activity.Ac12Az5 and Ac12Az9 at 1.0 μM can result in 80.0% and 88.9% of reversionof sensitivity in LCC6MDR resistant cell line, respectively. Ac12Az3,Ac12Az8 and Ac12Az10 resulted in about 53.3% to 72.7% of reversion.Az1-2 triazole dimers (Group C) were the third potent group because only2 out of 12 dimers gave modest P-gp-modulating activity. Ac3Az1 andAc7Az1 achieved 64.0% and 55.2% of reversion of sensitivity of LCC6MDRcells, respectively. Ac13 triazole dimers (Group H) were relatively poorP-gp-inhibitors because only 2 compounds, Ac13Az9 and Ac13Az10, showedmodest P-gp-modulating activity. They resulted in about 59.3% and 50.0%of reversion, respectively. Ac16 triazole dimers (Group K) were alsoweak in chemo-sensitizing Pgp-overexpressed LCC6MDR towards paclitaxelas all of them exhibited below 39.0% of reversion. Ac15 triazole dimers(Group J) were the poorest P-gp inhibitors as all of them gave below17.6% of reversion. Even at 0.5 μM lower concentration tested, Ac5triazole dimers (Group D) were still the most potent group of P-gpinhibitor. A total of 6 compounds in Group D reversed IC₅₀ of paclitaxelof LCC6MDR from 158.7 nM to below 10.0 nM. From the above data, it isclear that the Ac5 structure is the most critical components formodulating P-gp transporter.

In order to demonstrate that the formation of dimer is necessary forP-gp-modulation, we compared the activity of the dimer Ac12-Az9 at 1.0μM with a mixture of their respective monomer precursors Ac12 and Az9,each at 1.0 μM. The dimer Ac12Az9 is highly potent at 1.0 μM, withRF=88.2 and 88.9% reversion (Table 1, Group F). In contrast, the mixtureof their respective monomer precursors Ac12 and Az9 has a very weakP-gp-modulating activity (RF=8.8 and 8.9% reversion) (Table 1, Group G).Same is true for Ac12Az10 in Group G (compared to monomers Ac12 andAz10) or Ac13Az9 in Group I (compared to monomers Ac13 and Az10) orAc13Az10 in Group I (compared to monomers Ac13 and Az10). These resultsclearly indicate that bivalency approach is crucial for P-gp modulation.

MRP1-Modulating Activity of the Alkene-, Azide and Triazole-ContainingFlavonoids

Similar to P-gp modulating activity, all Ac monomers (Group A) and Azmonomers (Group B) displayed no or low MRP 1-modulating activity even atdoubled concentration (2.0 μM). On the other hand, the triazole dimersresulted in a very promising MRP1-inhibitory potency as compared to themonomers alone. Among the six groups of triazole dimers, Ac16 triazoledimers (Group K) were the most potent group of MRP1 chemosensitizers. Ofthe 7 compounds tested at 1.0 μM, 6 compounds exhibited significantMRP1-inhibitory potency except for Ac16Az13. Dimers Ac16Az1, Ac16Az2,Ac16Az3, Ac16Az7 and Ac16Az12 gave at least 204.5% of reversion ofsensitivity of 2008/MRP1 towards DOX. They dramatically reduced the IC₅₀of DOX of 2008/MRP1 from 419.9 nM to or below 25 nM. Ac16Az5, moderateMRP1-inhibitor, gave about 77.8% of reversion. Ac12 triazole dimers(Group F) were the second most potent group of MRP1 chemosensitizers. Ofthe 11 dimers tested at 1.0 μM concentration, 10 compounds exhibitedsignificant MRP1-inhibitory potency except for Ac12Az10. Dimers Ac12Az1to Ac12z4, Ac12Az7, Ac12Az11 and Ac12Az12 caused remarkably 80.4% to104.2% of reversion of sensitivity of 2008/MRP1 towards DOX. Theydramatically reduced the IC₅₀ of DOX of 2008/MRP1 from 412.8 nM to orbelow 62.3 nM. Dimers Ac12Az5, Ac12Az8 and Ac12Az9 gave modestMRP1-mediated resistance reversal potency and achieved about 51.8% to58.3% of reversion. The Az1-2 triazole dimers (Group C) belonged to thethird most active group of MRP1 inhibitors. Of the 12 dimersinvestigated, 6 compounds caused a pronounced re-sensitization of2008/MRP1 towards DOX. Dimers Ac1Az1, Ac2Az1, Ac3Az1 and Ac4(5OH)Az1achieved at least 92.3% of reversion at 1.0 μM. Dimers Ac8Az1 andAc10Az1 showed moderate reversal potency and caused about 52.5% and54.8% of reversion, respectively. The Ac5 triazole dimers (Group D) werethe fourth promising group in re-sensitizing the MRP1-overexpressed2008/MRP1 towards DOX. A total of 6 compounds gave significantMRP1-inhibitory activity. Dimers Ac5Az4, Ac5Az7 and Ac5Az15 caused atleast 95.1% of reversion at 1.0 μM. The modest MRP1 inhibitors includingAc5Az2, Ac5Az3 and Ac5Az9 with at least 53.9% of reversion was noted. Ofthe nine Ac15 triazole dimers (Group J), only 3 compounds gaveremarkable chemosensitization effect: Ac15Az1, Ac15Az2 and Ac15Az3notably caused at least 98.6% of reversion.

The Ac13 triazole dimers (Group H) appeared to be the poorest group ofMRP1-inhibitor. Only 1 compound of 11 dimers gave modest MRP1-modulatingactivity: Ac13Az8 in Group H caused about 55.9% of reversion. The abovedata demonstrates that coupling Ac16 monomer with more diverse Azmonomers may be a reasonable direction for identifying more potent MRP 1chemosensitizers. Combining 1.0 μM of Ac5 monomer with 1.0 μM of Az4 orAz7 monomers (Group E) and Ac12 monomer with Az2, Az3, Az4 or Az7monomers (Group G) showed about 6.7- to 10.4-fold poorer MRP1-mediatedresistance reversal potency as compared to their respective dimercounterparts. These combined monomers just gave about 10% of reversion.Once again, the bivalent nature of the triazole dimers is a necessaryand efficient design for increasing their affinity to inhibit thefunction of both P-gp and MRP1 transporters.

Other than DOX resistance reversal potency, the effect of all triazoledimers on re-sensitization of 2008/MRP1 towards another anticancer drug,vincristine, were also studied. Here, 2008/MRP1 displayed only about2.4-fold more resistance to vincristine than the parental wild type2008/P. Nevertheless, many of the triazole dimers showed very promisingMRP1-meidated vincristine resistance reversal potency and remarkablycaused over 100% of reversion of sensitivity of 2008/MRP1 towardsvincristine. At 1.0 μM concentration of most triazole dimers, the2008/MRP1 became several-fold more sensitive to the vincristine than thewild type 2008/P.

The mechanism of that hypersensitization with the triazole dimers hasnot yet been elucidated. It is possible that there may be a synergyresulting from the MRP 1-inhibition and an unknown cytotoxic effect oftriazole dimers together with the vincristine. Majority of the triazoledimers alone showed no inherent cytotoxicity towards 2008/P and2008/MRP1 cells. For the Ac12 triazole dimers (Group F), 5 (Ac12Az1 toAc12Az4 and Ac12Az7) out of 11 dimers dramatically reduced the IC₅₀ ofvincristine of 2008/MRP1 from 123.2 nM to below 10.0 nM and with RFvalues ranging from 14.0 to 24.6. Of the 18 Ac5 triazole dimers (GroupD) tested, 2 compounds (Ac5Az4 and Ac5Az15) showed remarkablevincristine resistance reversal potency and caused the IC₅₀ ofvincristine of 2008/MRP1 below 10.0 nM. No potent vincristine resistancereversal agent was found in Group H and Group J as all of them gave IC₅₀of vincristine of 2008/MRP1 above 13.0 nM. Combining of 1.0 μM of Ac12with 1.0 μM of Az2 or Az3 or Az4 monomers (Group G) showed 15.8- to20.5-fold weaker vincristine resistance reversal potency as compared totheir respective triazole dimers, possibly suggesting that bivalentnature of triazole dimers is not only essential for inhibition of MRP 1transporter, but also for the unknown synergistic cancer killing effectwith vincristine. Importantly, that pronounced hypersensitivity towardsvincristine induced by our triazole dimers may provide an opportunityfor use in treating MDR tumors.

BCRP-Modulating Activity of the Alkene-, Azide and Triazole-ContainingFlavonoids

In contrast to their P-gp and MRP 1-modulating activities, Ac monomers(Group A) and Az monomers (Group B) unexpectedly displayed remarkableBCRP-modulating activity. At 2.0 μM concentration, Ac4 monomer fromGroup A achieved about 42.1% of reversion of sensitivity in HEK293/R2towards topotecan. No such high level of reversal activity of Ac4monomer was observed in LCC6MDR or 2008/MRP1, respectively. Of the 12 Azmonomers (Group B) investigated, 5 of them have potent BCRP modulatingactivity. Az9 monomer at 2.0 μM gave a 100% of reversion which is aspotent as some of the dimers (see below). Az5, Az6, Az8 and Az10monomers gave modest BCRP modulating activity with 52.7% to 75.6% ofreversion at 2.0 μM.

Among different groups of triazole dimers, Ac12 triazole dimers (GroupF) were the most potent group in re-sensitizing BCRP-overexpressedHEK293/R2 cell line towards topotecan. Of the 11 triazole dimers, all ofthem displayed significant BCRP-modulating activity. Dimers Ac12Az5 andAc12Az8 to Ac12Az12 caused about 80.6% to 122.5% of reversion and withIC₅₀ of topotecan of HEK293/R2 below 20.0 nM. Dimers Ac12Az1 to Ac12Az4and Ac12Az5 achieved about 61.2% to 77.8% of reversion. The Ac15triazole dimers (Group J) were the second most active group of BCRPinhibitors in which 7 out of 9 dimers showed remarkableBCRP-chemosensitization effect. Dimers Ac15Az1, Ac15Az3, Ac15Az5,Ac15Az8 and Ac15Az9 achieved about 87.3% to 110.5% of reversion at 1.0μM. Dimers Ac15Az11 and Ac15Az12 were moderate reversal agents and gaveabout 77.5% and 79.4% of reversion, respectively.

The Ac13 triazole dimers (Group H) were the third most potent group ofBCRP inhibitors. A total of 5 compounds with pronounced BCRP-inhibitorypotency were found. Dimers Ac13Az5, Ac13Az8 to Ac13Az10 at 1.0 μM causedat least 85.9% of reversion of sensitivity of HEK293/R2 towardstopotecan. Dimers Ac13Az11 and Ac13Az12 were modest BCRP inhibitors andgave about 56.4% and 68.1% of reversion, respectively. The Ac5 triazoledimers (Group D) were the less potent in reversing BCRP-mediatedtopotecan resistance. Of the 18 triazole dimers, 7 compounds were foundto exhibit promising BCRP-modulating activity. Dimer Ac5Az12 achievedabout 80.2% of reversion. Other modest reversal agents including Ac5Az4,Ac5Az5 and Ac5Az8 to Ac5Az10 and Ac5Az11 with at least 54.9% ofreversion was noted.

The Az1-2 triazole dimers (Group C) were also weak in chemo-sensitizingHEK293/R2 towards topotecan as 5 out of 12 dimers gave modest BCRPinhibitory potency. Dimers Ac1Az1, Ac3Az1, Ac4(5OH)Az1, Ac10Az1 and Ac11Az1 caused about 50.5% to 74.2% of reversion. The Ac16 triazole dimers(Group K) were the poorest group of BCRP inhibitors as all of them gavebelow 40.0% of reversion. Generally, Az8 and Az9 monomers appeared to bethe crucial components for making active BCRP inhibitor as couplingAc12, Ac13 or Ac15 monomers with them resulted in remarkably potentBCRP-modulating activity with over 100% reversion.

Combining 1.0 μM of Ac5 monomer with 1.0 μM of Az5 or Az8 monomers(Group E), Ac12 monomer with Az8, Az9 or Az10 monomers (Group G) andAc13 monomers with Az8, Az9 or Az10 monomers (Group I) showed promisingBCRP-modulating activity with at least 35.1% of reversion. Ac12 or Ac13monomers with Az9 monomer even gave 81.4% and 87.8% of reversion,respectively. Such high level of reversal activity of those combinedmonomers might result from their potent Az monomers Az5, Az8, Az9 andAz10. Nevertheless, those combined monomers were still about 1.3- to2.8-fold weaker than their dimer counterparts in reversing topotecanresistance in HEK293/R2 cell line. Unlike the P-gp and MRP 1chemosensitizers, these results demonstrated that the bivalency approachis sufficient but not required for BCRP modulation.

Mitoxantrone selected cell line MCF7-MX100, which overexpressed BCRP,was also employed to study the BCRP-modulating activities of thetriazole flavonoid dimers. Ac4 monomer and some Az monomers (Az8, Az9and Az10) gave certain level of BCRP-modulating activity with about17.8% to 45.7% of reversion. For Az1-2 monomers (Group C), only 1 out of12 dimers exhibited modest BCRP-modulating activity. Ac3Az1 achievedabout 53.3% reversion of sensitivity in MCF7-MX100 towards topotecan.For the Ac5 triazole dimers (Group D), Ac5Az10 exhibited potent BCRPmodulating activity and achieved about 80.0% of reversion of sensitivityof MCF7-MX100 towards topotecan. Dimers Ac5Az8 and Ac5Az9 were moderateBCRP inhibitors and gave about 64.0% of reversion.

For the Ac12 (Group F), Ac13 (Group H) and Ac15 (Group J) triazoledimers, only Ac12Az8 to Ac12Az10, Ac13Az8 to Ac13Az10, Ac15Az8 andAc15Az9 were screened with BCRP-mediated resistance reversal potencyusing MCF7-MX100 cell line. All of these triazole dimers exhibitedsignificant BCRP inhibitory potency in HEK293/R2 cell line. DimersAc12Az8, Ac12Az9, Ac13Az8 and Ac13Az9 achieved about 80.0% of reversion,whereas Ac12Az10, Ac13Az10, Ac15Az8 and Ac15Az9 caused at least 53.3% ofreversion. For the Ac16 triazole dimers (Group K), Ac16Az1 gavesignificant BCRP-modulating activity with 80.0% of reversion. Themoderate BCRP inhibitors, A16Az2, Ac16Az3, Ac16Az5, Ac16Az7 and Ac16Az12caused about 53.3% to 64.0% of reversion. For the combined monomers(Groups E, G and I), Ac5 or Ac12 or Ac13 monomers with Az9 monomerdisplayed significant BCRP-mediated resistance reversal potency with64.0% of reversion.

Their BCRP reversal activity was nearly as strong as their respectivedimers. Such high level of reversal potency was mainly resulted from thepotent Az9 monomer. For other combined monomers, they also exhibitedabout 2.2- to 4.0-fold lower BCRP-modulating activity as compared totheir dimer counterparts except for Ac5 monomer with Az8 monomer whichdisplayed about 7.4-fold lower chemosensitization effect than Ac5Az8.

Overall, exploiting bivalency was found to be useful though not criticalin designing effective BCRP inhibitor. However, we cannot exclude thepossibility that monovalent azide especially Az9 is also a goodcandidate to reverse the BCRP-mediated drug resistance. The mechanismsfor re-sensitization of HEK293/R2 and MCF7-MX100 towards topotecan bybivalent triazole and monovalent azide have not been studied. However,it is likely that the triazole dimers inhibit the transport activity ofBCRP transporter in a manner similar to that observed in the modulationof P-gp and MRP 1 transporters by the synthetic flavonoid dimerspreviously studied.⁵⁷⁻⁵⁹

The possible reason responsible for the difference in MDR reversalactivity of monomeric azides (e.g. Az9) among P-gp, MRP1 and BCRPtransporters may be due to the structural difference of P-gp and MRP1with respect to the BCRP transporters. P-gp and MRP1 are composed of twohydrophobic membrane domains (TMDs) and two hydrophilic nucleotidebinding domains (NBDs). They are arranged in two repeated halves with 12and 17 TM α-helices, respectively, forming a funnel facing the outsideof the cell membrane.³⁻⁶ In contrast, BCRP is a half ABC transporterwith one NBD followed by one TMD.^(9,10) It is suggested that BCRPrequires homodimerization to exert its activity. A homotetramericconfiguration of BCRP has also been proposed.^(10,72) The substratespecificity of BCRP is overlapping with, but distinct from that of P-gpand MRP1.^(9,73) TM6 and TM12 of P-gp are reported to be involved indrug binding.⁷⁴ Interestingly, arginine at position 482 of BCRP which islocated within TM3 near the cytosolic membrane interface has beendemonstrated to be important in substrate binding and transportactivity.⁷⁵ Therefore, it is possible that an alternative substratebinding is solely applicable to BCRP but not for P-gp and MRP1transporters. Whether monomeric azide binds to the alternative substraterecognition site of BCRP or inhibits the BCRP dimerization processremains to be investigated.

Effect of Anti or Syn Orientation of Triazole Dimers on MDR ReversalActivity

Interestingly, both the anti-regioisomers Ac5Az1 (RF=69.0) and Ac5Az2(RF=48.1) showed higher P-gp-modulating activity than the syn-Ac5Az1(RF=30.5) and syn-Ac5Az2 (RF=3.0) (Table 1). These results suggestedthat the orientation of the triazole dimers is important in controllingbinding affinity of the triazole dimers toward P-gp. Syn-Ac5Az2 showedpoorer MRP1 inhibitory activity than the anti-isomer Ac5Az2. However,similar MRP1-reversal potency was noted in both the anti-isomer Ac5Az1and syn-Ac5Az1. Thus, the importance of orientation of the triazoledimers on MRP1-modulating activity may be compound-dependent. On theother hand, the orientation of the triazole dimers appears to have noeffect on controlling the BCRP-modulating activity as the RF values werevery similar for the anti-isomer Ac5Az1 (RF=10.6) and syn-Ac5Az1(RF=11.6). Similarly, the anti-isomer Ac5Az2 (RF=13.5) and syn-Ac5Az2(RF=9.3) (Table 1) have similar potencies.

Selectivity of the Alkene-, Azide and Triazole-Containing Flavonoids

Of the 69 triazole dimers and 21 monomers tested, they exhibiteddifferent potency against P-gp-, BCRP- and MRP1-mediated drugresistance. Generally, the triazole dimers library can be divided intomono-selective, dual-selective and multi-selective ABC transportermodulators. Table 2 summarizes the selectivity of different activetriazole dimers and some monomeric azides for the ABC transporters. Ofthe 56 active triazole compounds found, 2 compounds (Ac7Az1 and Ac5Az1)show mono-Pgp selectivity; 10 compounds (Ac2Az1, Ac8Az1, Ac5Az2,Ac15Az2, Ac16Az1, Ac16Az2, Ac16Az3, Ac16Az5, Ac16Az7 and Ac16Az12) showmono-MRP1 selectivity and 16 compounds (Az5, Az6, Az8, Az9, Az10,Ac11Az1, Ac5Az10, Ac5Az12, Ac13Az5, Ac13Az11, Ac13Az12, Ac15Az5,Ac15Az8, Ac15Az9, Ac5Az11 and Ac15Az12) show mono-BCRP selectivity. Atotal of 3 compounds (Ac5Az3, Ac5Az7 and Ac5Az15) have P-gp andMRP1-dual-selectivity; 6 compounds (Ac5Az5, Ac5Az8, Ac5Az11, Ac12Az10,Ac13Az9 and Ac13Az10) have Pgp- and BCRP-dual selectivity and 12compounds (Ac1Az1, Ac4(5OH)Az1, Ac10Az1, Ac12Az1, Ac12Az2, Ac12Az4,Ac12Az7, Ac12Az11, Ac12Az12, Ac13Az8, Ac15Az1 and Ac15Az3) have MRP1-and BCRP-dual selectivity. Finally, a total of 7 compounds (Ac3Az1,Ac5Az4, Ac5Az9, Ac12Az3, Ac12Az5, Ac12Az8, and Ac12Az9) showmulti-selectivity towards P-gp, MRP1 and BCRP transporters. About 57%and 32% of the triazole dimers were highly selective for the MRP1 andP-gp transporters, respectively. Overall, 73% of the active triazoledimers efficiently inhibited BCRP-mediated drug resistance. From thestudy, it seems that the simple monomeric azides could be a highlyBCRP-selective inhibitor. Some of the bivalent triazoles showedmulti-selectivity for ABC transporters. It is possible that differentlyselective (mono-, dual- and multi-) inhibitors of drug transporterscould be potentially useful tools for investigation of complicateddrug-resistance phenotypes and eventually, for treatment ofdrug-resistant cancers caused by overexpression of ABC transporters.

Effective Concentration (EC₅₀) and Therapeutic Index of the Alkyne-,Azide and Triazole-Containing Flavonoids

A good MDR chemosensitizer should possess high potency andnon-cytotoxicity to normal cells. Here, we have determined EC₅₀ andtherapeutic index (a ratio of cytotoxicity against L929 or Raw264.7cells to the EC₅₀ of the modulators) of these dimers and monomers. Table3 summarizes the EC₅₀ and therapeutic index of the active triazolecompounds. Verapamil, PSC833, cyclosporine A, 1 d(5,7H-6Me)n=5 and Ko143have been included as positive P-gp, MRP1 and BCRP controls forcomparison. In general, the active bivalent triazoles are safe MDRchemosensitizer because of their high value of therapeutic index. TheEC₅₀ of active bivalent triazole for reversing paclitaxel resistance ofLCC6MDR ranged from 141 to 340 nM and their therapeutic index were atleast above 263.2, indicating that they are highly selective tore-sensitize LCC6MDR cells towards paclitaxel at the nanomolar range andcaused no cytotoxicity to L929 cells. Overall, they possessed moreselective P-gp modulating activity than the first generation of P-gpinhibitor verapamil, but displayed weaker selectivity as compared tocyclosporine A and PSC833. The EC₅₀ values of bivalent triazoles forlowering DOX and vincristine resistance of 2008/MRP1 ranged from 78 to590 nM and 82 to 550 nM, respectively. The EC₅₀ values of the mostactive bivalent triazoles were comparable to the previous synthesizedactive flavonoid dimer, 1 d(5,7H-6Me)n=5. At such nanomolarconcentration, they selectively reversed the DOX and vincristineresistance of 2008/MRP1 without inducing cytotoxicity to the L929 cellsas indicated by their high therapeutic index.

Finally, most of the active triazole dimers were found to be moreselective for the BCRP transporter than the P-gp and MRP1 transportersas their EC₅₀ values for reversing topotecan resistance of HEK293/R2 andMCF7-MX100 were in the low nM range. In HEK293/R2 and MCF7-MX100, atotal of 11 compounds (Ac3Az 1, Ac5Az8, Ac5Az9, Ac5Az10, Ac12Az8,Ac12Az9, Ac13Az8, Ac13Az9, Ac15Az8, Ac15Az9 and Az9) were as potent asthe BCRP-inhibitor Ko143 because they possessed EC₅₀ values at or below10 nM. Overall, their therapeutic indices were higher than that of Ko143except for Az9. Therefore, the bivalent triazoles are not only superiorto the Ko143 in re-sensitization of HEK293/R2 and MCF7-MX100 towardstopotecan, but also highly selective for the BCRP transporter.

Summary Comments

In summary, various bioactive alkene-, azide and triazole-containingflavonoids have been efficiently synthesized. The trizole-containingflavonoids were prepared by the cycloaddition of azide-(Az) withalkyne-containing flavonoids (Ac). These flavonoids displayed promisingMDR reversal activity against P-gp-, MRP1- and BCRP-mediated drugresistance. Tables 4 to 8 summarize the MDR reversal activity ofdifferent combinations of Ac monomers and Az monomers. For the P-gpmodulating activity, the Ac5 monomer was found to be a good leadcomponent for making potent P-gp chemosensitizer as compared to otherAc12, Ac13, Ac15 and Ac16 monomers because the triazoles of Ac5 monomerand various Az monomers exhibited high RF values (Table 4). ForMRP1-modulating activity, Ac16 monomer was demonstrated to be importantcomponent for reversing MRP 1-mediated DOX drug resistance in 2008/MRP1(Table 5). Moreover, the combinations of Ac12 monomer with various Azmonomers or Az1 monomer with various Ac monomers resulted in relativelypotent DOX resistance and vincristine resistance reversal activity(Tables 5 and 6). For the BCRP-modulating activity, Az8, Az9 and Az10monomers were demonstrated to be potent components for generating BCRPinhibitor because coupling them with any Ac monomer (Ac5, Ac12, Ac13 andAc15) resulted in a significant BCRP-inhibitory potency in bothHEK293/R2 and MCF7-MX100 cells (Table 7 and 8).

Moreover, the active bivalent triazoles showed different levels ofselectivity for various transporters. Overall, they can be divided intomono-selective, dual-selective and multi-selective modulators for theP-gp, MRP1 and BCRP transporters (Table 2). The EC₅₀ values forreversing paclitaxel resistance of LCC6MDR (141-340 nM), DOX (78-590 nM)and vincristine (82-550 nM) resistance of 2008/MRP1 were at a nanomolarrange (Table 3). Interestingly, active bivalent triazoles or monomericazide Az9 showed EC₅₀ values for lowering topotecan resistance ofHEK293/R2 and MCF7-MX100 at or below 10 nM (Table 3), indicating thatthe bivalent triazoles more selectively inhibit BCRP than the P-gp andMRP1. Most of the bivalent triazoles are notably safe MDRchemosensitizers as indicated by their high therapeutic index values(Table 3). The present study demonstrates that the potential andimportance of developing bioactive triazole flavonoid dimers to treatMDR cancers.

Drug resistance in cancer patients renders many patients unresponsive tochemotherapeutic treatments. This new invention can generate a new classof highly potent compounds that can inhibit the mechanism which wouldotherwise pumps the drugs out of cancer cells, resulting in cancer drugresistance.

Many brain tumors are difficult to treat because of low accumulation ofcancer drugs in the brain, mainly due to the drug pump present in theblood brain barrier. Flavonoids developed here can be used to inhibitthe pumps and therefore increasing the cancer drug concentration in thebrain. This could make an otherwise ineffective cancer drug effective intreating brain tumor.

The approach of the present invention is to target the binding sites ofABC transporter using dimeric flavonoids. We have previously reportedthat, by using a bivalent approach, synthetic apigenin homodimers withpolyethylene glycol (PEG) linker can modulate the P-gp and MRP1transporters in human cancer⁵⁷⁻⁵⁹ and parasitic protozoan Leishmania.^(60, 61) Their reversal activities were much more potent than themonomeric apigenin. These results indicate that the bivalent approach issuccessful in enhancing the reversal activity of P-gp- and MRP1-mediatedresistance. Moreover, the modulating activity of the flavonoid dimers inhuman MDR cancer cells has recently been optimized by structuralmodification of the flavonoid ring⁵⁸ as well as the PEG linker.

The “click chemistry” is a rapid and versatile strategy for conjugatingtwo molecular fragments under very mild reaction condition. It has beenproved to be advantageous in yielding bioactive triazoles in numerousbiological settings.⁶²⁻⁶⁵ In this study, a novel series of triazolebridged flavonoid dimers derived from the precursor alkyne- andazide-containing flavonoids has been efficiently synthesized using“click chemistry” approach and their MDR reversal activities have beenevaluated on the P-gp-, BCRP-, and MRP1-overexpressed tumor cell lines.

REFERENCES

-   1. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.;    Gottesman, M. M. Targeting multidrug resistance in cancer. Nat Rev    Drug Discov 2006, 5, 219-34.-   2. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in    anti-cancer drug treatment. Curr Med Chem 2006, 13, 1859-76.-   3. Eckford, P. D.; Sharom, F. J. ABC efflux pump-based resistance to    chemotherapy drugs. Chem Rev 2009, 109, 2989-3011.-   4. Gros, P.; Croop, J.; Housman, D. Mammalian multidrug resistance    gene: complete cDNA sequence indicates strong homology to bacterial    transport proteins. Cell 1986, 47, 371-80.-   5. Lockhart, A. C.; Tirona, R. G.; Kim, R. B. Pharmacogenetics of    ATP-binding cassette transporters in cancer and chemotherapy. Mol    Cancer Ther 2003, 2, 685-98.-   6. Rosenberg, M. F.; Callaghan, R.; Ford, R. C.; Higgins, C. F.    Structure of the multidrug resistance P-glycoprotein to 2.5 nm    resolution determined by electron microscopy and image analysis. J    Biol Chem 1997, 272, 10685-94.-   7. Hipfner, D. R.; Almquist, K. C.; Leslie, E. M.; Gerlach, J. H.;    Grant, C. E.; Deeley, R. G.; Cole, S. P. Membrane topology of the    multidrug resistance protein (MRP). A study of glycosylation-site    mutants reveals an extracytosolic NH2 terminus. J Biol Chem 1997,    272, 23623-30.-   8. Kast, C.; Gros, P. Epitope insertion favors a six transmembrane    domain model for the carboxy-terminal portion of the multidrug    resistance-associated protein. Biochemistry 1998, 37, 2305-13.-   9. Polgar, O.; Robey, R. W.; Bates, S. E. ABCG2: structure, function    and role in drug response. Expert Opin Drug Metab Toxicol 2008, 4,    1-15.-   10. Xu, J.; Liu, Y.; Yang, Y.; Bates, S.; Zhang, J. T.    Characterization of oligomeric human half-ABC transporter    ATP-binding cassette G2. J Biol Chem 2004, 279, 19781-9.-   11. Honorat, M.; Falson, P.; Terreux, R.; Di Pietro, A.; Dumontet,    C.; Payen, L. Multidrug resistance ABC transporter structure    predictions by homology modeling approaches. Curr Drug Metab 2011,    12, 268-77.-   12. Klepsch, F.; Jabeen, I.; Chiba, P.; Ecker, G. F.    Pharmacoinformatic approaches to design natural product type ligands    of ABC-transporters. Curr Pharm Des 2010, 16, 1742-52.-   13. McDevitt, C. A.; Callaghan, R. How can we best use structural    information on P-glycoprotein to design inhibitors? Pharmacol Ther    2007, 113, 429-41.-   14. Saito, H.; An, R.; Hirano, H.; Ishikawa, T. Emerging new    technology: QSAR analysis and MO Calculation to characterize    interactions of protein kinase inhibitors with the human ABC    transporter, ABCG2 (BCRP). Drug Metab Pharmacokinet 2010, 25, 72-83.-   15. Hollt, V.; Kouba, M.; Dietel, M.; Vogt, G. Stereoisomers of    calcium antagonists which differ markedly in their potencies as    calcium blockers are equally effective in modulating drug transport    by P-glycoprotein. Biochem Pharmacol 1992, 43, 2601-8.-   16. Tsuruo, T.; Iida, H.; Nojiri, M.; Tsukagoshi, S.; Sakurai, Y.    Circumvention of vincristine and Adriamycin resistance in vitro and    in vivo by calcium influx blockers. Cancer Res 1983, 43, 2905-10.-   17. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of    vincristine resistance in P388 leukemia in vivo and in vitro through    enhanced cytotoxicity of vincristine and vinblastine by verapamil.    Cancer Res 1981, 41, 1967-72.-   18. Tsuruo, T.; Iida, H.; Kitatani, Y.; Yokota, K.; Tsukagoshi, S.;    Sakurai, Y. Effects of quinidine and related compounds on    cytotoxicity and cellular accumulation of vincristine and adriamycin    in drug-resistant tumor cells. Cancer Res 1984, 44, 4303-7.-   19. Ganapathi, R.; Grabowski, D.; Turinic, R.; Valenzuela, R.    Correlation between potency of calmodulin inhibitors and effects on    cellular levels and cytotoxic activity of doxorubicin (adriamycin)    in resistant P388 mouse leukemia cells. Eur J Cancer Clin Oncol    1984, 20, 799-806.-   20. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Increased    accumulation of vincristine and adriamycin in drug-resistant P388    tumor cells following incubation with calcium antagonists and    calmodulin inhibitors. Cancer Res 1982, 42, 4730-3.-   21. Chao, N. J.; Aihara, M.; Blume, K. G.; Sikic, B. I. Modulation    of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in    multidrug-resistant human leukemic cell lines and normal bone    marrow. Exp Hematol 1990, 18, 1193-8.-   22. Slater, L. M.; Sweet, P.; Stupecky, M.; Gupta, S. Cyclosporin A    reverses vincristine and daunorubicin resistance in acute lymphatic    leukemia in vitro. J Clin Invest 1986, 77, 1405-8.-   23. Slater, L. M.; Sweet, P.; Stupecky, M.; Wetzel, M. W.; Gupta, S.    Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites    carcinoma. Br J Cancer 1986, 54, 235-8.-   24. Twentyman, P. R.; Fox, N. E.; White, D. J. Cyclosporin A and its    analogues as modifiers of adriamycin and vincristine resistance in a    multi-drug resistant human lung cancer cell line. Br J Cancer 1987,    56, 55-7.-   25. Barnes, K. M.; Dickstein, B.; Cutler, G. B., Jr.; Fojo, T.;    Bates, S. E. Steroid treatment, accumulation, and antagonism of    P-glycoprotein in multidrug-resistant cells. Biochemistry 1996, 35,    4820-7.-   26. Gruol, D. J.; Zee, M. C.; Trotter, J.; Bourgeois, S. Reversal of    multidrug resistance by RU 486. Cancer Res 1994, 54, 3088-91.-   27. Ueda, K.; Okamura, N.; Hirai, M.; Tanigawara, Y.; Saeki, T.;    Kioka, N.; Komano, T.; Hori, R. Human P-glycoprotein transports    cortisol, aldosterone, and dexamethasone, but not progesterone. J    Biol Chem 1992, 267, 24248-52.-   28. Pirker, R.; FitzGerald, D. J.; Raschack, M.; Frank, Z.;    Willingham, M. C.; Pastan, I. Enhancement of the activity of    immunotoxins by analogues of verapamil. Cancer Res 1989, 49, 4791-5.-   29. Twentyman, P. R.; Bleehen, N. M. Resistance modification by    PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur    J Cancer 1991, 27, 1639-42.-   30. Hofmann, J; Wolf, A.; Spitaler, M.; Bock, G.; Drach, J.;    Ludescher, C.; Grunicke, H. Reversal of multidrug resistance by    B859-35, a metabolite of B859-35, niguldipine, verapamil and    nitrendipine. J Cancer Res Clin Oncol 1992, 118, 361-6.-   31. Germann, U. A.; Ford, P. J.; Shlyakhter, D.; Mason, V. S.;    Harding, M. W. Chemosensitization and drug accumulation effects of    VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug    resistant HL60/ADR cells expressing the multidrug    resistance-associated protein MRP. Anticancer Drugs 1997, 8, 141-55.-   32. Germann, U. A.; Shlyakhter, D.; Mason, V. S.; Zelle, R. E.;    Duffy, J. P.; Galullo, V.; Armistead, D. M.; Saunders, J. O.; Boger,    J.; Harding, M. W. Cellular and biochemical characterization of    VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated    multidrug resistance in vitro. Anticancer Drugs 1997, 8, 125-40.-   33. Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer.    Mechanisms, reversal using modulators of MDR and the role of MDR    modulators in influencing the pharmacokinetics of anticancer drugs.    Eur J Pharm Sci 2000, 11, 265-83.-   34. Thomas, H.; Coley, H. M. Overcoming multidrug resistance in    cancer: an update on the clinical strategy of inhibiting    p-glycoprotein. Cancer Control 2003, 10, 159-65.-   35. Gekeler, V.; Ise, W.; Sanders, K. H.; Ulrich, W. R.; Beck, J.    The leukotriene LTD4 receptor antagonist MK571 specifically    modulates MRP associated multidrug resistance. Biochem Biophys Res    Commun 1995, 208, 345-52.-   36. Payen, L.; Delugin, L.; Courtois, A.; Trinquart, Y.; Guillouzo,    A.; Fardel, O. The sulphonylurea glibenclamide inhibits multidrug    resistance protein (MRP1) activity in human lung cancer cells. Br J    Pharmacol 2001, 132, 778-84.-   37. Gollapudi, S.; Kim, C. H.; Tran, B. N.; Sangha, S.; Gupta, S.    Probenecid reverses multidrug resistance in multidrug    resistance-associated protein-overexpressing HL60/AR and H69/AR    cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR    cells. Cancer Chemother Pharmacol 1997, 40, 150-8.-   38. Draper, M. P.; Martell, R. L.; Levy, S. B. Indomethacin-mediated    reversal of multidrug resistance and drug efflux in human and murine    cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer    1997, 75, 810-5.-   39. Duffy, C. P.; Elliott, C. J.; O'Connor, R. A.; Heenan, M. M.;    Coyle, S.; Cleary, I. M.; Kavanagh, K.; Verhaegen, S.;    O'Loughlin, C. M.; NicAmhlaoibh, R.; Clynes, M. Enhancement of    chemotherapeutic drug toxicity to human tumour cells in vitro by a    subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J    Cancer 1998, 34, 1250-9.-   40. Li, Y.; Hayman, E.; Plesescu, M.; Rrakash, S. Synthesis of    potent BCRP inhibitor-Ko143. Tetrahedron Lett 2008, 49, 1480-1483.-   41. Wang, L.; Leggas, M.; Goswami, M.; Empey, P. E.; McNamara, P. J.    N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine    carboxamide (GF120918) as a chemical ATP-binding cassette    transporter family G member 2 (Abcg2) knockout model to study    nitrofurantoin transfer into milk. Drug Metab Dispos 2008, 36,    2591-6.-   42. Kuhnle, M.; Egger, M.; Muller, C.; Mahringer, A.; Bernhardt, G.;    Fricker, G.; Konig, B.; Buschauer, A. Potent and selective    inhibitors of breast cancer resistance protein (ABCG2) derived from    the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009,    52, 1190-7.-   43. Harborne, J. B. Nature, distribution and function of plant    flavonoids. Prog Clin Biol Res 1986, 213, 15-24.-   44. Castro, A. F.; Altenberg, G. A Inhibition of drug transport by    genistein in multidrug-resistant cells expressing P-glycoprotein.    Biochem Pharmacol 1997, 53, 89-93.-   45. de Castro, W. V.; Mertens-Talcott, S.; Derendorf, H.;    Butterweck, V. Effect of grapefruit juice, naringin, naringenin, and    bergamottin on the intestinal carrier-mediated transport of    talinolol in rats. J Agric Food Chem 2008, 56, 4840-5.-   46. Limtrakul, P.; Khantamat, O.; Pintha, K Inhibition of    P-glycoprotein function and expression by kaempferol and quercetin.    J Chemother 2005, 17, 86-95.-   47. Mitsunaga, Y.; Takanaga, H.; Matsuo, H.; Naito, M.; Tsuruo, T.;    Ohtani, H.; Sawada, Y. Effect of bioflavonoids on vincristine    transport across blood-brain barrier. Eur J Pharmacol 2000, 395,    193-201.-   48. Zhang, S.; Morris, M. E. Effect of the flavonoids biochanin A    and silymarin on the P-glycoprotein-mediated transport of digoxin    and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003,    20, 1184-91.-   49. Zhang, S.; Sagawa, K.; Arnold, R. D.; Tseng, E.; Wang, X.;    Morris, M. E. Interactions between the flavonoid biochanin A and    P-glycoprotein substrates in rats: in vitro and in vivo. J Pharm Sci    2010, 99, 430-41.-   50. Leslie, E. M.; Mao, Q.; Oleschuk, C. J.; Deeley, R. G.;    Cole, S. P. Modulation of multidrug resistance protein 1    (MRP1/ABCC1) transport and atpase activities by interaction with    dietary flavonoids. Mol Pharmacol 2001, 59, 1171-80.-   51. Nguyen, H.; Zhang, S.; Morris, M. E. Effect of flavonoids on    MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003, 92,    250-7.-   52. van Zanden, J. J.; Wortelboer, H. M.; Bijlsma, S.; Punt, A.;    Usta, M.; Bladeren, P. J.; Rietjens, I. M.; Cnubben, N. H.    Quantitative structure activity relationship studies on the    flavonoid mediated inhibition of multidrug resistance proteins 1 and    2. Biochem Pharmacol 2005, 69, 699-708.-   53. Cooray, H. C.; Janvilisri, T.; van Veen, H. W.; Hladky, S. B.;    Barrand, M. A. Interaction of the breast cancer resistance protein    with plant polyphenols. Biochem Biophys Res Commun 2004, 317,    269-75.-   54. Imai, Y.; Tsukahara, S.; Asada, S.; Sugimoto, Y.    Phytoestrogens/flavonoids reverse breast cancer resistance    protein/ABCG2-mediated multidrug resistance. Cancer Res 2004, 64,    4346-52.-   55. Yoshikawa, M.; Ikegami, Y.; Sano, K.; Yoshida, H.; Mitomo, H.;    Sawada, S.; Ishikawa, T. Transport of SN-38 by the wild type of    human ABC transporter ABCG2 and its inhibition by quercetin, a    natural flavonoid. J Exp Ther Oncol 2004, 4, 25-35.-   56. Zhang, S.; Yang, X.; Morris, M. E. Flavonoids are inhibitors of    breast cancer resistance protein (ABCG2)-mediated transport. Mol    Pharmacol 2004, 65, 1208-16.-   57. Chan, K. F.; Zhao, Y.; Burkett, B. A.; Wong, I. L.; Chow, L. M.;    Chan, T. H. Flavonoid dimers as bivalent modulators for    P-glycoprotein-based multidrug resistance: synthetic apigenin    homodimers linked with defined-length poly(ethylene glycol) spacers    increase drug retention and enhance chemosensitivity in resistant    cancer cells. J Med Chem 2006, 49, 6742-59.-   58. Chan, K. F.; Zhao, Y.; Chow, T. W.; Yan, C. S.; Ma, D. L.;    Burkett, B. A.; Wong, I. L.; Chow, L. M.; Chan, T. H. Flavonoid    dimers as bivalent modulators for p-glycoprotein-based multidrug    resistance: structure-activity relationships. Chem Med Chem 2009, 4,    594-614.-   59. Wong, I. L.; Chan, K. F.; Tsang, K. H.; Lam, C. Y.; Zhao, Y.;    Chan, T. H.; Chow, L. M. Modulation of multidrug resistance protein    1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin    homodimers and their derivatives. J Med Chem 2009, 52, 5311-22.-   60. Wong, I. L.; Chan, K. F.; Burkett, B. A.; Zhao, Y.; Chai, Y.;    Sun, H.; Chan, T. H.; Chow, L. M. Flavonoid dimers as bivalent    modulators for pentamidine and sodium stiboglucanate resistance in    leishmania. Antimicrob Agents Chemother 2007, 51, 930-40.-   61. Wong, I. L.; Chan, K. F.; Zhao, Y.; Chan, T. H.; Chow, L. M.    Quinacrine and a novel apigenin dimer can synergistically increase    the pentamidine susceptibility of the protozoan parasite Leishmania.    J Antimicrob Chemother 2009, 63, 1179-90.-   62. Boechat, N.; Ferreira, V. F.; Ferreira, S. B.; Ferreira, M. D.;    da Silva, F. D.; Bastos, M. M.; Costa, M. D.; Lourenco, M. C.;    Pinto, A. C.; Krettli, A. U.; Aguiar, A. C.; Teixeira, B. M.; da    Silva, N. V.; Martins, P. R.; Bezerra, F. A.; Camilo, A. L.; da    Silva, G. P.; Costa, C. C. Novel 1,2,3-Triazole Derivatives for Use    against Mycobacterium tuberculosis H37Rv (ATCC 27294) Strain. J Med    Chem 2011, 54, 5988-5999.-   63. Kumar, S.; Arya, D. P. Recognition of HIV TAR RNA by triazole    linked neomycin dimers. Bioorg Med Chem Lett 2011, 21, 4788-92.-   64. Wangler, C.; Schafer, M.; Schirrmacher, R.; Bartenstein, P.;    Wangler, B. DOTA derivatives for site-specific    biomolecule-modification via click chemistry: synthesis and    comparison of reaction characteristics. Bioorg Med Chem 2011, 19,    3864-74.-   65. Zhang, H. L.; He, X. P.; Sheng, L.; Yao, Y.; Zhang, W.; Shi, X.    X.; Li, J.; Chen, G. R. Synthesis of novel 6-triazologlycolipids via    click chemistry and their preliminary cytotoxicity assessments. Mol    Divers 2011.-   66. Gujadhur, R.; Venkataraman, D.; Kintigh, J. T. Formation of    aryl-nitrogen bonds using a soluble copper(I) catalyst. Tetrahedron    Lett. 2001, 42, 4791-4793.-   67. Zhang, P. Y.; Wong, I. L.; Yan, C. S.; Zhang, X. Y.; Jiang, T.;    Chow, L. M.; Wan, S. B. Design and syntheses of permethyl ningalin B    analogues: potent multidrug resistance (MDR) reversal agents of    cancer cells. J Med Chem 2010, 53, 5108-20.-   68. Zhang, L.; Chen, X.; Xue, P.; Sun, H. H.; Williams, I. D.;    Sharpless, K. B.; Fokin, V. V.; Jia, G. Ruthenium-catalyzed    cycloaddition of alkynes and organic azides. J Am Chem Soc 2005,    127, 15998-9.-   69. Rasmussen, L. K.; Boren, B. C.; Fokin, V. V. Ruthenium-catalyzed    cycloaddition of aryl azides and alkynes. Org Lett 2007, 9, 5337-9.-   70. Soenen, D. R.; Hwang, I.; Hedrick, M. P.; Boger, D. L. Multidrug    resistance reversal activity of key ningalin analogues. Bioorg Med    Chem Lett 2003, 13, 1777-81.-   71. Tao, H.; Hwang, I.; Boger, D. L. Multidrug resistance reversal    activity of permethyl ningalin B amide derivatives. Bioorg Med Chem    Lett 2004, 14, 5979-81.-   72. McDevitt, C. A.; Collins, R. F.; Conway, M.; Modok, S.; Storm,    J.; Kerr, I. D.; Ford, R. C.; Callaghan, R. Purification and 3D    structural analysis of oligomeric human multidrug transporter ABCG2.    Structure 2006, 14, 1623-32.-   73. Mao, Q.; Unadkat, J. D. Role of the breast cancer resistance    protein (ABCG2) in drug transport. AAPS J 2005, 7, E118-33.-   74. Loo, T. W.; Clarke, D. M. Determining the dimensions of the    drug-binding domain of human P-glycoprotein using thiol    cross-linking compounds as molecular rulers. J Biol Chem 2001, 276,    36877-80.-   75. Honjo, Y.; Hrycyna, C. A.; Yan, Q. W.; Medina-Perez, W. Y.;    Robey, R. W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S. E.    Acquired mutations in the MXR/BCRP/ABCP gene alter substrate    specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001,    61, 6635-9.

TABLE 1 FIG. legends Cytotoxicity and MDR reversal activity of triazoledimers and their monomers.

The IC₅₀ value was determined after exposure to a series of anti-cancerdrugs including paclitaxel, DOX, vincristine and topotecan withdifferent triazole, azide or acetylene compounds using LCC6MDR,2008/MRP1, HEK293/R2 and MCF7-MX100 cells, as described in theexperiment section. Relative fold (RF)=(IC₅₀ without modulator)/(IC₅₀with modulator), % of reversion=(IC₅₀ of wild type)/(IC₅₀ of resistantcells with modulators)×100%. Positive controls including verapamil,cyclosporine A, PSC833, 1 d(5,7H-6Me)n=5 and Ko143 were included forcomparison. N=1-8 independent experiments and values were presented asmean±standard error of mean. ^(a)All compounds were dissolved in DMSOfor testing and the final % of DMSO was 0.05% and 0.1%. ^(b)The triazoledimers were tested at 1.0 μM. ^(c)The triazole dimers were tested at 0.5μM. ^(d)The monomers were tested at 2.0 μM. ^(e)1.0 μM of Ac monomer and1.0 μM of Az monomer were combined for testing. ^(f)LCC6MDR, HEK293/R2,MCF7-MX100 and 2008/MRP1 were used without modulators. ^(g)LCC6, 2008/P,HEK293/pcDNA3.1 and MCF7 were used without modulators. For cytotoxicityassay, IC₅₀ of different triazole compounds for LCC6, LCC6MDR, 2008/P,2008/MRP1 and L929 cell lines were determined N=1-3 independentexperiment and the values were presented as mean±standard error of mean.L929: mouse fibroblasts. ND=not determined.

TABLE 2 Selectivity of triazole dimers and their monomers for variousABC transporters.

The selectivity of active triazole compounds for various ABCtransporters was determined from the Table 1. It would be considered asstrongly selective if it causes >80% of reversion. It would beconsidered as moderately selective if it results in 79-50% of reversion.Overall, the active triazole compounds can be divided into mono-, dual-and multi-selective for P-gp, MRP1 and BCRP transporters.

TABLE 3 EC₅₀ and therapeutic index of triazole dimers and theirmonomers. Cytotoxicity (IC₅₀, μM) Paclitaxel resistance of LCC6MDR DOXresistance of 2008/MRP1 Compounds L929 Raw264.7 EC₅₀ (nM) Therapeuticindex EC₅₀ (nM) Therapeutic index Ac1Az1 60.2 ± 16.3 ND ND ND 127.5 ±32.5  472.2 Ac2Az1 >100 ND ND ND 145.0 ± 25.0  >689.7 Ac3Az1 >100 ND NDND 137.0 ± 16.2  >730.0 Ac4(5OH)Az1 >100 ND ND ND 110.0 ± 15.0  >909.1Ac11AZ1 >100 ND ND ND ND ND Ac5Az1 >57 ND ND ND 250.0 >228.0 Ac5Az4 >100ND ND ND 161.7 ± 10.9  >618.4 Ac5Az5 >100 ND ND ND ND ND Ac5Az7 >100 ND157.0 >636.9 191.7 ± 33.5  >521.6 Ac5Az8 >100 ND ND ND ND ND Ac5Az9 >100ND ND ND ND ND Ac5Az10 >100 ND ND ND ND ND Ac5Az11 >100 ND 160.0 ±21.0  >625.0 175.0 ± 17.6  >571.4 Ac5Az12 >100 ND 141.0 ± 1.0  >709.2131.7 ± 38.4  >759.3 Ac12Az1 >100 ND ND ND ND ND Ac12Az2 >50 ND ND ND167.5 ± 12.5  >298.5 Ac12Az3 >50 ND 190.0 >263.2 149.8 ± 15.8  >333.8Ac12Az4 >100 ND ND ND 190.3 ± 5.2  >525.5 Ac12Az7 >100 ND ND ND 172.3 ±31.1  >580.4 Ac12Az8 >100 ND ND ND ND ND Ac12Az9 >100 ND ND ND ND NDAc12Az10 >100 ND 330.0 >303.0 ND ND Ac12Az11 >100 ND ND ND 114.0 ±11.0  >877.2 Ac12Az12 >100 ND ND ND 135.0 ± 10.0  >740.7 Ac13Az8 >100 NDND ND ND ND Ac13Az9 >100 ND ND ND ND ND Ac13Az10 >100 ND 340.0 >294.1 NDND Ac15Az1 >100 ND ND ND ND ND Ac15Az2 >100 ND ND ND 530.0 ±120.4 >188.7 Ac15Az3 >100 ND ND ND 475.0 ± 25.1  >210.5 Ac15Az5 >100 NDND ND ND ND Ac15Az8 >100 ND ND ND ND ND Ac15Az9 >100 ND ND ND ND NDAc16Az1 >100 ND ND ND 77.7 ± 16.5 >1287.0 Ac16Az2 >100 ND ND ND 98.8 ±18.3 >1012.1 Ac16Az3 >100 ND ND ND 137.7 ± 21.4  >726.2 Ac16Az5 >100 NDND ND 301.7 ± 93.0  >331.5 Ac16Az7 >100 ND ND ND 123.0 ± 13.0  >813.0Ac16Az12 >100 ND ND ND 208.0 ± 32.0  >480.8 Ac16Az13 >100 ND ND ND590.0 >169.5 Az8 67.5 ND ND ND ND ND Az9 20.6 ND ND ND ND ND Az10 51.0ND ND ND ND ND Verapamil 89.2 ± 8.2  ND 445.7 ± 40.7  200.1 ND NDPSC833 >100 ND 2.3 ± 0.5 >43478.3 ND ND Cyclosporine A 33.9 ± 5.2  ND32.0 ± 1.0  1059.4 ND ND 1d(5,7H-6Me)n = 5 ND >100 ND ND 110.7 ±24.6  >903.3 Ko143 29.2 ± 1.6  ND ND ND ND ND Vincristine resistance of2008/MRP1 Topotecan resistance of HEK293/R2 Topotecan resistance ofMCF7-MX100 Compounds EC₅₀ (nM) Therapeutic index EC₅₀ (nM) Therapeuticindex EC₅₀ (nM) Therapeutic index Ac1Az1 ND ND 12.3 ± 4.8  4894.3 23.1 ±10.8 2606.1 Ac2Az1 ND ND ND ND ND ND Ac3Az1 ND ND 5.4 ± 1.6 >18518.517.5 ± 8.1  >5714.3 Ac4(5OH)Az1 ND ND 12.6 ± 4.6  >7936.5 51.0 ±29.1 >1960.8 Ac11AZ1 ND ND 48.0 ± 10.0 >2083.3 31.0 >3225.8 Ac5Az1 ND NDND ND ND ND Ac5Az4 117.0 ± 16.0  >854.7 18.0 >5555.6 ND ND Ac5Az5 ND ND33.0 >3030.3 ND ND Ac5Az7 115.0 >869.6 ND ND ND ND Ac5Az8 ND ND 3.6 ±0.2 >27777.8 4.0 ± 2.3 >25000.0 Ac5Az9 ND ND 2.8 ± 0.7 >35714.3 0.9 ±0.3 >111111.1 Ac5Az10 ND ND 16.0 >6250.0 7.5 ± 1.0 >13333.3 Ac5Az11135.0 ± 10.0  >740.7 28.0 ± 2.0  >3571.4 135.0 ± 25.1  >740.7 Ac5Az1292.5 ± 2.5  >1081.1 32.0 ± 4.0  >3125.0 62.5 >1600.0 Ac12Az1 84.0 ±11.0 >1190.5 ND ND ND ND Ac12Az2 132.3 ± 19.2  >377.9 ND ND ND NDAc12Az3 81.5 ± 20.6 >613.5 ND ND ND ND Ac12Az4 135.7 ± 17.6  >736.9 NDND ND ND Ac12Az7 93.3 ± 20.5 >1071.8 ND ND ND ND Ac12Az8 ND ND3.9 >25641.0 5.6 ± 1.7 >17857.1 Ac12Az9 ND ND 0.9 ± 0.1 >111111.1 1.4 ±0.6 >71428.6 Ac12Az10 ND ND 20.0 ± 5.0  >5000.0 34.2 ± 12.0 >2924.0Ac12Az11 169.0 >591.7 30.0 >3333.3 ND ND Ac12Az12 168.0 >595.234.0 >2941.2 ND ND Ac13Az8 ND ND 4.1 ± 0.5 >24390.2 6.0 >16666.7 Ac13Az9ND ND 1.7 ± 0.4 >58823.5 2.0 ± 0.7 >50000.0 Ac13Az10 ND ND 16.5 ±2.5  >6060.6 118.3 ± 35.7  >845.3 Ac15Az1 ND ND 111.0 ± 9.0  >900.9 NDND Ac15Az2 550.0 >181.8 ND ND ND ND Ac15Az3 535.0 ± 62.6  >186.9 36.0 ±4.0  >2777.8 ND ND Ac15Az5 ND ND 48.0 >2083.3 ND ND Ac15Az8 ND ND 4.5 ±3.5 >22222.2 1.3 ± 0.7 >76923.1 Ac15Az9 ND ND 2.4 ± 1.5 >41666.7 2.0 ±0.6 >50000.0 Ac16Az1 ND ND ND ND ND ND Ac16Az2 ND ND ND ND ND ND Ac16Az3ND ND ND ND ND ND Ac16Az5 ND ND ND ND ND ND Ac16Az7 ND ND ND ND ND NDAc16Az12 ND ND ND ND ND ND Ac16Az13 ND ND ND ND ND ND Az8 ND ND 80.3 ±24.1 840.6 120.0 562.5 Az9 ND ND 8.5 ± 1.3 2423.5 10.2 ± 1.6  2019.6Az10 ND ND 32.0 1593.8 ND ND Verapamil ND ND ND ND ND ND PSC833 ND ND NDND ND ND Cyclosporine A ND ND ND ND ND ND 1d(5,7H-6Me)n = 5 120.0 ±13.2  >833.3 ND ND ND ND Ko143 ND ND 11.4 ± 2.4  2561.4 9.0 ± 1.5 3244.4EC₅₀ values were presented as mean ± standard error of mean. N = 1-4independent experiments. Therapeutic index = (IC₅₀ of triazoles towardsL929 fibroblasts or Raw264.7 cells)/(EC₅₀ of triazoles for reversingdrug resistance). ND = not determined.

TABLE 4 Summary of triazoles for the P-gp mediated paclitaxel resistancereversal potency in LCC6MDR.

The P-gp modulating activity of different triazole dimers was measuredas relative fold (RF). RF = (IC₅₀ without modulator)/(IC₅₀ withmodulator). A color gradient was used to discriminate a low-to-highreversal activity of dimers. The pale color represents the low RF valuesand the dark color represents the high RF values. ND = not determined

TABLE 5 Summary of triazoles for the MRP1-mediated DOX resistancereversal potency in 2008/MRP1.

The DOX resistance reversal activity of different triazole dimers wasmeasured as relative fold (RF). RF = (IC₅₀ without modulator)/(IC₅₀ withmodulator). A color gradient was used to discriminate a low-to-highreversal activity of dimers. The pale color represents the low RF valuesand the dark color represents the high RF values. ND = not determined.

TABLE 6 Summary of triazoles for the MRP 1-mediated vincristineresistance reversal potency in 2008MRP1.

The vincrisitine resistance reversal activity of different triazoledimers was measured as relative fold (RF). RF = (IC₅₀ withoutmodulator)/(IC₅₀ with modulator). A color gradient was used todiscriminate a low-to-high reversal activity of dimers. The pale colorrepresents the low RF values and the dark color represents the high RFvalues. ND = not determined.

TABLE 7 Summary of triazoles for BCRP-mediated topotecan resistancereversal potency in HEK293/R2.

The BCRP-modulating activity of different triazole dimers was measuredas relative fold (RF). RF = (IC₅₀ without modulator)/(IC₅₀ withmodulator). A color gradient was used to discriminate a low-to-highreversal activity of dimers. The pale color represents the low RF valuesand the dark color represents the high RF values. ND = not determined.

TABLE 8 Summary of triazoles for the BCRP-mediated topotecan resistancereversal potency in MCF7-MX100.

The BCRP-modulating activity of different triazole dimers was measuredas relative fold (RF). RF = (IC₅₀ without modulator)/(IC₅₀ withmodulator). A color gradient was used to discriminate a low-to-highreversal activity of dimers. The pale color represents the low RF valuesand the dark color represents the high RF values. ND = not determined

TABLE 9 Anti-triazole bridged flavonoid dimers synthesized (Y, 65compounds).

1. A compound of formula I:flavonoid-linker-(flavonoid)  I wherein the flavonoid is selected fromthe group consisting of chalcone, flavone, flavonol, flavanone,anthocyanin, and isoflavonoid; n is 1 or 2; and the linker is a grouphaving at least one triazole bridged unit.
 2. The compound of claim 1,wherein the linker has 1 to 10 triazole bridged unit.
 3. The compound ofclaim 2, wherein the linker has 1 to 5 triazole bridged unit.
 4. Thecompound of claim 3, wherein the linker has 1 to 3 triazole bridgedunit.
 5. The compound of claim 1, wherein the at least one triazolebridged unit further comprises at least one polyethylene glycol unit. 6.A compound of formula II comprising of a flavonoid containing anacetylene group:flavonoid-linker-CCH  II wherein the flavonoid is selected from thegroup consisting of chalcone, flavone, flavonol, flavanone, anthocyanin,and isoflavonoid; and the linker is a group having at least one carbonatom.
 7. The compound of claim 6, wherein the linker is selected fromthe group consisting of alkylene group, group having a plurality ofethylene glycol units, group having a plurality of propylene glycolunits, group having a plurality of amino alkyl units, and combinationsthereof.
 8. A compound of formula III comprising of a flavonoidcontaining an azide group:Flavonoid-linker-N₃  III wherein the flavonoid is selected from thegroup consisting of chalcone, flavone, flavonol, flavanone, anthocyanin,and isoflavonoid; and the linker is a group having at least one carbonatom.
 9. The compound of claim 8, wherein the linker is selected fromthe group consisting of alkylene group, group having a plurality ofethylene glycol units, group having a plurality of propylene glycolunits, group having a plurality of amino alkyl units, and combinationsthereof.
 10. A process of synthesizing a compound of the formula I asdefined in claim 1, comprising reacting a compound of formula II asdefined in claim 6 with a compound of formula III as defined by claim 8by catalytic 1,3-dipolar cycloaddition.
 11. The process of claim 10,wherein the catalytic 1,3-dipolar cycloaddition is regioselective. 12.The process of claim 11, wherein the catalytic 1,3-dipolar cycloadditionis Cu(I) catalyzed or Ru catalyzed.
 13. A method of reducingP-glycoprotein based multidrug resistance including the step ofadministering an effective amount of a compound of formula I as definedin claim 1 or a compound of formula II as defined in claim 6 or acompound of formula III as defined in claim
 8. 14. A method of reducingMRP1-based multidrug resistance including the step of administering aneffective amount of a compound of formula I as defined in claim 1 or acompound of formula II as defined in claim 6 or a compound of formulaIII as defined in claim
 8. 15. A method of reducing BCRP-based multidrugresistance including the step of administering an effective amount of acompound of formula I as defined in claim 1 or a compound of formula IIas defined in claim 6 or a compound of formula III as defined in claim8.
 16. A method of reducing resistance of a drug caused byoverexpression of ABC transporters including the step of administeringan effective amount of a compound of formula I as defined in claim 1 ora compound of formula II as defined in claim 6 or a compound of formulaIII as defined in claim
 8. 17. A method of treating drug-resistancecancers caused by overexpression of ABC transporters including the stepof administering an effective amount of a compound of formula I asdefined in claim 1 or a compound of formula II as defined in claim 6 ora compound of formula III as defined in claim
 8. 18.-22. (canceled) 23.A medicament for reducing P-glycoprotein based multidrug resistance orfor reducing MRP-1 based multidrug resistance or for reducing BCRP-basedmultidrug resistance, said medicament including a compound of formula Ias defined in claim 1 or a compound of formula II as defined in claim 6or a compound of formula III as defined in claim
 8. 24. A medicament forreducing resistance of a drug caused by overexpression of ABCtransporter, said medicament including a compound of formula I asdefined in claim 1 or a compound of formula II as defined in claim 6 ora compound of formula III as defined in claim
 8. 25. A medicament fortreating drug-resistant cancers caused by overexpression of ABCtransporter, said medicament including a compound of formula I definedin claim 1 or a compound of formula II as defined in claim 6 or acompound of formula III as defined in claim
 8. 26. A method ofgenerating a library of a predetermined number of compounds of theformula I as defined in claim 1, comprising: a) providing a flavonoidcontaining an acetylene group of formula II as defined in claim 6; b)selectively reacting the flavonoid containing an acetylene group offormula II as defined in claim 6 with the flavonoid containing an azidogroup of formula III as defined in claim 8; and c) repeating steps (a)and (b) a predetermined number of times to obtain a predetermined numberof compounds of the formula I as defined in claim
 1. 27. (canceled)